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Abstract
Background
Preterm infants often require mechanical ventilation. Volume targeted ventila-
tion has been shown to reduce both complications and the duration of required
mechanical ventilation. The recommended tidal volumes vary from 4-8 mL/kg,
but the optimal tidal volume remains elusive.
Aims and objectives
To compare volume ventilation at a lower (4-5 mL/kg) with a higher (7-8
mL/kg) tidal volume during volume guarantee ventilation (VG) of respiratory
distress syndrome (RDS) in very preterm infants.
Methodology
The randomised trial was conducted at North Tees Hospital in North East
England from 2013 to 2016. Babies <32 weeks’ gestation or <1500 grams
birthweight requiring mechanical ventilation within 12 hours of life from RDS
were included in the study. Babies were randomised to receive lower (4-5
mL/kg) or higher (7-8 mL/kg) tidal volume using Volume Guarantee (VG).
The primary outcome was the time to achieve a 25% reduction from the initial
peak inspiratory pressure (PIP). Secondary outcomes included the duration
of mechanical ventilation, as well as respiratory and non-respiratory complic-
ations.
Results
Babies in both groups were similar at baseline with regard to maternal, demo-
graphic and clinical characteristics. There was no di erence in the primary
i
outcome of time di erence to reach a 25% reduction in baseline peak pres-
sure between the two groups. There were no di erences in short term sec-
ondary outcomes (air leak, pulmonary haemorrhage, sepsis, IVH, NEC, PDA
and ROP) or medium term complications (Bronchopulmonary Dysplasia at
28 days’ life and 36 weeks PMA, severity of Bronchopulmonary Dysplasia,
amount of home oxygen, survival to discharge and survival without Bronchop-
ulmonary Dysplasia at 36 weeks PMA). The minute volume, paCO2 or FIO2
requirements were not significantly di erent either.
Summary and conclusions
This trial did not find statistically significant di erences between lower versus
higher tidal volume delivery in a population of 70 infants with RDS. It is
possible that both tidal volume ranges selected for study are at functional
residual capacity and this might be one reason for negative results of the
study.
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Chapter 1
Introduction
The World Health Organisation (WHO) defines preterm birth as births before 37
completed weeks of gestation or fewer than 259 days from the first date of a woman’s
last menstrual period (LMP) (Who (1977)).
Blencowe et al. (Blencowe et al. (2012)) collated data from 99 countries and estim-
ated the 2010 global prevalence of premature births at 11.1% (95% CI: 9.1%–13.4%).
The authors also reported on the national variation on estimates of preterm birth
rates, which ranged from approximately 5% in some European countries to 18% in
some African countries. Premature births account for significant resource utilisa-
tion and bed occupancy. Though only 1% of all births are very low birth weight
(less than 1500 grams) (O ce of National Statistics (ONS), UK bulletin, 2017),
this small group of infants are at particularly high risk of adverse outcomes; infant
mortality rate at 10–15% and incidence of cerebral palsy at 5–10% (Larroque et al.
(2008), Zeitlin et al. (2008)).
This is an area of modern medicine which has witnessed one of the most dramatic
changes in practice and improvement in outcomes in the last century. It was not
long ago, in 1960, when the perinatal mortality for very low birth weight babies
was approximately 800 per 1,000 live births (Fryer and Ashford (1972)).
According to the O ce of National Statistics (ONS), UK bulletin 2015, very low
birth weight babies, born of less than 32 weeks gestation, account for 15% of all
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Figure 1.1: Percentage of infant deaths and number of live births by gestation
week, babies born in 2014 (Source: O ce of National Statistics, 2015)
preterm births; and approximately 50% of all neonatal deaths are due to prematur-
ity related issues. The same bulletin also identified that ’of those live births that
occurred at under 32 weeks’ gestation, 14.9% resulted in an infant death’ (Figure
1.1).
While mortality of preterm infants has come down in the last 50 years, there are
concerns that this could be at the cost of increasing incidence of disabled children.
This concern has refocussed our attention on reducing morbidity and long-term
complications of prematurity.
Respiratory management of preterm infants is an integral part of neonatal intens-
ive care. The most common immediate and long term complications of preterm
infants include respiratory distress syndrome (surfactant deficient lung disease)
and chronic lung disease respectively. Mechanical ventilation remains the standard
management of respiratory distress syndrome although ventilation induced lung
injury and the development of chronic lung disease are commonly associated with
its use.
Historically, initial accounts of the use of intubation and ventilation date back to
the 17th century (Stern et al. (1970)). Almost 200 years later, in the 19th century,
a device dedicated to ventilation of newborn infants was used. In the 1940s, Dr
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Julius Hess opened the first Premature Centre at the Michael Reese Hospital in
Chicago. In 1953, Donald and Lord (Donald and Lord (1953)) reported their
experience with a patient-cycled, servo-controlled respirator in the treatment of
several newborn infants with respiratory distress. This heralded the era of modern
ventilation in newborn infants. In 1963, a premature son of President Kennedy,
born at 34 weeks weighing 2.1kg, died at 39 hours of age. The infant had received
hyperbaric oxygen to deal with lung disease. This unfortunate event brought into
focus the needs of premature infants’ ventilation and this decade is regarded as
that of the birth of neonatology.
The success in dealing with respiratory distress syndrome has led to improved sur-
vival of premature babies with the antecedent complication identified as bronchop-
ulmonary dysplasia (BPD) (Northway et al. (1967)). The association of oxygen
therapy and retinopathy of prematurity was already reported, and this highlighted
the complications secondary to intensive care interventions to deal with respiratory
distress syndrome.
Subsequently, development of continuous distending pressure (Gregory et al. (1971)),
the concept of longer inspiration (Reynolds and Taghizadeh (1974)) and the use of
continuous gas flow (Kirby et al. (1972)) led to the design of a ventilation technique
combining mechanical and spontaneous breaths called the “Intermittent Mandat-
ory Ventilation" (IMV).
In the 1990s, further development in technology led to the ability to use synchron-
isation, a patient-triggered mode of ventilation and pressure support ventilation in
newborn infants. This helped to reduce the sedation requirement and bedside ad-
justment of ventilation. The next generation of ventilators used electronic controls
and microprocessors to enable delivery of very small inspiratory time while facilitat-
ing the monitoring of ventilatory parameter measurements (inspiratory: expiratory
ratio, mean airway pressure). This triggered the debate for the best modality to
provide ventilation.
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At this time, animal studies by Dreyfuss and Hernandez et al. (Dreyfuss et al.
(1988), Hernandez et al. (1989), Dreyfuss and Saumon (1998)) addressed the ques-
tion of which of the two, volutrauma or barotrauma, contributed more towards
ventilator-induced lung injury. This prompted a number of clinical studies, leading
to evidence of the superiority of volume targeting in newborn infants (Wheeler
et al. (2011)). This marked the shift in the technique of ventilation in the last
decade to volume targeting and this is now widely used as the default mode for
newborn respiratory management.
With continuing development in ventilation technology, it is now feasible to combine
di erent modes of ventilation and deliver respiratory support using "hybrid modes"
of ventilation, e.g., Volume Guarantee (VG), Pressure Regulated Volume Control
(PRVC) and Volume Assured Pressure Support (VAPS). With the development
of these modes, the target tidal volume can be set as per the baby’s needs and
advanced microprocessor technology delivers the set parameters. This brought us
to a new question now being asked on a regular basis – what is the appropriate
tidal volume for respiratory support using mechanical ventilation? Tidal volume is
the volume of medical gas delivered by the ventilator per breath. Its importance
lies in the fact that it is crucial to deliver the tidal volume within a narrow range
and avoid fluctuations. The new generation of ventilators have the capability to
target the set tidal volume. However, high tidal volume can lead to volutrauma
and hypocarbia, while low tidal volume can cause atelectotrauma and hypercarbia.
In adults and older children, this dilemma has been extensively studied. However,
there is a paucity of studies in neonatal population which can be explained by the
lack of availability of technology until recently, to deliver such small tidal volumes.
Williams et al. (Williams et al. (2011)) studied Vt of 43 non-ventilated (CPAP
or spontaneous breathing) preterm newborns and noted that the range of tidal
volume, measured with two di erent methods, was between 4–11 ml/kg.
In a recent international cross-sectional study by van Kaam et al. (van Kaam et al.
4
1. Introduction
(2010)) of the local ventilation practices in Neonatal Intensive Care Units authors
reported that although the majority of infants were ventilated with tidal volumes
between 4 and 7 ml/kg, 18% were ventilated with tidal volumes >7 ml/kg.
Experts have suggested that the tidal volume range should be 4-8 ml/kg, but
there is limited evidence to guide clinicians as to whether low or high normal tidal
volumes should be targeted (van Kaam (2011)).
The lower end of tidal volume has been extrapolated from studies in adults, but
this strategy of employing low tidal volume is not without its shortfalls. A study by
Chowdhury et al. (Chowdhury et al. (2012)) evaluated work of breathing in preterm
babies using tidal volumes of 4-6 ml/kg. It reported that a Vt of 4 ml/kg led to
increased work of breathing and therefore recommended an increased targeted tidal
volume of 6 ml/kg. Hence, while the lower tidal volumes could limit volutrauma,
this study suggests that such low total volumes in turn could lead to increased
work of breathing.
In summary, while volume targeting appears to be superior to pressure targeting,
it is not clear what the optimal tidal volume set is on the hybrid modes widely
used across the world. This remains a vital question that needs investigation.
After this literature search, we found that it was an appropriate question to address
in a randomised control setting. We decided to use the volume guarantee modality,
the commonest and most widely used hybrid mode, to address this question. The
volume guarantee applies principles of pressure and volume ventilations using a
software algorithm which helps to maintain expiratory tidal volume delivered to
the baby with the aid of a feedback loop. Arguably, volume guarantee is the most
commonly used and researched of the hybrid modes. Therefore, its use makes the
results of the study more widely applicable than it could have been if any other
mode were to have been used. Such a study has not been done so far, and with
volume guarantee being a relatively new mode, we decided to go for a pilot project
which would help us address the feasibility of performing this research on a much
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larger multicentre basis.
This prospective randomised controlled trial allowed collection of important data
on various respiratory and non-respiratory parameters. We could also compare the
outcome with the babies who could not be enrolled for any reason. The study
was carried out in a clinical setting hence replicating the common issues which
could arise during clinical management of preterm infants and aimed to provide
practical solutions. This made the study highly relevant to clinical practice. The
study also used a standardised protocol which can be used in managing infants
with volume-targeted ventilation.
This thesis is divided into di erent chapters describing a critical review of published
literature, methods including inclusion and exclusion criteria, results, discussion,
summary and conclusion. The illustrative tables and flow diagrams have been used
to present the data of the findings and the appendices give the details of other
materials used in the study.
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Chapter 2
Resume of Literature
2.1 Premature babies and respiratory distress
syndrome
Preterm birth is defined by the World Health Organisation as the delivery of an
infant before 37 completed weeks (259 days) of gestational duration. Its incidence
has been steadily rising before plateauing in 2008 when it occurred in 12.3% of
births in the United States (Martin J.A. (2010)). It is also considered to be the
most common cause of perinatal (McCormick (1985)) and infant (Callaghan et al.
(2006)) mortality in the United States. It is associated with about one third of all
infant deaths in the United States and accounts for approximately 45% of children
with cerebral palsy, 35% of children with vision impairment and 25% of children
with cognitive or hearing impairment.
2.1.1 Very low birth weight infants
Very low birth weight infants are defined as newborn infants with birth weight less
than 1,500 grams. These infants are known to have higher morbidity and mortality
due to significant immaturity and circumstances surrounding birth. While it was
widely known that these infants have a high risk of morbidity and mortality, Stewart
et al. (Stewart et al. (1981)) compiled the data from 22 reports from developed
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Figure 2.1: Historical data about secular trends of morbidity and mortality in
VLBW infants (Æ1500 grams) - adapted from Stewart et al. (Stewart et al. (1981))
world describing the outcome for infants of very low birth weight born since 1946.
They pooled the data according to the quinquennium of birth and subjected it to
statistical tests and analysis. The authors then divided the historical outcome into
three phases (Figure 2.1):
Phase 1 - 1940s and 1950s, very few VLBW infants survived because of inadequate
treatment and knowledge of neonatal diseases.
Phase 2 - In the late 50s and 60s, knowledge concerning the normal physiology
of VLBW infants and derangement which causes death and damage in newborns
increased. Treatments were developed and the mortality rate started declining
but sometimes at the expense of increased prevalence of handicap amongst the
survivors.
Phase 3 - From the early 1960s onward, chances of healthy survival of VLBW
infants increased and prevalence of handicap remained stable and relatively low, 6
to 8% of total VLBW births.
Stoelhorst et al. (Stoelhorst et al. (2005)) also studied the secular trends (data over
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long term) in the mortality pattern of preterm infants of less than 32 weeks (The
Leiden Follow-up Project on Prematurity, LFUPP-1996/97). The authors found
that whilst comparing infants born in 1996-97 (The Leiden Follow-Up Project on
Prematurity, LFUPP-1996/97) with ones born in 1983, (Project On Preterm and
Small for Gestational Age Infants, POPS-1983), the absolute number of preterm
births in the study region increased by 30%. 73% of the LFUPP-1996/97 infants
were treated antenatally with glucocorticosteroids compared with 6% of the POPS-
1983 infants. 42% of the LFUPP-1996/97 infants received surfactant. In-hospital
mortality decreased from 30% in the 1980s to 11% in the 1990s. Mortality of
the extremely preterm infants (<27 weeks) fell from 76% to 33%. The incidence
of respiratory distress syndrome remained the same; approximately 60% in both
groups. Mortality from respiratory distress syndrome, however, decreased from
29% to 8%. The incidence of bronchopulmonary dysplasia increased from 6% to
19%. For the surviving infants, the average length of stay in the hospital and
the mean number of NICU days stayed approximately the same (approximately
67 days total admission time and 44 NICU days in both groups). Including the
infants who died, the mean NICU admission time increased from 27 days in the
1980s to 41 days in the 1990s. There was no change in adverse outcome (dead or
an abnormal general condition) at the time of discharge from hospital (+/-40%
in both groups). The authors concluded that the secular trends demonstrated an
increase in the absolute number of very preterm births in this study region, leading
to a more significant burden on the regional NICUs. They also speculated as to
whether improvements in perinatal and neonatal care had led to increased survival
of especially extreme preterm infants; which in turn had resulted in more morbidity,
mainly bronchopulmonary dysplasia, at the moment of discharge from the hospital.
In a multi-centre prospective study of preterm infants born in France “EPIPAGE
(epidemiological study on small gestational ages)” (Pierrat et al. (2017)), the au-
thors reported that survival at two years corrected age was 51.7% at 22-26 weeks’
gestation and 93.1% at 27-31 weeks’ gestation. Survival without severe or moder-
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ate neuro-motor or sensory disabilities among live births increased between 1997
and 2011, from 45.5% to 62.3% at 25-26 weeks’ gestation. At 32-34 weeks’ gest-
ation, there was a non-statistically significant increase in survival without severe
or moderate neuro-motor or sensory disabilities (p=0.61), but the proportion of
survivors with cerebral palsy declined (p=0.01). In <32 weeks group, an incid-
ence of severe neuro-motor or sensory disability was 1.7% and incidence of survival
without moderate to severe disability was 96.4%. Survival at two years corrected
age was 84.3%. When comparing the same group of babies to 14 years earlier (2011
versus 1997) (Larroque et al. (2001)), the authors noted that there was an increase
in two year survival from 79.4% to 84.1% (p=0.001). Both adjusted as well as
unadjusted mean di erences were highly significant. Similarly, the proportion of
babies surviving without major disability increased from 74.5% to 80.5%. This was
also statistically significant.
During the past decade, survival has improved, particularly in infants with ex-
tremely low birth weight (Lemons et al. (2001), Fanaro  et al. (2007)). Whilst
there have been improvements in survival, the incidence of most short term major
medical complications associated with prematurity has remained relatively stable.
2.1.2 Respiratory distress syndrome
Respiratory distress syndrome (RDS), formerly known as hyaline membrane dis-
ease, is a common problem in preterm infants. This disorder is caused primarily by
a deficiency of pulmonary surfactant in an immature lung. RDS is a major cause
of morbidity and mortality in preterm infants.
The incidence of RDS increases with decreasing gestational age. The risk is highest
in extremely preterm infants as illustrated by a study from the National Institute
of Child Health and Human Development Neonatal Research Network. This study
found a 93% incidence of RDS in a cohort of 9,575 extremely preterm infants
(gestational age 28 weeks or below) born between 2003 and 2007 (Stoll et al. (2010)).
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The European agency for neonatal data in 2010 reported respiratory distress syn-
drome incidence of 92% at 24–25 weeks’ gestation, 88% at 26–27 weeks, 76% at
28–29 weeks and 57% at 30–31 weeks (EuroNeoStat (2010)).
Knowledge of the normal foetal lung development is central to understanding the
pathophysiology of neonatal RDS as it is due to inadequate surfactant activity
resulting from lung immaturity.
2.1.3 Pulmonary surfactant
The primary cause of RDS is a deficiency of pulmonary surfactant, which is develop-
mentally regulated. The foetal lung is filled with fluid and provides no respiratory
function until birth. In preparation for air breathing, the surfactant is expressed in
the lung during the third trimester of pregnancy (Frank and Sosenko (1987)). Sur-
factant reduces the alveolar surface tension, thereby facilitating alveolar expansion
and reducing the likelihood of alveolar collapse atelectasis.
Because of the developmental regulation of surfactant production, the most com-
mon cause of surfactant deficiency is preterm delivery. In the preterm infants,
both a decrease in the quantity and quality of surfactant contributes to decreased
surfactant activity resulting in RDS. In addition to low surfactant production seen
with decreasing gestational age, the surfactant produced in preterm infants com-
pared to surfactant from term infants has reduced activity because of di erences
in lipid and protein composition (Hallman et al. (1976)).
2.1.3.1 Pathophysiology
In the premature lung with inadequate surfactant activity, the resultant higher sur-
face tension leads to instability of the lung at end expiration, low lung volume and
decreased compliance. These changes in lung function cause hypoxaemia primarily
due to a mismatch between ventilation and perfusion due to a collapse of large por-
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tions of the lung (atelectasis) and additional contributions of ventilation/perfusion
mismatch from intrapulmonary and extrapulmonary right to left shunts.
Surfactant deficiency also leads to lung inflammation and respiratory epithelial
injury, which may result in pulmonary oedema and increased airway resistance.
These factors further exacerbate lung injury and worsen lung function. At the
same time, abnormal fluid absorption results in the ine cient clearing of lung
liquid in the injured, oedematous lung which also impedes gas exchange.
The relationship of the inflating pressure, surface tension and radius of curvature
is illustrated by the model of a distal alveolus as a sphere connected to a distal
airway described by LaPlace’s law. According to LaPlace’s law, the pressure (P)
necessary to keep the sphere open is proportional to the surface tension (T) and
inversely proportional to the radius (R) of the sphere, as shown by the formula:
P = 2T/R
If the surface tension is high and the alveolar volume is small (i.e., the radius is low),
as occurs at end expiration, the higher pressure is necessary to keep the alveolus
open. If this increased pressure cannot be generated, the alveolus collapses. Di use
atelectasis occurs when an alveolar collapse occurs throughout the lung, which leads
to hypoxaemia. Pulmonary surfactant reduces the surface tension, even at low
volumes, leading to a decrease in the required pressure, thus maintaining alveolar
volume and stability.
Inflammation and lung injury
The role of inflammation in the pathogenesis of RDS is suggested by animal exper-
iments in which surfactant deficiency was also associated with the rapid accumula-
tion of neutrophils in the lung and evidence of pulmonary oedema (Carlton et al.
(1997)).
In this model, depletion of neutrophils prevented pulmonary oedema. In addition,
as noted above, surfactant deficiency causes atelectasis that may lead to injury of
the respiratory epithelium and the alveolar capillary endothelium, which can trigger
12
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a cytokine mediated inflammatory response. A further injury may be caused by
positive pressure ventilatory support or excessive oxidant exposure (Clark et al.
(2001), Naik et al. (2001)).
The inflammation and lung injury may, in turn, lead to accumulation of protein
rich pulmonary fluid that can deactivate any surfactant, which is present, thereby
further exacerbating the underlying surfactant deficiency (Nitta and Kobayashi
(1994)).
Pulmonary oedema
In infants with RDS, pulmonary oedema often occurs because of the following
contributory factors: inflammation and lung injury, reduced pulmonary fluid ab-
sorption and low urine output.
Surfactant inactivation
In addition to decreased surfactant production and synthesis of a less active sur-
factant, surfactant inactivation further reduces the e ective surfactant pool size.
Factors that contribute to surfactant inactivation are inhaled meconium and blood
which can inactivate surfactant activity and increase proteinaceous oedema and
inflammatory products.
Its impact on pulmonary function and gas exchange includes low compliance, low
lung volume (functional residual capacity) and mildly increased total lung resist-
ance.
Hypoxaemia
It is due primarily to mismatch of ventilation and perfusion with right-to-left shunt-
ing of blood past substantial regions of the lung that are poorly ventilated.
Metabolic acidosis
It may be present due to lactic acid production from anaerobic metabolism in
response to hypoxaemia and compromised tissue perfusion.
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2.1.4 Clinical manifestations and clinical course of RDS
Because RDS is primarily a developmental disorder of deficient surfactant produc-
tion it presents within the first minutes or hours after birth. If untreated, RDS
progressively worsens over the first 48 hours of life. In some cases, infants may not
appear ill immediately after delivery but develop respiratory distress and cyanosis
within the first few hours of age. The a ected infant is almost always premature
and exhibits signs of respiratory distress that include: tachypnoea, nasal flaring,
expiratory grunting, intercostal and subcostal retractions and cyanosis. On phys-
ical examination, auscultated breath sounds are decreased and infants may be pale
with diminished peripheral pulses.
Clinical course
Prior to surfactant use, uncomplicated RDS typically progressed for 48 to 72 hours.
This was followed by an improvement in respiratory function associated with in-
creased production of endogenous surfactant and resolution of the respiratory dis-
order by one week of age.
Now we know that the natural history of RDS can be significantly modified by
treatment with an exogenous surfactant, which dramatically improves pulmonary
function, leading to the resolution of symptoms and shortens the clinical course.
Diagnosis
RDS is diagnosed by the clinical picture of a premature infant with the onset of
progressive respiratory failure shortly after birth. A characteristic chest radiograph
can also reveal low lung volume and the classic di use reticulo-granular ground-
glass appearance with air bronchogram.
2.1.5 Prevention of respiratory distress syndrome
Going by the axiom – “prevention is better than cure”, the best way to deal with
respiratory distress syndrome would be to avoid premature delivery altogether.
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As we know this is easier said than done. However, there are a few strategies
successfully employed to prevent the occurrence or reduce the severity of RDS in
premature babies.
They include the following:
2.1.5.1 Administration of antenatal corticosteroids
In a systematic review of randomised trials comparing antenatal corticosteroid
therapy versus placebo/no treatment by Roberts et al. (Roberts et al. (2017)), the
authors found that the use of antenatal steroids led to reduction in RDS (average
RR 0.66) as well as moderate/severe RDS (average RR 0.59). They concluded
that the evidence from the review supported the use of a single course of antenatal
corticosteroids to accelerate foetal lung maturation in women at risk of preterm
birth.
In another systematic review by Crowther et al. (Crowther et al. (2011)), the
authors reported that the treatment of women who remained at risk of preterm
birth seven or more days after an initial course of prenatal corticosteroids with
repeat dose(s), compared with no repeat corticosteroid treatment, reduced the risk
of their infants experiencing the primary outcomes of respiratory distress syndrome
(RR 0.83) and serious infant outcome (RR 0.84).
2.1.5.2 Administration of exogenous surfactant
Several clinical trials have shown the benefit of surfactant administration in preterm
infants born of less than 30 weeks’ gestation who are at the greatest risk for RDS.
The use of surfactant has been further analysed as to whether it is prophylactic or
rescue and whether animal-derived or synthetic.
Prophylaxis by synthetic surfactant
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In a meta-analysis by Soll et al. (Soll and Ozek (2010)), the authors analysed
seven randomised controlled trials which demonstrated a decrease in the risk of
pneumothorax, pulmonary interstitial emphysema and neonatal mortality.
The authors concluded that prophylactic use of synthetic surfactant improved clin-
ical outcome whilst increasing the risk of developing patent ductus arteriosus and
pulmonary haemorrhage. However, these complications did not overshadow the
impact on overall outcome (neonatal mortality or late mortality).
Prophylaxis by natural/animal derived
In another meta-analysis by Soll (Soll (2000)), initially performed in 2000 and up-
dated in 2010, the author concluded that prophylactic intra-tracheal administration
of animal-derived surfactant extract to infants judged to be at risk of developing
respiratory distress syndrome led to decreased risk of pneumothorax, a reduced
risk of PIE, a reduced risk of mortality and a reduced risk of BPD or death. The
author also highlighted the lack of long term data in such studies.
Treatment of RDS by synthetic surfactant
In a meta-analysis by Soll (Soll (2000)), the author reported that the use of syn-
thetic surfactant led to a statistically significant decrease in the risk of pneumo-
thorax, pulmonary interstitial emphysema, patent ductus arteriosus, intraventricu-
lar haemorrhage, bronchopulmonary dysplasia, neonatal mortality, bronchopul-
monary dysplasia or death at 28 days, mortality prior to hospital discharge and a
decrease in the risk of mortality during the first year of life.
Treatment of RDS by animal derived surfactant
In a meta-analysis by Seger et al. (Seger and Soll (2009)), the authors reported
that the meta-analysis supported a significant decrease in the risk of any air leak,
pneumothorax or pulmonary interstitial emphysema. There was a substantial de-
crease in the risk of neonatal mortality, bronchopulmonary dysplasia (BPD) or
death at 28 days of age. No di erences were reported in the risk of patent ductus
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arteriosus (PDA), necrotising enterocolitis (NEC), intraventricular haemorrhage
(IVH), bronchopulmonary dysplasia (BPD) or retinopathy of prematurity (ROP).
Less invasive surfactant administration (LISA) versus intubation for sur-
factant delivery
In a meta-analysis of six studies, Aldana-Aguirre et al. (Aldana-Aguirre et al.
(2017)) reported that LISA technique for surfactant delivery resulted in a lesser
need for mechanical ventilation in infants with RDS, reduction in the composite
outcome of death or BPD at 36 weeks amongst survivors.
2.1.5.3 Provision of assisted non-invasive ventilation
In a meta-analysis by Rojas-Reyes et al. (Rojas-Reyes et al. (2012)), the authors
analysed two studies with a routine application of CPAP, which demonstrated a
decrease in the risk of air leak and neonatal mortality associated with prophylactic
administration of surfactant. However, the analyses of studies that allowed for
routine stabilisation on CPAP demonstrated a decrease in the risk of chronic lung
disease or death in infants stabilised on CPAP. When all the studies were evaluated
together, the benefits of prophylactic surfactant could no longer be demonstrated.
The authors concluded that recent large trials reflecting current practice (includ-
ing higher utilisation of maternal steroids and routine post-delivery stabilisation
on CPAP) did not exhibit any di erences in a ecting the risk of chronic lung dis-
ease or death when using initial stabilisation on CPAP with selective surfactant
administration to infants requiring intubation.
2.1.6 Management of respiratory distress syndrome
Surfactant deficiency leads to increased surface tension in the air-liquid interface at
the terminal respiratory units resulting in impaired lung expansion. As the disease
advances, progressive atelectasis results in both ventilation-perfusion mismatching
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and increased intra and extra pulmonary shunting that may lead to respiratory
failure.
Intubation and mechanical ventilation have been used to correct atelectasis and
provide breathing support till the spontaneous production of surfactant.
This involves the use of supplemental oxygen and maintaining mean airway pres-
sures. These while helpful in improving hypoxaemia, also contribute to the de-
velopment of bronchopulmonary dysplasia. In particular, the pulmonary injury
is caused by volutrauma and barotrauma (associated with intermittent positive
pressure ventilation) and oxygen toxicity (due to high concentrations of supple-
mental oxygen). In addition, other complications associated with intubation and
mechanical ventilation include pulmonary air leak and injury due to intubation.
2.1.6.1 Non invasive / Less invasive Ventilation
This involves avoiding using mechanical ventilation either by using CPAP with or
without surfactant. Fischer et al. (Fischer and Buhrer (2013)) carried out a meta-
analysis of studies comparing the use of mechanical ventilation versus strategies
to avoid ventilation and concluded that strategies aimed at avoiding mechanical
ventilation in infants <30 weeks’ gestation age had a small but significant beneficial
impact on preventing bronchopulmonary dysplasia (BPD).
Because of the increased risk of bronchopulmonary dysplasia (BPD) with inter-
mittent positive pressure ventilation, other less invasive modes of ventilation have
been evaluated to reduce atelectasis and pulmonary injury in preterm infants at
risk of or with established RDS. These include:
• Nasal continuous positive airway pressure (nCPAP)
• Nasal intermittent positive pressure ventilation (NIPPV)
• High flow nasal cannulae
18
2.1.6.1. Non invasive / Less invasive Ventilation
Nasal continuous positive airway pressure (nCPAP)
In premature infants at risk of or with established RDS without respiratory failure,
nasal continuous positive airway pressure (nCPAP) is an alternative to endotracheal
intubation and mechanical ventilation for prevention of atelectasis (Rojas-Reyes
et al. (2012)).
As mentioned earlier, Fischer et al.’s meta-analysis demonstrated that use of CPAP
led to less incidence of death or BPD. Vaucher et al. (Vaucher et al. (2012)) carried
out a follow-up study of one of the included trials in the review (SUPPORT study)
and reported that there were no significant di erences in the composite outcome
of death or neurodevelopmental impairment among extremely premature infants
randomly assigned to early CPAP or early surfactant administration.
Nasal intermittent positive pressure ventilation
Nasal intermittent positive pressure ventilation (NIPPV) augments nCPAP by de-
livering ventilator breaths via nasal prongs (or nasal mask). Although NIPPV
avoids the trauma of endotracheal placement tube, it still is a delivery mode of pos-
itive pressure ventilation. However, clinical trials have failed to show that NIPPV
is superior to nCPAP as an initial treatment for non-invasive respiratory support.
Meneses et al. (Meneses et al. (2012)) carried out a meta-analysis in 2012 where
the authors compared NIPPV with nCPAP and reported that among preterm
infants with respiratory distress syndrome, NIPPV decreased the need for invasive
ventilation within the first 72 hours of life compared with NCPAP.
The meta-analysis was followed by a multi-centre clinical trial, NIPPV study, led
by Kirpalani et al. (Kirpalani et al. (2013)), whereby researchers set out to compare
NIPPV versus nasal CPAP in preterm infants. They reported that in extremely
low birth weight infants, the rate of survival to 36 weeks of postmenstrual age
without bronchopulmonary dysplasia did not di er significantly after non-invasive
respiratory support with nasal IPPV as compared with nasal CPAP.
Humidified High flow nasal cannula (HHFNC) therapy
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Humidified high flow nasal cannula (HHFNC) therapy is increasingly being used to
provide positive distending pressure with or without oxygen instead of traditional
nCPAP devices. However, clinical trials have not shown HHFNC to be superior to
nCPAP and pressure delivery is highly variable.
In a multicentre, randomised, unblinded study of 432 infants (Yoder et al. (2013))
with gestational age between 28 and 42 weeks (mean gestational age 33 weeks)
and birth weight Ø 1000g, there was no di erence in failure rate between patients
randomly assigned HHFNC versus those who received nCPAP. There were also
no di erences in the subsequent intubation rates or the risk of adverse outcomes
including air leak, bronchopulmonary dysplasia (BPD) and need for oxygen on
discharge. However, the median duration of intervention was longer for infants
assigned to HHFNC (four versus two days). This study included infants who met
criteria for non-invasive respiratory support for either early primary therapy for
neonatal respiratory distress or following extubation.
In a multicentre Australian trial (Manley et al. (2013)), Manley et al. compared
HHFNC to nCPAP for providing non-invasive support post-extubation. The au-
thors recruited 303 preterm infants (gestational age of less than 32 weeks). They
reported that the use of HHFNC was non inferior to the use of CPAP for the
primary outcome of treatment failure within seven days after extubation.
Roberts et al. (Roberts et al. (2016)) compared HHFNC with CPAP in their
multicentre trial to provide primary support after birth. Researchers recruited 564
preterm infants (gestational age Ø 28 weeks 0 days) with early respiratory distress
who had not received surfactant replacement. These were then treated with either
nasal high-flow therapy (HHFNC) or nasal CPAP. Authors concluded that when
used as primary support for preterm infants with respiratory distress, HHFNC
resulted in a significantly higher rate of treatment failure than CPAP.
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2.1.6.2 Mechanical ventilation
Along with other technological advancements, such as the administration of ante-
partum corticosteroids and replacement surfactant therapy, mechanical ventilation
has led to improved neonatal survival, especially for premature infants born of less
than 30 weeks’ gestation with immature lung function. Approximately two-thirds
of all infants admitted to the NICU have been reported to receive positive pressure
ventilation (McCallion et al. (2005)).
Benefits of mechanical ventilation
The principal benefits of neonatal mechanical ventilation during respiratory failure
are as follows:
• Improved gas exchange, primarily by lung recruitment to improve ventila-
tion/perfusion (V/Q) matching.
• Decreased work of breathing.
• Provision of adequate minute ventilation (i.e. carbon dioxide removal) in
infants with respiratory depression or apnoea.
Complications of mechanical ventilation
• Barotrauma
• Volutrauma
• Atelectotrauma
• Biotrauma
• Rheotrauma
These are covered in much more detail in a dedicated section (section number 2.3).
Types of ventilation
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Ventilators used in the NICU can be divided into two broad categories based on
how minute ventilation is provided.
1. Conventional mechanical ventilation (CMV) involves an intermittent exchange
of bulk volumes of gas, which are similar in volume to physiologic tidal volume
within the airway tree. Delivery of conventional ventilation varies by how the
breath is initiated (ventilator or patient triggered), how the delivered tidal
volume is regulated (e.g. pressure or volume control), how the breath is
terminated (e.g. volume, time, or flow regulated) and the rate of ventilation.
2. High frequency ventilation (HFV) is based upon the delivery of small volumes
of respiratory gas, which are equal to or smaller than the anatomic dead space,
at an extremely rapid rate (300 to 1,500 breaths per minute).
Conventional mechanical ventilation is further sub-divided into two broad categor-
ies: pressure limited and volume limited (Lozano and Newnam (2016)).
Pressure limited ventilation
The continuous flow of circuit gas allows for spontaneous patient breathing, and
weaning can occur by progressively reducing PIP and mandatory ventilator rate.
PIP and mean airway pressure (MAP) can be adjusted to optimise gas exchange
and attempt to minimise the contribution of these factors to chronic lung injury.
The advantage of the pressure limited ventilator is that it is relatively easy to
use and less expensive. The main disadvantage of this modality is that there is a
variation of tidal volume from breath to breath. Delivered tidal volume varies with
alterations in lung compliance and resistance, circuit compressed gas volume and
endotracheal (ET) tube leak.
In a study of preterm infants, exhaled tidal volume was greater than the tar-
geted volume for 25% of the breaths and less than the targeted volume for 36%
of breaths (Keszler and Abubakar (2004)). These large variations in delivered
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volume over time subjected the immature lungs of preterm infants to risks of
both over distension and collapse of air spaces resulting in lung injury (volut-
rauma/atelectotrauma).
Volume targeted ventilation
The development of volume-targeted neonatal ventilation was prompted by evid-
ence that volume distension of the lung rather than peak airway pressure, induced
lung injury (Dreyfuss et al. (1988), Hernandez et al. (1989), Dreyfuss and Saumon
(1998)).
As discussed above, pressure limited ventilation poorly controls the delivered tidal
volume, resulting in a wide range of breath to breath tidal volumes leading to
episodes of over distension and atelectasis.
Pressure versus volume ventilation?
Traditionally pressure limited ventilation has been the most frequent mode of vent-
ilation in neonatal units.
The major disadvantage of pressure limited ventilation lies in the variable tidal
volume that results from changes in lung compliance. Such changes may occur
quite rapidly, especially in the immediate postnatal period, as a result of clearing
of lung fluid, optimisation of lung volume and administration of newer, more rap-
idly acting exogenous surfactant preparations (Keszler (2006)). The consequences
of such rapid improvements in compliance are inadvertent hyperventilation and
lung damage from excessively large tidal volumes as identified by Bjorklund et al.
(Bjorklund et al. (1997)) in their animal model study on lambs. One lamb in each
pair was randomly selected to receive six high volume manual inflations of 35-40
mL/kg (“bagging”) before the start of mechanical ventilation, a volume roughly
corresponding to the inspiratory capacity. Subsequently authors noted that lambs
subjected to high volume bagging failed to show the improvement in compliance
otherwise observed in control lambs. These lambs were also more di cult to ventil-
ate and tended to have less well expanded alveoli and more widespread lung injury
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in histologic sections. The authors concluded that a few large volume inflations
in surfactant-deficient lungs immediately at birth compromised the e ect of sub-
sequent surfactant rescue treatment.
With recent evidence coming from trials comparing the two, more and more units
are preferring to switch to volume targeted ventilation. In a 2011 international
survey, volume-targeted ventilation had replaced pressure-limited ventilation in 25
of the 50 neonatal tertiary units surveyed (Klingenberg et al. (2011)).
Several studies have shown that as compared with pressure limited ventilation,
volume targeted ventilation was associated with the following additional benefits:
• It maintained tidal volume closer to the targeted goal and reduced the incid-
ence of hypocapnoea (an indicator of overventilation) (Keszler and Abubakar
(2004)).
• It provided an e ective gas exchange while reducing the number of high
volume mechanical breaths (Herrera et al. (2002)).
• It decreased peak inspiratory pressure (PIP) of triggered ventilations while
maintaining the targeted tidal volume (McCallion et al. (2008)).
• It has been shown to improve outcome with the reduction in the death or
BPD at 36 weeks’ gestation (Klingenberg et al. (2017)).
• It was associated with reduced rates of pneumothorax (Klingenberg et al.
(2017)), reduced days of mechanical ventilation (Klingenberg et al. (2017))
and reduced rates of hypocarbia (Klingenberg et al. (2017)).
• It was also associated with reduced rates of grade 3 or 4 intraventricular
haemorrhage and the combined outcome of periventricular leucomalacia with
or without grade 3 or 4 intraventricular haemorrhage (Klingenberg et al.
(2017)).
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• VTV modes were not associated with any increased adverse outcomes (Klin-
genberg et al. (2017)).
While these results suggest that volume targeted ventilation improves short term
outcome with a reduction in the rate of complications associated with mechan-
ical ventilation, some commentators have voiced the following concerns to suggest
further study of this technique in the neonatal intensive care setting is required:
• Randomised studies have been criticised for not being blinded. This has
led to quality of evidence considered as moderate to low (Klingenberg et al.
(2017)).
• No individual trial demonstrated a reduction in mortality, death or BPD,
grade III or IV IVH, or PVL. Only the pooled data from the meta-analysis
reached statistical significance (Davis and Morley (2006)).
• Studies were conducted by investigators with expertise in the use of volume
targeted ventilation. In general, it was found that these ventilators are more
di cult to operate than the simple TCPL (Time Cycled Pressure Limited)
ventilators which have been the standard mode of ventilation for many years.
As a result, it is unclear whether these results would be replicated in a wider
application of this modality by less experienced clinicians. Care providers
would need to be fully trained to optimally use volume targeted ventilators
in neonates (Davis and Morley 2006).
• Several di erent ventilatory modalities (VG, PRVC, and VC) and modes
(patient-triggered and mandatory ventilation) were used in these studies. At
present it is not possible to determine which ventilator or mode of ventilation
accounted for the reported di erences in outcome (Grover and Field (2008)).
• There were variations in the delivery of tidal volume, inflation time and peak
pressures amongst the volume targeted ventilators used in the studies them-
selves (Sharma et al. (2007)).
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• Air leak around non-cu ed endotracheal tubes makes monitoring of expired
tidal volume problematic. As a result, if volume triggered ventilation is used,
it remains uncertain what the optimal tidal volume is (Lista et al. (2006)).
2.2 Volume Guarantee (VG)
Acknowledgement of superiority of volume targeting and development of micro-
processor technology has led to the development of "hybrid modes" which help to
deliver precise tidal volume by adopting the most optimum pressure needed for
the baby by using a feedback system. This section is devoted to discussion of the
various hybrid modes. As we identified volume guarantee (VG) to deliver the tidal
volume in our study, we will also review the evidence in support of the use of
volume guarantee.
2.2.1 Newer Hybrid Modes
Improvements in technology and increasing acceptance of volume targeting in con-
ventional ventilation has led to the development of "hybrid" modes of ventilation
where, with the help of microprocessor technology, the prefixed tidal volume is
achieved by using di erent algorithms. At present three di erent modalities are in
use (Keszler et al. (2009)).
2.2.1.1 Pressure regulated volume control (PRVC)
Pressure-regulated volume control (PRVC) is a pressure-limited, time-cycled mode
that when initially activated, adjusts inspiratory pressure to target a set Vt, based
on the pressure required to achieve the target Vt of four test breaths. Subsequent
adjustments are based on the Vt of the previous breath. Breath to breath increment
is limited to 3 cm H2O or up to 5 cm H2O below the set upper pressure limit.
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2.2.1.2 Volume-assured pressure support (VAPS)
The volume-assured pressure support (VAPS) mode is a hybrid mode designed to
ensure that targeted Vt is reached. Each breath starts as a pressure-limited breath,
but if the set Vt is not reached, the device converts to the flow-cycled mode by
prolonging the Ti with a passive increase in peak pressure. Hence the algorithm in
VAPS is based on achieving the set inspiratory tidal volume.
The regulation of delivered volume based on inspiratory Vt has both advantages
and disadvantages. It allows the device to respond within the given breath, but it
is more susceptible to leakage around the endotracheal tube which is larger during
inspiration.
2.2.1.3 Volume Guarantee (VG)
Like PRVC, the VG mode is a volume-targeted, time-cycled, pressure limited form
of ventilation. The operator chooses a target Vt (expiratory) with a pressure limit.
The microprocessor compares the Vt of the previous breath, using exhaled Vt to
minimise possible artefact due to an air leak and adjusts the working pressure
up or down to achieve the set Vt. The algorithm limits the amount of pressure
increase from one breath to the next to avoid over correction leading to excessive
Vt. This, and the fact that the exhaled Vt of the prior breath is used means that
with very rapid changes in compliance or patient inspiratory e ort, several breaths
are needed to reach target Vt.
To overcome the potential disadvantage of using the exhaled Vt of the previous
breath and to minimise the risk of excessively large Vt, the microprocessor opens
the expiratory valve, terminating any additional pressure delivery if inspiratory Vt
exceeds 130% of the target, a volume-limit function. It has a slower adjustment for
low Vt and more rapid adjustment for excessive, potentially dangerous Vt. There
is a separate algorithm for spontaneous (assisted) and untriggered machine breaths
to ensure that the target Vt is more stable when the infant’s respiratory drive is
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inconsistent. The auto-regulation of inspiratory pressure makes VG a self-weaning
mode. Because weaning occurs in real time, rather than intermittently in response
to blood gases, VG has been considered to have the potential to achieve faster
weaning from mechanical ventilation.
Volume guarantee can be combined with any of the standard ventilator modes,
such as assist control, synchronised intermittent mandatory ventilation or pressure
support ventilation. The clinician chooses a target tidal volume and a maximum
peak inspiratory pressure limit to avoid excessive pressures.
2.2.2 Evidence in favour of volume guarantee
Whilst supremacy of volume targeting was being established, volume guarantee
along with other hybrid modes provided the means to use feedback mechanisms to
obtain precise expiratory tidal volume.
2.2.2.1 SIMV+VG versus SIMV
In a first-ever attempt to use VG in very low birth weight infants, Harrera et al.
(Herrera et al. (1999)) carried out a randomised crossover study comparing VG
with SIMV for its short-term safety and e cacy in very low birth weight infants
recovering from respiratory failure. In their study, the authors reported that spon-
taneous minute ventilation (VE spt) was higher during VG. They concluded that
VG allowed VLBW infants to increase their inspiratory e ort during the weaning
phase.
Dawson et al. (Dawson and Davies (2005)) reported that infants ventilated with
VG ventilation had more acceptable pCO2 levels at the first blood gas measurement
and during the first 48h of life.
Polimeni et al. (Polimeni et al. (2006)) reported that VG combined with SIMV
could reduce the duration of the hypoxaemic episodes.
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Guven et al. (Guven et al. (2013)) reported that when used as the primary mode,
infants ventilated with VG mode had a significantly shorter duration of ventilation
and needed less amount of total supplemental oxygen. The incidences of oxygen
related short-term complications including BPD, ROP and IVH were also signific-
antly lower in these infants. The authors concluded that their data favoured the
use of VG ventilation in respiratory support of premature infants.
Erdemir et al. (Erdemir et al. (2014)) compared VG against SIMV for weaning
in preterm infants and reported that the VG group had reduced frequency of post
extubation atelectasis.
In a crossover study by Harrera et al. (Herrera et al. (2002)), the authors com-
pared VG combined with SIMV with conventional SIMV in stable extreme preterm
infants with birth weight from 600-1,200g. They reported that in comparison to
conventional SIMV, short-term use of SIMV+VG resulted in the automatic wean-
ing of the mechanical support and enhancement of the spontaneous respiratory
e ort.
Cheema et al. (Cheema and Ahluwalia (2001)) carried out a crossover randomised
cross trial comparing the feasibility and e cacy of the use of VG for utility in the
recovery phase of RDS. They reported that VG could achieve equivalent gas ex-
change using statistically significant lower peak airway pressures and mean airway
pressures while using SIMV during the recovery phase of RDS.
In a crossover trial by Scopesi et al. (Scopesi et al. (2007)), researchers set out
to compare patient-ventilator interactions and Vt variability in premature infants
recovering from respiratory distress syndrome (RDS) who were weaned by various
ventilator modes. Each mode combined with VG discharged comparable Vts, which
were very close to the target volume.
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2.2.2.2 VG+SIPPV versus SIPPV
Cheema et al. (Cheema and Ahluwalia (2001)) also assessed the utility of VG for
the early phase of RDS and reported that VG could achieve equivalent gas ex-
change using statistically significant lower peak airway pressures and mean airway
pressures.
Subsequently moving on from crossover studies, Keszler et al. (Keszler and Abubakar
(2004)) carried out an RCT and found that VG significantly reduced hypocarbia
and excessively large Vt.
Cheema et al. (Cheema et al. (2007)) also used volume guarantee in their ran-
domised controlled trials and found that VG groups had fewer out-of-range pCO2
values and fewer instances of hypocarbia.
In their crossover trial, Scopesi et al. (Scopesi et al. (2007)), researchers reported
that each mode combined with VG discharged comparable Vts which was very close
to the target volume. They also found that when SIPPV+VG was compared with
SIMV+VG, SIPPV+VG showed the greater stability of Vt, fewer large breaths,
lower respiratory rate and allowed for lower peak inspiratory pressure. They con-
cluded that with regards to the weaning phase, among combined modes, those in
which every breath is supported (SIPPV/PSV) are likely to be the most e ective in
the delivery of stable Vt using a low working pressure. Therefore, authors believed
that at least in the short term, SIPPV+VG was likely to be gentler for the neonatal
lung.
2.2.2.3 PSV+ VG versus PSV
In 2004, Lista et al. (Lista et al. (2004)) carried out an RCT on preterm infants
born at less than 32 weeks’ gestation by evaluating lung inflammatory response in
these preterm infants with respiratory distress syndrome. The authors concluded
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that volume targeted ventilatory strategy reduced acute inflammatory response in
preterm infants with RDS.
2.2.2.4 PSV+VG versus SIMV
Nafday et al. (Nafday et al. (2005)) in their pilot RCT compared PSV+VG to
SIMV for the first 24 hours of life. The overall outcomes were not significantly
di erent between the two groups. The authors concluded that PSV-VG did not
o er any ventilatory advantage over SIMV in the initial management of surfactant-
treated premature newborns with RDS except for minimising the number of times
blood gases need to be monitored.
Abd El-Moneim et al. (Abd El-Moneim et al. (2005)) also explored the utility of
VG combined with PSV against conventional SIMV in their crossover pilot study of
preterm infants in the weaning phase. The authors reported that infants ventilated
with PSV-VG required significantly lower ventilation pressures and achieved better
infant-ventilator synchrony.
In summary, there has been extensive research to compare VG to conventional
modes of ventilation thus has demonstrated that it is a safer mode of ventilation
with benefits of better maintaining tidal volume, minute volume and carbon dioxide
levels while using lower PIP to achieve the objectives of ventilation.
2.3 Ventilator induced lung injury
Mechanical ventilation is a life-saving therapy that has become the mainstay of
management for patients with acute respiratory failure. Since its widespread use
was initiated in the mid-1950s for the treatment of paralytic poliomyelitis, the un-
derstanding of the impact of mechanical ventilation on gas exchange, pulmonary
mechanics and heart-lung interactions concerning mechanical ventilation has in-
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creased tremendously. Also, the complications of mechanical ventilation have also
become more apparent (Tremblay and Slutsky (2006)).
2.3.1 Definition
Most universally accepted definitions of lung injury due to mechanical ventilation
are from international consensus conferences in intensive care medicine. According
to these, an acute lung injury that develops during mechanical ventilation is termed
ventilator induced lung injury (VILI) if it can be proven that the mechanical vent-
ilation caused the acute lung injury and ventilator-associated lung injury (VALI)
if a causative relationship cannot be proven. Many experts consider VALI as the
more appropriate term in most clinical situations because it is virtually impossible
to prove causation outside of the research laboratory.
2.3.2 Pathology
Ventilator Associated Lung Injury (VALI) is a strain due to excess pressure or
volume in the alveoli. The pathological features associated are: high permeab-
ility interstitial alveolar oedema, altered surface tension, alveolar haemorrhage,
hyaline membranes, loss of functional surfactant and alveolar collapse (Rouby and
Brochard (2007)).
Greenfield et al. (Greenfield et al. (1964)) ventilated closed-chest dogs for 2 hours
at 26–32 cm H2O peak inspiratory pressure. The animals underwent thoracotomy
after 24 hours. On gross examination, there were zones of atelectasis. Extracts of
these lungs had increased surface tension, suggesting altered surfactant properties.
In this experiment, the researchers demonstrated one of the mechanisms behind
VALI.
Webb et al. (Webb and Tierney (1974)) conducted their study in intact animals
which unambiguously demonstrated that mechanical ventilation may produce pul-
monary oedema and that the role of positive pressure ventilation (barotrauma) was
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a mechanism for ventilation induced lung injury. They subjected rats to positive
airway pressure ventilation with peak pressures of 14, 30, and 45 cm H2O. No ab-
normality was observed after 1 hour of ventilation with 14 cm H2O peak pressure.
Animals ventilated with higher peak pressures showed not only pulmonary oedema
but also, extent of this oedema was directly proportional to the peak pressure which
confirmed the role of positive pressure as a means for causing ventilation induced
lung injury by barotrauma.
2.3.3 Pathogenesis
The main initiators of ventilator induced lung injuries are - alveolar over distension
and cyclic atelectasis
2.3.3.1 Alveolar over distension
Rouby et al. (Rouby et al. (1993)) examined post-mortem histological specimens
obtained from young, critically ill patients and found that 86% of them had evidence
of airspace enlargement. They also reported that the patients with severe airspace
enlargement (2.6-40 mm internal diameter) had a significantly higher incidence of
pneumothorax, had been ventilated using higher peak airway pressures and tidal
volumes and had been exposed significantly longer to toxic levels of oxygen than
patients with mild airspace enlargement (1-2.5 mm internal diameter).
Over distension of the alveoli has been blamed on excess pressure (barotrauma),
and excess volume (volutrauma) applied during mechanical ventilation. The studies
on ventilator induced lung injury while conclusively establishing over distension as
one of the most important modes of injury also led to the question: which of the
two, volutrauma or barotrauma is more harmful?
Volutrauma versus Barotrauma
A study by Dreyfuss et al. (Dreyfuss et al. (1988)) compared the consequences
of normal and high tidal volume ventilation in mechanically ventilated rats at a
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normal and high airway pressure. They created three models: low pressure-low
tidal volume; high pressure-high tidal volume and high pressure-low tidal volume.
The high pressure-low tidal volume model was obtained by strapping the chest to
avoid over expansion of the alveoli while rats were ventilated with high pressures.
The researchers reported that lungs of rats ventilated with high pressure and low
tidal volume (strapped chest) were same as controls (rats ventilated with low
pressure-low tidal volume). They also reported that the lungs from the rats vent-
ilated with high volume ventilation (due to unstrapped high pressure ventilation)
had significant permeability type oedema. This study highlighted the importance
of volume as the decisive factor in causing lung injury.
In a similar landmark study, Harnandez et al. (Hernandez et al. (1989)) compared
lung injury in mechanically ventilated immature rabbits by subjecting them to high
pressure plus high tidal volumes and high pressure plus low tidal volumes.
White rabbits were assigned to one of three protocols with di erent degrees of
inspiratory volume limitation: intact closed chest animals (CC) and closed chest
animals with a full body plaster cast (C). The intact animals were ventilated at
15, 30, or 45 cm H2O PIP for 1 hour, and the lungs of the CC and C groups were
placed in an isolated lung perfusion system. The markers were compared against
baseline permeability. It was the same as the baseline in the CC group ventilated
with 15 cm H2O PIP. In the CC group permeability increased by 31% after 30
cm H2O PIP and 43% after 45 cm H2O PIP. Inspiratory volume limitation by the
plaster cast in the C group prevented any significant increase in permeability at
the PIP values used. The authors concluded that volume distension of the lung
rather than high PIP per se produced microvascular damage.
Dreyfuss et al. (Dreyfuss et al. (1995)) compared the e ect of low and high tidal
volume and the relation of the severity of the tidal volume to the magnitude of
the tidal volume on previously damaged lungs in rats. The authors ventilated
these rats by using 7 ml/kg body weight tidal volume mechanical ventilation for
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2 minutes with that of 25 (HV25), 33 (HV33), and 45 (HV45) ml/kg body weight
high tidal volume in anesthetised rats previously exposed or not exposed to alpha-
naphthylthiourea (ANTU). High tidal volume alone resulted in permeability oed-
ema in which severity was proportional to the magnitude of the tidal volume.
These studies demonstrated that it is the high tidal volumes that cause lung injury
and not the airway pressure.
2.3.3.2 Alveolar collapse/Atelectotrauma
Subsequently, researchers also demonstrated that ventilation induced lung injury
can still occur at low pressures highlighting other modes of injury other than high
peak positive pressure. It is proposed that cyclic alveolar expansion (during inspir-
ation) and collapse (during expiration) creates shear forces that distend adjacent
alveoli and cause injury in animal models.
2.3.3.3 Rheotrauma
Rheotrauma is a term used for lung injury due to high gas flows delivered by
mechanical ventilation.
Rich et al. (Rich et al. (2000)) studied the influence of flow rates in causing
ventilator induced lung injury.
They performed their experiment on sheep whereby they ventilated sheep with
varying pressure support, respiratory rate and flow rate. They reported that lim-
iting the inspiratory flow rate (LIFR) reduced histologic injury, decreased intra-
alveolar neutrophils and reduced wet-dry lung weight. The authors concluded that
the experiment showed that the reduction of inspiratory flow provides pulmonary
protection.
Bach et al. (Bach et al. (2009)) studied this relatively neglected aspect of role of flow
rates in term lambs. Researchers found that there was no di erence in ventilatory
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parameters until very low flow rates were used. The study, though analysing the
therapeutic impact of flow rates, did not assess the lung injury aspect of flow rates.
This study was followed by a study of lung injury by the same researchers. Bach
et al. (Bach et al. (2012)) ventilated preterm lambs with bias gas flow of 8 L/min,
18 L/min or 28 L/min. Control lung tissue was collected from unventilated age-
matched foetuses. The authors reported that pulmonary mRNA levels of the injury
markers, EGR1 and CTGF, were highest in lambs ventilated with bias gas flows
of 18 L/min. High bias gas flows also resulted in increased cellular proliferation
and abnormal deposition of elastin, collagen, and myofibroblasts in the lung. They
concluded that flow rate contributed to ventilator induced lung injury and bron-
chopulmonay dysplasia.
2.3.3.4 Biotrauma
Mechanical stretch can cause a release of mediators associated with activation of the
immune response, further adding to injury and potentially causing remote injury
to other organs; this is termed as “biotrauma”.
While alveolar over-distension, lung strain and atelectasis are key inciting features
of VILI, numerous studies over the past 20 years have demonstrated the possibility
of a subtler form of injury, with the release of various mediators into the lung, pul-
monary recruitment of leukocytes, and local initiation of inflammatory processes.
The biotrauma hypothesis postulates that the circulating mediators have the po-
tential to cause local lung injury as well as systemic upset (Slutsky and Tremblay
(1998)).
In 1985 Kawano et al. (Kawano et al. (1987)) noted that previous studies had
shown a large number of granulocytes in the damaged lung. They set out to
demonstrate that these cells contributed to lung injury by comparing two lung
models in rabbits; one with normal granulocytes, the other depleted of granulo-
cytes by pre-treatment with nitrogen mustard. The non-depleted rabbits had a
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poor gas exchange, a substantial protein leak into the lung and extensive hyaline
membranes. The depleted animals had a good gas exchange, a tiny protein leak,
and no hyaline membranes. Repletion of granulocytes from donor rabbits led to
poor gas exchange and hyaline membrane formation. The authors concluded that
lung lavage causes prompt margination of granulocytes, which become activated
by the on-going epithelial barotrauma of conventional ventilation.
Tremblay et al. (Tremblay et al. (1997)) studied rats by randomising them to
receive ventilation with moderate Vt with or without PEEP and ventilation with
high Vt without PEEP.
Authors reported maximum levels of cytokines in rats ventilated with Zero PEEP
in combination with high volume ventilation (HVZP group). There was a gradual
reduction in cytokines levels from HVZP (High Volume Zero PEEP group), MVZP
(Moderate Volume Zero PEEP group), MVHP (Moderate Volume High PEEP
group) and control (low volume normal PEEP) reinforcing role of cytokines asso-
ciated with ventilation associated lung injury.
These data suggest that mechanical ventilation plays a role in initiating or propagat-
ing a local and possibly systemic inflammatory response.
Study of cytokines in humans was performed by Ranieri et al. (Ranieri et al. (1999))
in which researchers studied the impact of traditional ventilation or lung protective
ventilation using inflammatory markers in plasma and alveolar fluid. The authors
used lower levels of cytokines to validate the utility of lung protective ventilation.
2.3.4 Prevention of Ventilator induced lung injury
The evidence so far has shown that the following strategies help in preventing the
lung injury.
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2.3.4.1 High PEEP
Mechanical ventilation using PEEP at inflection point helps in preventing the col-
lapse of lungs even during expiration which not only reduces the work of breathing
but also has been shown to reduce ventilation induced lung injury.
Argiras et al. (Argiras et al. (1987)) demonstrated this on surfactant deficient
rabbits in whom lung lavage was performed to produce surfactant-deficient lungs.
The authors reported that the animals in the high PEEP group had a significantly
greater arterial pO2 than those in the low PEEP group and less incidence of hyaline
membranes. However, the mean survival time for each group was similar.
Sandhar et al. (Sandhar et al. (1988)) replicated the findings by comparing low
PEEP (1-2cm) versus high PEEP (PEEP at inflection point) keeping mean airway
pressure the same in surfactant deficient rabbits. The authors demonstrated that
animals with high PEEP showed significantly less hyaline membrane as a marker
of lower ventilator induced lung injury.
Muscedere et al. (Muscedere et al. (1994)) assessed the impact of low PEEP (PEEP
below inflection pressure, Pinf) in their study on isolated, non-perfused, lavaged
rat lungs. Researchers ventilated these lungs with physiologic tidal volumes (5 to 6
ml/kg) at di erent end-expiratory pressures and studied the e ect on compliance
and lung injury. Lung injury assessed morphologically was significantly higher in
the groups ventilated with a low PEEP, and in these groups, the site of injury
was dependent on the level of PEEP. The group ventilated without PEEP had
significantly greater respiratory and membranous injury to bronchioles, while the
group ventilated with PEEP of 4 cm H2O had significantly greater alveolar duct
injury. It was concluded that in addition to high airway pressures, end-expiratory
lung volume is an essential determinant of the degree and site of lung injury during
positive-pressure ventilation. The authors speculated that ventilation at very low
lung volumes worsens lung injury by repeated opening and closing of the airway
and alveolar duct units as ventilation occurs from below to above the inflection
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point. This study helped to establish the vital role of PEEP in ventilation to avoid
atelectotrauma.
2.3.4.2 High Frequency Ventilation
Sugiura M et al. (Sugiura et al. (1994)) , in their experiments on New Zealand
rabbits, used high frequency ventilation with high oxygen as atelectasis minimising
measure in surfactant depleted animals. The surfactant replete animals on con-
ventional ventilation acted as controls. The researchers noted that the surfactant
depleted animals on conventional ventilation showed a higher degree of neutrophil
activation than the ones with measures to minimise atelectasis. The authors con-
cluded that lung injury could be minimised by preventing cyclic alveolar/airway
expansion and collapse in the surfactant-deficient lung by use of appropriate vent-
ilator patterns. The study also demonstrated that ventilator patterns selected
during such early phases had a powerful impact on the extent of the inflammatory
response.
2.3.4.3 Low tidal volume
In adult patients with ARDS, a multicentre randomised trial (Brower et al. (1999))
found that mechanical ventilation using tidal volumes of 6 mL/kg of ideal body
weight improved mortality. The trial was stopped midway because in the group
treated with lower tidal volumes had significantly lower mortality and more num-
ber of days without ventilator use. The authors concluded that using mechanical
ventilation with a lower tidal volume than is traditionally used in patients with the
acute lung injury and acute respiratory distress syndrome, resulted in decreased
mortality and duration on ventilator. This multicentre trial established the utility
of low tidal volumes in adults with ARDS as lung protective measure.
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2.3.4.4 Lung protection strategies
Use of low tidal volume coupled with moderate PEEP (or PEEP above the low in-
flection point on the pressure-volume curve) has been proposed as a "lung protective
strategy." It is also called “open lung ventilation”. In patients with ALI/ARDS,
randomised trials demonstrated that open lung ventilation improved clinical out-
comes. One randomised trial (IMPROVE) (Futier et al. (2013)) of patients at high
risk of pulmonary complications following major abdominal surgery compared an
intraoperative non-protective ventilation strategy ( Vt 10 to 12 mL/kg of PBW
(patient’s body weight); no PEEP; no recruitment) with a lung protective strategy
(Vt 6 to 8 mL/kg of PBW; PEEP at 6 to 8 cm of water; recruitment manoeuvres
every 30 minutes). At seven days, lung protective ventilation was associated with
a reduction in adverse pulmonary and extra pulmonary events, need for mechan-
ical ventilation and a shorter length of stay in the hospital. However, the lung
protective strategy did not protect against the development of ARDS nor was it
associated with a benefit in mortality rates.
2.3.4.5 Preventing cyclic atelectasis
In a study looking at the impact of spontaneous breathing versus muscular paralysis
in an animal model, Yoshida et al. (Yoshida et al. (2013)) reported that in animals
with mild lung injury spontaneous breathing was beneficial to lung recruitment;
however, in animals with severe lung injury, spontaneous breathing fared worse
than recruitment measures.
2.4 Inflammatory markers of lung injury
There is a realisation in the neonatalology community that dependence on tradi-
tional clinical and pathological methods to identify lung injuries associated with
mechanical ventilation is leading to delayed diagnosis with limited options to inter-
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vene. With the development of technology and a better understanding of biochem-
ical molecules, the focus has now shifted to cytokines to help identify the presence
and extent of lung injury at an early stage. Their role however, is still very early
and in an experimental phase. Once established, cytokines also would have ad-
ded benefit of a quicker measure to interventions designed to protect against lung
injury.
2.4.1 Cytokines
Cytokines are low-molecular-weight soluble proteins that transmit signals between
the cells involved in the inflammatory response. (Figure 2.2 (Strieter et al. (2002)).
Cytokines are released in response to external threat, PAMP (Pathogen associated
molecular patterns), internal tissue injury and damage, DAMP (Damage Associ-
ated molecular Patterns) and alarmins (a subset of DAMP released as a result
of unprogrammed cell death). TLR (Toll like receptors) and NLR (Nodd like re-
ceptors) are the receptor proteins programmes to release inflammatory cascade in
response to external (PAMP, extracellular DAMP and alarmins) and intracellular
danger signals (DAMP and alarmins) respectively. (Figure 2.3).
Cytokines are important mediators of immune responses which allow integration of
the behaviour of cells in time and geographical location as immune responses are
generated. These are hormone-like proteins that enable immune cells to communic-
ate, and they play an integral role in the initiation, perpetuation and subsequent
down-regulation of the immune response.
In the lungs, they are produced by bronchial, bronchiolar alveolar epithelial cells,
alveolar macrophages, and neutrophils (Pugin et al. (1998), Tremblay et al. (2002)).
Whilst ventilator induced lung injury is known to be associated with the presence
of polymophonuclear cells in alveoli, the mere presence of polymophonuclear cells
has not led to lung injury in experimental studies (Martin et al. (1989)). The
activation and attraction of leucocytes are carried out by IL-1, IL-8 and TNF-–.
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Figure 2.2: Basic components of the immune system and their respective functions
(Shah 2017)
Figure 2.3: Stimulus for release of cytokines causing inflammatory response (Shah
2017)
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The inflammatory e ect of the cytokines is also exacerbated by reducing apoptosis
of leucocytes in alveoli which is mediated by IL-2 and IL-8.
Surfactant dysfunction or deficiency is one of the prominent features of lung injury.
Inflammation and more specifically cytokines such as TNF≠– and IL-1 are thought
to decrease surfactant components either directly or indirectly by inducing alveolar
leakage of proteins that subsequently inhibit surfactant function (Kobayashi et al.
(1991), Rimensberger (2002)).
Cytokine release can take place due to the following mechanisms (Halbertsma et al.
(2005)):
• Mechanotransduction - alterations in the cytoskeletal structure without ul-
trastructural damage.
• Decompartmentalisation - stress failure of the alveolar barrier.
• Necrosis - stress failure of the plasma membrane.
• E ects on the vasculature independent of stretch or rupture.
Mechanotransduction
It is mediated by transmembrane receptors such as integrins, which are stretch-
activated ion channels and start various intracellular processes. Most alveolar cells
can produce pro- and anti-inflammatory mediators such as TNF-–, IL-1, IL-6, IL-
8, and IL-10 when stretched in vitro or when ventilated with a large tidal volume
(Vt) in ex-vivo and in-vivo experiments.
Translocation and decompartmentalisation
Direct trauma to the plasma membrane of alveolar cells and loss of cell integrity
also leads to the release of intracellular cytokines to the interstitium resulting into
decompartmentalisation to both the alveolar space and the systemic circulation.
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2.4.1.1 Cytokines in VILI
Whilst the role of the cytokines is still being studied, they o er one explanation for
the role of antenatal and postnatal steroids in preventing the incidence of chronic
lung disease. Three major cytokines have been studied in the field of lung injury –
Interleukin - 6 (IL-6) Interleukin - 8 (IL-8) Tumour Necrosis Factor - alpha (TNF–)
2.4.1.2 Interleukin 6 (IL-6)
Human IL-6 is made up of 212 amino acids, including a 28-amino-acid signal pep-
tide.
Process of the release of IL-6
IL-6 functions as a mediator to notify the occurrence of an emerging inflammatory
event. It is generated in an infectious lesion and has an impact in all parts of the
body. Monocytes and macrophages recognise the signature of exogenous pathogens,
known as pathogen associated molecular patterns (PAMPs). PAMPs are sensed
by evolutionarily conserved, host sensors known as pathogen recognition receptors
(PRRs) (Kumar et al. (2011)). These PRRs comprise toll like receptors, retinoic
acid inducible gene 1 like receptors, nucleotide binding oligomerisation domain
like receptors, and DNA receptors. They stimulate a range of signalling pathways
including NF-ŸB and enhance the transcription of the mRNA of inflammatory
cytokines such as interleukin 6, tumour necrosis factor – and IL-1—. TNF-– and
IL-1— also help in increasing the production of IL-6 by activating transcription
factors.
Functions
IL-6 performs a variety of functions. This can be identified by the fact that his-
torically few proteins were deemed to be responsible for these functions. However,
it later transpired that it is one protein in itself. IL-6 is involved in many steps
of the activated immune system, and its function helps to explain many of the
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physiological e ects of chronic inflammation. Because of the activity at so many
levels, dysregulated continual production of IL-6 leads to the onset or development
of various diseases (Figure 2.4).
• After its local synthesis in the initial stage of inflammation, IL-6 moves to the
liver and plays a vital role in the rapid induction of acute phase proteins such
as C-reactive protein (CRP), serum amyloid A, fibrinogen, haptoglobin and
–1-antichymotrypsin (Heinrich et al. (1990)). It also reduces the production
of fibronectin, albumin, and transferrin.
• IL-6 promotes megakaryocyte maturation leading to the release of plate-
lets (Ishibashi et al. (1989)). Of note, these haematological and biochem-
ical changes are used for the evaluation of inflammatory severity in routine
clinical laboratory examinations.
• IL-6 performs an important function in the linking of innate to acquired
immune response by promoting specific di erentiation of naive CD4+ T cells.
• IL-6 promotes T-follicular helper cell di erentiation as well as the production
of IL-21 (Ma et al. (2012)), which regulates immunoglobulin (Ig) synthesis
and IgG4 production in particular.
• IL-6 induces the di erentiation of CD8+ T cells into cytotoxic T cells (Okada
et al. (1988)).
• IL-6 induces the di erentiation of activated B cells into antibody-producing
plasma cells, so that continuous over synthesis of IL-6 results in hypergam-
maglobulinemia and autoantibody production.
• IL-6 is responsible for enhanced angiogenesis and increased vascular permeab-
ility by inducing production of Vascular Endothelial Growth Factor, leading
to some of the common pathological features of inflammatory lesions.
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Treg - regulatory T cell; RANKL - recepter activator of nuclear factor ŸB(NF-ŸB) ligand; VEGF - vascular
endothelial growth factor
Figure 2.4: IL-6 in inflammation, immunity and disease (Tanaka et al. (2014))
• IL-6 reduces serum iron levels (Hashizume et al. (2009) by inducing hepcidin
production, which blocks the action of iron transporter ferroportin on gut
and hence is also responsible for hypoferremia (Nemeth et al. (2004)) and
anaemia associated with chronic inflammation (Liuzzi et al. (2005)).
• IL-6 stimulates the RANKL which is indispensable for the di erentiation and
activation of osteoclasts and leads to bone resorption and osteoporosis (Poli
et al. (1994)).
2.4.1.3 Interleukin 8 (IL-8)
The protein, consisting of 72 amino acids in its mature form, is identified as a basic
and heparin-binding protein (Matsushima et al. (1988)).
Source
IL-8 production has been observed in vitro monocytes, T lymphocytes, neutrophils,
vascular endothelial cells, dermal fibroblasts, keratinocytes, hepatocytes (Strieter
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et al. (1989),Thornton et al. (1990)).
Process of the release of IL-8 cytokines
Levels of IL-8 increase rapidly following an appropriate stimulus and have been
demonstrated to correlate with important clinical parameters in patients with
sepsis.
IL-8 production is stimulated by numerous stimuli viz., TNF, Pathogen associated
molecular patterns (PAMPs) such as bacterial and viral products, and cellular
stress.
Functions
• IL-8 is a powerful attractant and stimulator of neutrophils and plays an im-
portant role in the body’s inflammatory response (Harada et al. (1994)).
• IL-8 stimulates neutrophil degranulation (Walz et al. (1987)), upregulates
expression of adhesion molecules, and increases production of reactive oxy-
gen species (ROS). It has a vital role in stimulating chemotaxis and regu-
lates transvenular tra c during acute inflammatory responses (Huber et al.
(1991)).
• In particular, IL-8 is thought to play a key role in the epithelial and physiolo-
gic dysfunction observed in acute lung injury and acute respiratory distress
syndrome.
2.4.1.4 Tumour Necrosis Factor alpha (TNF-–)
Tumour necrosis factor (TNF) is a cytokine involved in systemic inflammation (Id-
riss and Naismith (2000)). It is a member of a group of cytokines that participates
in the acute phase reaction. TNF-– has been dubbed the “master regulator” of
inflammatory cytokine production because of its early and broad role in mediating
downstream cytokine production. TNF’s central role is in the regulation of immune
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cells. In studies using injections of TNF-–, animal and human subjects manifest
a clinical response resembling systemic inflammatory response syndrome or septic
shock. Dysregulation of TNF has been implicated in a variety of human diseases -
autoimmune diseases, insulin resistance, and cancer.
Source
TNF-– is produced by a wide variety of cells, most notably monocytes and mac-
rophages.
Process of release and mode of action
It is initially synthesised as a membrane-bound 26 kDa molecule that is sub-
sequently cleaved by a TNF converting enzyme to form a soluble 17 kDa protein.
TNF-– binds to two distinct receptors, TNFR1 and TNFR2, which initiate a broad
cascade of pro-inflammatory events leading to the production and release of down-
stream inflammatory mediators. TNF-– is rapidly transcribed, translated and
released within 30 minutes of an inciting event. Bacterial endotoxin is a powerful
stimulus for TNF-– release, along with the IL-1 family of cytokines.
TNF exerts its e ect(s) by binding to, as a trimer and clustering high-a nity re-
ceptors present in great numbers on most cell membranes. The ligand/receptor
complex is rapidly internalised via clathrin-coated pits and ends up in secondary
lysosomes where it is degraded. TNF exerts its e ects by activating a number of
secondary proteins that provoke a variety of responses within the cell such as activa-
tion of gene transcription and/or production of reactive oxygen or nitrogen radicals
(e.g., NO). Activated proteins include G-Protein, transcription factors (e.g., NF- B,
AP-1), protein kinases (e.g. CK II, erk-1, erk-2, and MAP2), phospholipases (e.g.
PLA2, PLC, PLD and sphingomyelinase) mitochondrial proteins (e.g. manganese
superoxide dismutase) and serine and cysteine proteases, known as caspases.
Although TNF-– and IL-1 are structurally distinct, their biologic functions in the
inflammatory response overlap considerably. In animal and human models, IL-1
and TNF-– have been shown to act synergistically to mediate the early inflammat-
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ory response and induce a shock-like state characterised by vascular permeability,
loss of vascular tone, pulmonary oedema, and haemorrhage.
Functions
• Like IL-1, TNF-– acts on macrophages, neutrophils, and endothelial cells.
TNF-– causes increased production of macrophages, stimulates macrophage
activity and prolongs macrophage survival.
• In endothelial cells, TNF-– increases the expression of adhesion molecules,
including intercellular adhesion molecule-1, vascular cell adhesion molecule-1
and chemokines.
• TNF-– promotes extravasation of neutrophils into the tissue by increasing
adhesion via integrins.
• Along with IL-1, TNF-– is a main mediator of a hypercoagulable state in
sepsis, in part by upregulating endothelial expression of procoagulant.
• Together with IL-1, TNF-– activates macrophages to secrete additional in-
flammatory cytokines such as IL-6 and IL-8 and other mediators such as nitric
oxide, which contribute to vascular instability and may depress myocardial
function in sepsis.
• TNF binding mediates alterations in cell volume associated with necrosis/apoptosis
by inducing regulation of the activities of several anion/cation channels.
2.4.2 Experimental studies
Experimental studies consist of both in-vitro, ex-vivo and in-vivo models, using
di erent species and applying various techniques, which probably explains some of
the observed inconsistencies in cytokine response. The involvement of TNF-– in
the pathogenesis of VILI is still under debate. Increased TNF-– levels after mech-
anical ventilation were found in most but not all uninjured lung models, surfactant
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depletion and acute lung injury (ALI) models and sepsis models. Endotracheal in-
stillation of anti-TNF-– antibody attenuates VILI in both the previously uninjured
and injured lung, suggesting a role for TNF-–. However, lack of TNF-– signalling
(TNF-– receptor -/- mice) does not show diminished VILI.
In a randomised controlled trial on lambs, Hillman et al. ((Hillman et al. (2012))
demonstrated that ventilation at moderate levels could lead to inflammation in
lungs. The authors found that ventilation increased pro-inflammatory cytokines
as compared with controls and lambs on continuous positive airway pressure, with
the recruitment of primarily monocytes to bronchoalveolar lavage fluid. They also
noted that brief exposure to 95% oxygen did not alter lung inflammation. The
researchers used cytokines in their study to conclude that it was the ventilation
and not the oxygen which was responsible for lung injury.
Imai et al. ((Imai et al. (1994)) isolated and studied polymophonuclear cells and
Inflammatory chemical mediators and reported that the numbers of polymopho-
nuclear cells and the levels of PAF and TXB2 in lung lavage fluid were signi-
ficantly greater during conventional mechanical ventilation than during high fre-
quency oscillation (HFOV). This led them to conclude that the high frequency
oscillation (HFOV) was superior to conventional ventilation. Brew et al. ((Brew
et al. (2011))used assessment of cytokines as a mean to study the injury and repair
in the premature lung. Authors reported that even a brief period (two hours in
their study) of mechanical ventilation induced severe injury in the very immature
lung and that these lungs could repair spontaneously in the absence of further
ventilation.
In a critical review of the relationship between cytokines and lung injury by Hal-
bertsma et al. ((Halbertsma et al. (2005)), the authors reviewed 57 articles on
cytokines in in-vitro settings (n=5), ex-vivo models in-vitro models and clinical
trials. The reviewers concluded that there was strong circumstantial evidence that
the release of cytokines into the systemic circulation contributed to the pathogenesis
of multiple organ dysfunction syndromes and hence cytokines were good surrogate
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endpoints in exploring the pathogenesis and pathophysiology of ventilator induced
lung injury in both experimental and clinical studies.
In general, most of the animal studies showed a more pronounced increase in cy-
tokine levels with larger tidal volumes or absent PEEP or when animals are con-
comitantly subjected to other injurious strategies such as hyperoxia. It is to be
noted that the observed pro-inflammatory response has been demonstrated to be
parallel to the observed histopathology. The injured lung appears to be far more
susceptible for VILI than the healthy lung (two-hit model).
Stuber et al. ((Stuber et al. (2002)) showed that increasing Vt from 6 to 12 ml/kg
in ARDS patients increased cytokine levels in both BAL fluid and plasma within
one hour. These findings were consistent with both the results demonstrated by
and ARDSnet trial ((Parsons et al. (2005)). In this study by Parsons et al., authors
found that the baseline plasma levels of interleukin-6 and interleukin-8, were each
associated with an increased risk of death, significant decrease in ventilator free
and organ failure free days. They also reported that lower tidal volume strategy
(6 mL/kg) on day 3 was associated with a greater decrease in interleukin-6 and
interleukin-8 levels. Authors concluded that the low tidal volume ventilation was
associated with a more rapid attenuation of the inflammatory response.
Wrigge et al. (Wrigge et al. (2004)) reported that while cytokine levels were elevated
after elective surgery in patients with normal lungs, there was no di erence between
patients ventilated with Vt 15 ml/kg and those with Vt 6 ml/kg.
Encouraged by the animal and in-vivo studies in adults, these inflammatory mark-
ers have also been used by neonatal researchers as surrogate markers to compare
ventilatory modalities.
Lista et al. (Lista et al. (2008)) studied IL-6, IL-8, and TNF-– on day 1, 3 and 7 in
tracheal aspirates of preterm infants ventilated with either volume guarantee (VG)
or high frequency oscillation (HFO). They found that in the HFOV group IL-6 levels
were significantly higher on day 3. The authors concluded that VG ventilation is
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an e ective lung-protective strategy to be used in acute RDS, inducing a lower
expression of early inflammation markers than HFOV.
In another study explained in more detail in the next section, the same group of
researchers (Lista et al. (2006)) also used cytokines assessment in tracheal aspirate
to compare two di erent tidal volumes (3 ml/kg versus 5 ml/kg) and demonstrated
that raised cytokines levels were well correlated with longer duration of mechanical
ventilation observed in babies ventilated with 3ml/kg tidal volume.
Whether these inflammatory markers are of only short-term significance or if they
can help predict medium to long-term clinical issues like chronic lung disease is not
answered. Bose et al. addressed this question (Bose et al. (2008)) in their review of
biomarkers and their relationship to chronic lung disease. The authors highlighted
that:
• Increased concentrations of IL-1— in tracheal aspirates predict the require-
ment for mechanical ventilation and oxygen supplementation.
• Increased concentrations of IL-1, TNF-–, IL-6, and IL-8 correlate with the
duration of supplemental oxygen and mechanical ventilation and are increased
in infants who develop bronchopulmonary dysplasia (BPD) compared with
infants of similar gestational age who do not develop bronchopulmonary dys-
plasia (BPD).
• Increased IL-1— concentrations and IL-1—/IL-6 ratios are also associated with
risk factors for bronchopulmonary dysplasia (BPD), specifically colonisation
with Ureaplasma urealyticum.
• TNF-–, which appears during the early phases of an inflammatory response,
is raised in BAL samples from ventilated preterm infants with poor pulmon-
ary outcomes.
Finally, in longitudinal studies in neonates, elevated pro-inflammatory cytokine
levels are associated with more severe lung injury and worse outcomes, supporting
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the concept that lung injury is partly the result of a massive pro-inflammatory
response (Groneck et al. (1994), Hitti et al. (1997),Jonsson et al. (1997),Munshi
et al. (1997)).
All the evidence so far suggests that the cytokines are indeed very useful markers of
ventilator associated lung injury. Currently, they are used in experimental settings,
but in future with better availability and economy, they have the potential to guide
management in both respiratory distress syndrome as well as established chronic
lung disease.
2.5 Tidal volume
This is the final section of the chapter where evidence so far has been explored from
all possible sources – animal, adult, paediatric and neonatal studies. This provides
insight into the enormous e orts of researchers in dealing with the question of ideal
tidal volume as well as the lack of evidence in helping to manage preterm and term,
newborn infants.
What is tidal volume?
Tidal volume is the volume of air delivered by the ventilator per breath.
Why is it important?
Physiological studies in animal models cited in the previous section demonstrated
that it has a stronger association with lung injury as compared to pressures. Also,
while high tidal volume can potentially lead to volutrauma and hypocarbia, which
in turn increases the risk of cerebral injury, a low tidal volume can cause atelecto-
trauma and hypercarbia.
2.5.1 Lessons from animal studies
In a randomised trial by Kozian et al. (Kozian et al. (2011)), it was found that
ventilation with high Vt increased aeration and tidal recruitment in animal models
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of one lung ventilation (OLV).
Hillman et al. (Hillman et al. (2012)) studied the impact of normal and high tidal
volume ventilation at birth in causing lung injury. Researchers studied the extent
of lung injury using pro-inflammatory cytokines and bronchoalveolar lavage fluid
for inflammatory cells and concluded that degree of lung injury was less with low
Vt (6 mL/kg) than with higher Vt ventilation (15 mL/kg). Ratner et al. (Ratner
et al. (2013)) explored the impact of large tidal volume and small tidal volume in
altering bioenergetics. The authors concluded that their data suggested that the
failure of bioenergetics to support normal lung development was caused by large
tidal volume and prolonged ventilation.
Zick et al. (Zick et al. (2013)) found that high tidal volumes increased regional res-
piratory system compliance in a porcine model of ALI and better lung recruitment
in healthy animals. In a study on infant rats with lung injury induced by acid,
Sly et al. (Sly et al. (2013)) showed that high tidal volume (21 mL/kg) compared
with low tidal volume (7 mL/kg) did not exacerbate lung injury. The authors also
found that tissue elastance and airway resistance were less deteriorated and there
were no di erences in histologic lung scores or the concentration of IL-6 in bron-
choalveolar lavage fluid in the high tidal volume group. In this study, in contrast to
experimental studies with adult rats, short-term mechanical ventilation with high
Vt - low PEEP was not deleterious when compared to low Vt - high PEEP in both
healthy and pre-injured infant rat lungs. In this study, the authors challenged the
use of the conventional lung protective model of low PIP/Vt and high PEEP in
children based on adult studies.
2.5.2 Lessons from studies in adults
Tidal volumes have been compared in adults in di erent clinical scenarios like
ARDS (Adult Respiratory Distress Syndrome) (Amato et al. (1998), Gajic et al.
(2004), Brower et al. (2000), Petrucci and Iacovelli (2004), Wheeler et al. (2006),
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Villar et al. (2006), Futier et al. (2013)); without ARDS (Determann et al. (2010),
Gajic et al. (2004), Serpa Neto et al. (2012), Neto et al. (2015)) and single lung
ventilation (Licker et al. (2009), Michelet et al. (2006), Yang et al. (2011), Maslow
et al. (2013), El Tahan et al. (2017)).
These studies have been summarised as follows.
The studies reported that low tidal volume was associated with favourable outcome
as it was associated with
• Decreased mortality (Amato et al. (1998), Brower et al. (2000), Petrucci and
Iacovelli (2004), Wheeler et al. (2006), Villar et al. (2006), Serpa Neto et al.
(2012)).
• Decreased duration of mechanical ventilation (Amato et al. (1998), Brower
et al. (2000), Villar et al. (2006)).
• Lower development of lung injury (Amato et al. (1998), Determann et al.
(2010), Gajic et al. (2004), Serpa Neto et al. (2012)).
• Decreased risk of acute lung injury (Gajic et al. (2004), Licker et al. (2009)).
• Lower rates of pulmonary complications (Futier et al. (2013), Neto et al.
(2015).
• Lower rates of extrapulmonary complications (e.g., sepsis) (Futier et al. (2013)).
• Less intensive care unit (ICU) and hospital days ((Licker et al. (2009)).
• Greater paO2/FiO2 ratio (Michelet et al. (2006), Yang et al. (2011)).
• Better preservation of postoperative oxygenation (El Tahan et al. (2017)).
• Reduction in airway pressures and lung infiltrates (El Tahan et al. (2017)).
High tidal volume was found to be better in being associated with
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• Lower alveolar atelectasis and higher dynamic pulmonary compliance (Maslow
et al. (2013)).
• Better gas exchange (El Tahan et al. (2017)).
Studies also reported that both were comparable in their e ect on
• Short term or long-term mortality (Petrucci and Iacovelli (2004), Futier et al.
(2013), Licker et al. (2009), Michelet et al. (2006), Yang et al. (2011)).
• Development of ARDS (Futier et al. (2013)).
• Hospital or ITU stay (Michelet et al. (2006), Yang et al. (2011), Maslow et al.
(2013), El Tahan et al. (2017)).
• Pulmonary or extra pulmonary morbidity (Michelet et al. (2006), Yang et al.
(2011), Maslow et al. (2013), El Tahan et al. (2017)).
2.5.3 Lessons from Paediatric studies
Sousse et al. (Sousse et al. (2015)) carried out a comparison of high versus low
tidal volume in children with inhalation injury in a prospective cross-over study.
Researchers reported that the high tidal volume was associated with significantly
decreased ventilator days and maximum positive end-expiratory pressure and sig-
nificantly increased maximum peak inspiratory pressure compared with those in
patients with low tidal volume. The incidence of atelectasis and ARDS was signi-
ficantly decreased with high Vt compared with low Vt. However, the incidence of
pneumothorax was significantly increased in the high Vt group compared with the
low Vt group.
In a recent meta-analysis by de Jager et al. (de Jager et al. (2014)), the au-
thors aimed to identify an association of tidal volume with mortality in critically
ill, mechanically ventilated patients. The authors identified eight studies which
included 1,765 patients.
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In a recent meta-analysis by de Jager et al. (de Jager et al. (2014)), the authors
aimed to identify an association of tidal volume with mortality in critically ill,
mechanically ventilated patients. The authors identified eight studies which in-
cluded 1,765 patients. The authors reported that there was no association between
tidal volume and mortality when the tidal volume was dichotomised at 7, 8, 10, or
12 mL/kg. The authors concluded that a relationship between tidal volume and
mortality in mechanically ventilated children could not be identified, irrespective
of the severity of the disease. They suggested that the significant heterogeneity
observed in the pooled analyses necessitated future studies in well-defined patient
populations to understand the e ects of tidal volume on patient outcome.
The meta-analysis identified the di culty in interpretations when the criteria of low
and conventional (high) tidal volume varied. The population included did not meet
uniform criteria as well. The study, therefore also highlighted lack of consensus as
to what can be constituted as ideal low or high tidal volume in children.
2.5.4 Lessons from Neonatal studies
The tidal volume range has been suggested to be 4-8 mL/kg. Previous studies in
newborn infants targeted this successfully (Piotrowski et al. (1997), Sinha et al.
(1997), Courtney et al. (2002)). However, there is limited data to guide clinicians
whether low or high normal tidal volumes should be targeted (van Kaam (2011)).
Historically studies using volume targeted ventilation as performed by Piotrowski
et al. (Piotrowski et al. (1997)) and Sinha et al. (Sinha et al. (1997)) have used a
tidal volume of 5-8 mL/kg.
The lower end of tidal volume has been extrapolated from studies in children, but
as shown by Sly et al. (Sly et al. (2013)) in their study on infant rats, this strategy
of employing low tidal volume is not without its shortfalls.
Some uncontrolled studies using volume targeted ventilation have reported that us-
ing high Vt (5–6mL/kg) is more appropriate in the acute phase of RDS (Abubakar
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and Keszler (2001),Keszler and Abubakar (2004)).
As discussed earlier; historically, pressure targeting has been the mainstay of
providing support for children and young infants. While volume targeting was
increasingly recognised in adult breathing support, it could not be tried because
of a lack of technology. In 1983, Cote et al. (Cote et al. (1983)), in their in vivo
study demonstrated that the use of adult circuits was very unreliable in providing
the precise level of tidal volume as required in the paediatric population due to
their highly compliant nature.
In one of the very first studies using "volume targeting," Courtney et al. (Courtney
et al. (2002)), in their study compared high-frequency ventilation versus conven-
tional SIMV using the tidal volume of 4-7 mL/kg. The study was remarkable in
that researchers paid strict attention to expiratory tidal volume. The authors jus-
tified their insistence on maintaining a close watch and control based on evidence
at that time in maintaining minute volume.
In a prospective interventional study on preterm infants <32 weeks and <2,000
grams by Mishra et al. (Mishra et al. (2003)), the authors reduced PIP from 20 to
10 while monitoring arterial pCO2. The authors showed that despite the decrease in
PIP leading to reduced Vt, pCO2 was maintained due to increase in respiratory rate
leading to maintenance of MV. They concluded that this demonstrated that given
an opportunity, preterm infants have the aptitude to modulate their respiratory
rate in response to changes in tidal volume.
In the crossover study by Herrera et al. (Herrera et al. (2002)), quoted earlier
in VG section, authors also compared VG + SIMV(3 mL/kg) with SIMV+VG
(4.5 mL/kg). In this study, peak inspiratory pressure and mean airway pressures
were significantly lower during SIMV+VG 3.0 when compared to both SIMV and
SIMV+VG 4.5. The authors noted that both groups maintained similar minute
volume which could be attributed to an increase in spontaneous minute volume
during SIMV+VG 3.0. Although there was no di erence in arterial oxygen satura-
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tion by pulse oximetry and transcutaneous carbon dioxide tension, transcutaneous
carbon dioxide tension increased slightly during SIMV VG 3.0.
In this study, carbon dioxide tension increased by the end of the period babies
were ventilated using lower Vt and rise was found to be non-significant. It could
have resulted in statistically significant hypercarbia if the period of observation
was longer or the study recruited more babies than in the trial. Also, it was
noted that though the minute volume remained similar, with babies on 3mL/kg,
spontaneous breaths contributed a higher proportion of total minute volume giving
rise to concerns about whether a smaller tidal volume meant the baby had to work
harder to achieve an acceptable tidal volume.
These studies brought the question of normal tidal volume of the term and preterm
infants to the fore of ventilatory world.
Williams et al. (Williams et al. (2011)), in their prospective observational study
aimed to find out the normal range of tidal volumes in term and preterm infants in
43 infants between 23-41 weeks gestation, chronological age 2-111 days. Out of 43,
23 infants were receiving CPAP and 20 were breathing spontaneously. The authors
found that Vt ranged from 2.3–10.4 mL/kg.
Van Kaam et al. (van Kaam et al. (2010)) conducted a prospective international
cross-sectional survey between April 2007 and May 2008 which included 535 infants
(mean gestational age 28 weeks and birth weight 1,024 grams) in 173 European
NICUs in 21 countries. This was a live collection of data over two predetermined
days. The authors aimed to assess contemporary ventilation practices in newborn
infants. To make sure that the results provided an accurate reflection of daily
clinical practice, this study collected data on neonatal ventilation “live” at the
bedside and not by questionnaire. The authors reported that tidal volumes were
measured in 84% of the patients on conventional ventilation, with a mean tidal
volume of 5.7 mL/kg (Figure 2.5). In 66% of the patients, the tidal volume was
between 4-7 mL/kg and in 18% of the patients, the tidal volume was above 7mL/kg.
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Figure 2.5: Distribution of the expiratory tidal volumes in patients on conventional
mechanical ventilation (Adapted from van Kaam et al.) (van Kaam et al. (2010))
Mian et al. (Mian et al. (2015)) examined the temporal course of lung aeration
at birth in preterm infants. The researchers observed tidal volume of the first 100
breaths of preterm infants on CPAP born at less than 33 weeks’ gestation. The
researchers found that babies’ tidal volume for first 30 breaths, 20 breaths, and 50
final breaths was 5-6 mL/kg, 7-8 mL/kg and 4-6 mL/kg respectively. The authors
suggested that targeting tidal volume to these normal values could be an e ective
means of regulating the administration of PPV to high-risk newborns that require
respiratory assistance. Researchers excluded any breaths with mask leak > 30% as
they would have underestimated the expired tidal volume.
Though the researchers aimed to examine the first 100 breaths, they did not include
the initial breath before mask application which has the potential to limit its inter-
pretation. Also, the criteria to apply CPAP rather than provide mask ventilation
was arbitrary as well.
Whereas some authors have also observed variation in tidal volume requirement
based on the age of preterm infants, Keszler et al. (Keszler (2009)) in their pro-
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spective observational study showed an evolution of tidal volume requirement dur-
ing the first three weeks of life in infants <800 grams ventilated with volume-
guarantee. The authors measured tidal volumes matched with normocapnoea from
birth until three weeks of life in preterm infants less than 800 grams and found
that mean expiratory tidal volume rose from 5.15 mL/kg at birth to 6.07 mL/kg
at three weeks of age. The increase in tidal volume occurred despite accounting for
hypercapnoea.
Sharma et al. (Sharma et al. (2015)) in their retrospective, case-controlled, study
compared tidal volume requirement of successfully ventilated newborn infants with
meconium aspiration syndrome. To find out the tidal volume requirement, they
used only those Vt values with the corresponding partial pressure of carbon dioxide
between 35-60 mm Hg (4.6-8 kPa) were included. Mean Vt/kg and MV/kg were
calculated for each patient. The control patients were the term and late preterm
infants without meconium aspiration and were ventilated during the same period
for severe lung diseases such as respiratory distress syndrome (RDS) or pneumonia.
Authors found that infants required Vt/kg (mean, SD) 6.11, 1.05 and 4.86, 0.77
mL/kg for MAS and controls respectively (p = < 0.0001). Similarly, the MV was
di erent between the two groups as it was found to be 371, 110 (mean, SD) and
262, 53 (mean, SD) mL/kg/minute for MAS and controls respectively as well (p
= <0.0001). The authors concluded that infants with MAS required 26% higher
Vt and 42% higher MV compared with controls in order to maintain equal paCO2.
They felt that the need for larger Vt and higher total MV to achieve similar alveolar
ventilation was consistent with the pathophysiology of MAS.
This study involved babies with meconium aspiration syndrome who have a dif-
ferent pathology to preterm infants with respiratory distress syndrome. This was
also a single centre, a retrospective study based on written observations rather
than electronic records. The MV was a calculated value rather than actual minute
volume.
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The same group (Sharma et al. (2015)) also reviewed tidal volumes of babies
with the congenital diaphragmatic hernia and found no di erence between the
two groups.
Patel et al. (Patel et al. (2009)) carried out a prospective cross-over study on
preterm infants to determine the impact of di erent tidal volumes on the work of
breathing. The researchers recruited 20 preterm infants with a median gestation
age of 28 weeks who were being weaned from respiratory support. They meas-
ured the transdiaphragmatic pressure-time product as an estimate of the work of
breathing. They did this by measuring transdiaphragmatic pressure-time product
first without volume targeting (baseline) and then at targeting tidal volumes of 4,
5, and 6mL/kg, delivered in random order. They found that work of breathing was
least at a higher tidal volume of 6 mL/kg. The work of breathing at 6mL/kg was
less than baseline itself.
The authors concluded that low volume-targeted levels increased the work of breath-
ing during volume-targeted ventilation. They speculated that their results sugges-
ted that, during weaning, a higher volume-targeted level of 6 mL/kg, rather than
a lower level, could be used to avoid an increase in the work of breathing.
In this study, the authors noted that at all tidal volumes, minute volume was
maintained which was due to increased respiratory rates at lower tidal volumes
which further explained the higher work of breathing at lower tidal volumes. As
researchers did not go beyond 6mL/kg, they also speculated whether the work of
breathing could be lower at tidal volumes higher than 6mL/kg.
Chowdhury et al. (Chowdhury et al. (2012)) evaluated work of breathing using
tidal volumes of 4-6mL/kg in term or near-term babies (>34 weeks in gestation
at birth ) in their prospective crossover study. These infants were also studied
first without Vt (baseline) and then at Vt levels of 4, 5 and 6mL/kg delivered in
a random order. The researchers had similar findings as observed by Patel et al.
in their study of premature infants, i.e., low Vt levels (4 mL/kg) during volume
62
2.5.4. Lessons from Neonatal studies
targeted ventilation increased the work of breathing in ventilated infants born at
term or near term.
The infants in this study behaved similarly to preterm infants in the previous study
including maintenance of minute volume across the tidal volumes. The researchers
did note that rather than compensations for minute volume by increasing respir-
atory rate, the infants in this study compensated by increasing the depth of their
respiratory e orts and tidal volume exchange and hence their work of breathing
was increased at the lower Vt level.
Lista et al. (Lista et al. (2006)) used the measurement of cytokine levels to compare
the tidal volumes – 3 mL/kg to 5 mL/kg in their prospective RCT in preterm infants
(25-32 weeks) in the acute phase of RDS. Researchers measured pro-inflammatory
cytokines (interleukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor al-
pha (TNF-–) in the tracheal aspirate on 1, 3, and 7 days’ of life. They reported
that IL-8 and TNF-– levels collected on day 7 were significantly higher in the low
tidal volume group (tidal volume 3mL/kg). This group also had a longer dura-
tion of mechanical ventilation. The authors concluded that ventilation with Vt =
5mL/kg when compared with 3mL/kg, reduced inflammatory response as well as
the length of ventilation. The study, however, did not assess whether the di erence
was related to the incidence of bronchopulmonary dysplasia in these infants.
Hence while the lower tidal volumes could limit volutrauma, the studies mentioned
above by Patel, Chowdhury and Lista et al. suggest that such low tidal volumes,
in turn, can lead to increased work of breathing or raised inflammatory markers.
In summary, while volume targeting appears to be superior to pressure targeting, it
is not clear what the optimal Vt set is on the volume guarantee hybrid modes widely
used across the world. This remains a vital question that needs investigation.
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The invention of a mechanical ventilator, while helping to improve survival in
babies, also gave rise to debate about ventilator associated lung injury in the form
of barotrauma or volutrauma (Tremblay and Slutsky (2006)). Since then, there
have been debates about which of two were more harmful. Legendary studies by
Dreyfuss and Hernandez (Dreyfuss et al. (1988), Hernandez et al. (1989), Dreyfuss
and Saumon (1998)) demonstrated the superiority of volume targeting in animal
models. This triggered the debate of this being clinically applicable in the area
of ventilation. Their research inspired studies in babies with respiratory distress
syndrome and in these, volume targeted ventilation came out as a better mode of
ventilation than a pressure targeted. This was also supported by the studies as well
as meta-analyses (Herrera et al. (2002), Keszler and Abubakar (2004), McCallion
et al. (2008), Klingenberg et al. (2017)).
The development of microprocessor technology and the establishment of volume
targeting as the better mode helped to develop the next generation of hybrid modes
of ventilation. These help to deliver precise tidal volume to very small babies.
Arguably, volume guarantee is the most studied and commonly used hybrid mode
in ventilating extremely preterm infants with respiratory lung disease. In view of
this overwhelming evidence in support of volume guarantee, its uptake has been
rapid. This has led to the question of ideal tidal volume for babies which has been
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addressed by di erent studies in animals, adults and children.
In view of this overwhelming evidence in support of volume guarantee, its uptake
has been rapid. This has led to the question of ideal tidal volume for babies which
has been addressed by di erent studies in animals, adults and children.
Historically, studies using volume targeted ventilation as performed by Piotrowski
et al. (Piotrowski et al. (1997)) and Sinha et al. (Sinha et al. (1997)) have used
a tidal volume of 5-8 mL/kg. Some researchers have tried to establish the normal
tidal volume for term and preterm infants. Williams et al. (Williams et al. (2011))
in their prospective observational study of non-ventilated term and preterm infants
found the normal range of tidal volumes in term and preterm infants to be 2.3-10.4
mL/kg. Whereas in their cross sectional study of ventilated preterm infants, van
Kaam et al. (van Kaam et al. (2010)) found that in 66% of the patients the tidal
volume was between 4-7 mL/kg.
As demonstrated by studies in adults and children, the e orts to compare the tidal
volumes have also disclosed varied ranges under the definition of low and high tidal
volumes. Most of these studies were also limited by their design in being either
cross sectional or focussed on very limited clinical aspects.
Understanding these limitations, studies in newborns so far have shown that
• Low tidal volume fared better in providing breathing support with lower
airway pressures (Herrera et al. (2002)).
• There were no di erences in maintained minute volume, arterial oxygen satur-
ation by pulse oximetry, transcutaneous carbon dioxide tension and fraction
of inspired oxygen (Herrera et al. (2002)).
• High tidal volume fared better in providing support with lower work of breath-
ing (Patel et al. (2009), Chowdhury et al. (2012)), reduced inflammatory
response and length of ventilation (Lista et al. (2006)).
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In the absence of clear evidence, experts have suggested the tidal volume range to
be 4-8 mL/kg but there is limited data to guide clinicians as to whether low or
high normal tidal volumes should be targeted (van Kaam (2011)).
In summary, while volume targeting appears to be superior to pressure targeting, it
is not clear what the optimal Vt set is on the volume guarantee hybrid modes widely
used across the world. This remains a vital question that needs investigation.
Aims
Through this study, we aimed to ascertain an improved way to provide respiratory
support to premature babies. By targeting the ideal tidal volume, we believed
that we would be able to maximise the e cacy of ventilation while minimising the
adverse e ects due to ventilation induced lung injury
Objectives
In order to compare high normal versus low normal tidal volumes we set out to
study the di erences between: the time to achieve 25% reduction in peak pressure
(the primary outcome).
Respiratory distress syndrome in very low birth preterm infants is characterised
by poorly compliant lungs. Preterm infants with significant respiratory distress
syndrome therefore need mechanical ventilation support with high peak pressures
reflective of poor compliance at time of birth. As the lungs improve, the compliance
gradually increases enough for them to be able to breathe with no or non-invasive
support.
Peak inspiratory pressure is a quantitative marker of compliance in presence of a
constant tidal volumes. In traditional pressure targeted ventilation, with improve-
ment in compliance, a baby’s ventilatory support is gradually reduced by manual
reduction of peak inspiratory pressure. As volume guarantee works by using a feed-
back mechanism, the peak inspiratory pressure is tailored to the set tidal volume.
Similar to pressure targeted ventilation, this peak inspiratory pressure is initially
high to be able to deliver the required tidal volume. But contrary to pressure tar-
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Figure 3.1: Pressure volume loops
geted ventilation, in volume guarantee, with improvement in compliance, peak in-
spiratory pressure reduces gradually, a phenomena also dubbed as “auto-weaning”.
Pressure and volume loops demonstrate this phenomena very well(Figure 3.1).
As the study was conducted in a real life clinical setting, it was necessary for us to
have an objective parameter to assess the impact of the randomisation arm. Due
to lack of any previous studies, we chose a 25% drop in peak inspiratory pressure as
the primary outcome, as in our experience, peak inspiratory pressure at extubation
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was 75% of initial PIP. Primary outcome was achieved when initial PIP dropped
to final PIP by 25% hence it can be mathematically explained as
End point PIP => Final PIP = 3/4(Initial PIP)
We also set out to study the following clinically relevant parameters as our second-
ary outcomes.
• Duration of mechanical ventilation
• Incidence of pulmonary and non-pulmonary complications
• Survival to discharge without significant bronchopulmonary dysplasia
As this was a pilot project, we also aimed to evaluate the operational feasibility of
such a study for potential roll out at a larger, multicentre level.
Research Question (with null hypothesis): Null hypothesis:
There is no di erence in the time needed to achieve 25% reduction in peak pressure
using either 7-8 mL/kg or 4-5 mL/kg tidal volume.
Alternative hypothesis:
The time needed to achieve a 25% reduction in peak pressure in very premature
babies receiving mechanical breathing support using volume-targeted ventilation is
less using high normal tidal volume (7-8 mL/kg) as compared to low normal tidal
volume (4-5 mL/kg).
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Methodology
4.1 Setting
This study was conducted at the neonatal unit of the University Hospital of North
Tees, Stockton-On-Tees in the United Kingdom. It was one of four level 3 neonatal
units in North-East England. It had 3500 deliveries per year and 80-100 admissions
to the intensive care unit for ventilator support. While most of these admissions
were from in-house deliveries, 10-20 babies per year were admitted after ex-utero
transfer having been born in one of the regional level-1 district general hospitals
or other level 3 units if they surpass their capacity. The majority (80%) of these
babies were born premature and needed intensive care and breathing support for
immature lungs. These babies were born to mothers who either went into early
labour (maternal indication) or had to be delivered for poor growth (foetal growth
restriction also known as intra-uterine growth retardation). For this pilot study we
aimed to enrol 70 babies from an expected cohort of 90-100 eligible babies admitted
during the study period.
4.1.1 Subjects
We enrolled extremely low birth weight babies between 500 to 1500 grams or less
than 32 weeks completed weeks’ gestation at birth.
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4.1.2 Intervention
4.1.2.1 Identification of potential recruits
To study the impact of intervention on respiratory distress syndrome, we random-
ised the babies when they were commenced on ventilation. All of these babies were
ventilated soon after birth or in the first 12 hours of life. As a standard practice,
when eligible mothers arrived in labour, they received information on premature
delivery from the obstetric team. The neonatal team was also informed who in
turn counselled mothers and their families about what to expect after a preterm
delivery. Depending on the mother’s condition, information about research on the
unit and this trial was provided and they were invited to consider if their baby
could be included in the studies.
For our study, we provided verbal information to prospective mothers along with
a patient information leaflet. (appendix 1). Once born the preterm babies were
either intubated from birth depending on the condition or managed on non-invasive
respiratory support as per standard practice. If babies on non-invasive respiratory
support were deemed to be struggling with spontaneous breathing, they were in-
tubated with an appropriate sized tracheal tube. The tracheal aspirate in all babies
was collected before ventilation (after intubation).
4.1.2.2 Inclusion Criteria
1. Preterm babies weighing 500-1500g
2. Requirement of intubation and mechanical ventilation
4.1.2.3 Exclusion Criteria
1. Serious underlying congenital anomaly
• Congenital diaphragmatic hernia
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• Cyanotic congenital heart disease
• Airway anomalies
• Abdominal wall defects
2. Babies initiated on ventilation after 12 hours of life or transferred from other
centres.
For babies born of multiple pregnancies – only the first-born was randomised; the
others received the same strategy.
4.1.2.4 Collection of tracheal aspirate
Tracheal aspirate was collected by following method: Materials used – 2.5 ml syr-
inge, needle, trachea suction set (unomedical), 5 ml saline vial and suction catheter
(Figure 4.2)
Steps:
1. 1.0 ml saline was aspirated into the syringe using needle.
2. This saline then was instilled through the endotracheal tube.
3. The baby received intermittent positive pressure ventilation for 30 seconds.
4. Using the suction catheter size 5-6, the endotracheal aspirate was sucked from
the endotracheal tube. The aspirate by this procedure was collected in the
suction bottle of the trachea suction set.
5. As there was aspirate in the catheter as well, this was flushed into the suction
bottle by using the remaining saline in the ampoule (4.0 ml) which helped to
standardise the volume of the aspirate.
6. This suction bottle was then transferred to hospital research freezer and
stored at -80 degree C temperature. The sample was stored in the freezer
until it was processed.
71
4.1.2.5. Randomisation
7. These samples were then assessed by the research scientist for TNF-–, IL-6
and IL-8.
The baby then received 200 mg/kg surfactant (poractant alphaR•) through the
endotracheal tube.
4.1.2.5 Randomisation
The baby was then brought to the neonatal unit and weighed by the nursing team.
Once the team confirmed that the baby had fulfilled the criteria for the trial, baby
was randomised by opening the envelope before commencing the ventilation.
Assignment of the ventilation mode (low tidal volume or high tidal volume) was
done by computer generated block randomisation using opaque sealed envelopes.
This randomisation sequence was created by a member of research team not directly
involved in the trial and was kept hidden from the clinical and researchers directly
involved in the trial. Aim of the block randomisation was to keep the numbers of
the subjects in the two groups closely balanced at all times. Block randomisation
was done with a fixed block design of four per block. Study babies were stratified
into two groups – Babies weighing Æ1000 grams and >1000 gram.
Block sizes of four with the following sequences for the two stratification groups
were used. ‘L’ for ‘Low TV’ and ‘H’ for ‘High TV’ Æ1000 grams birth weight HHLL
LHHA HLHL LLHH LHLH HLLH > 1000 grams birth weight LHHL LHLH HHLL
HLHL LLHH HLLH
Two sets of envelopes (one for each birth weight strata) within opaque, sealed, seri-
ally numbered envelopes in the above sequence were created. Babies were weighed
just after admission to the unit and when they were ready for randomisation, they
were allocated to the trial group according to the above sequence. The randomisa-
tion envelopes were not drawn or opened by the principle researcher. The envelope
was drawn by the clinician caring for the baby or a member of the clinical team. No
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attempts were made to blind the clinicians to the assigned group of tidal volume
group as it was not practically feasible.
The baby’s ventilator was then set as per defined tidal volume as follows Æ1000
gram – low – 4ml/kg; high 7 ml/kg >1000 gram = low – 5 ml/kg; high 8 ml/kg
The baby was then ventilated as per the protocol as in appendix D.
4.1.2.6 Initial ventilation strategy
The attending senior doctor (registrar or consultant) set the ventilator (AveaR• or
Dräger R•) (Figure 4.1) as follows
• Mode: Pressure Assist control (Pr AC) with volume guarantee (VG)
• Rate – 40/min
• PEEP – 5cm H2O
• Ti - Æ1000 gram – 0.26 second; >1000 gram – 0.30 seconds
• FiO2 – as per the requirement
• Pmax – initially 50 and then readjusted to 10 cm above the required peak
inspiratory pressure.
4.1.2.7 Management of baby in the unit (appendix D)
Then baby was assessed by the attending doctor for respiratory and cardiovascular
status by checking saturations, heart rate, blood pressure, capillary refill time,
air entry, heart sounds and peripheral pulses. Following assessment, peripheral
intravenous access was obtained and a blood sample sent for full blood count,
culture and group and save and blood gas. As these babies were going to require
a stable central access, the attending doctor secured umbilical venous and arterial
access. If arterial access was not possible or not attempted then blood gas analysis
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was performed on capillary blood samples obtained from heel prick. A chest x-
ray for obtained to assess lung condition, position of tracheal tube and position of
umbilical catheter tips.
A blood gas (capillary or arterial) sample was obtained in first two hours to gauge
the status of ventilation by ascertaining pCO2. If the pCO2 was within normal
limits (i.e., between 4.5-6.5 kPa) the ventilation was continued unchanged. If the
pCO2 was low the mode of ventilation changed to Pressure SIMV with volume
guarantee with rate of 40/min. If the pCO2 was high then respiratory rate was
increased in steps of 10 until a rate of 60 was achieved. If the baby continued
to have raised pCO2 the baby was taken out of the trial and switched to high
frequency oscillation.
The oxygenation was optimised by adjusting PEEP. The level of oxygenation was
ascertained by maintaining a saturation of 90-95% and watching the required oxy-
gen content (FIO2) to deliver that. If the oxygen requirement was more than 0.4
then PEEP could be increased to 6 cm H2O and if the oxygen requirement was
less than 0.3, PEEP could be brought down to 4 cm H2O.
4.1.2.8 Criteria for extubation
With the progress of time, the ventilator requirements of the baby reduced. This
was ascertained by pCO2 on blood gases. Once we had established hyperventilated
blood gases, the baby was deemed to be weanable and switched onto Pressure SIMV
(with VG with original tidal volume). With continuing improvement, the rate on
SIMV reduced in steps of 10 until the baby was deemed to eligible for extubation
if they met extubation readiness criteria -
(a) Mean airway pressure was less than 8.
(b) Baby was initiating more than 50% of his breaths (good respiratory drive).
(c) Baby was not on any sedation and had received a loading dose of ca eine.
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4.1.2.9 Minute ventilation test (appendix E)
Once the baby met extubation readiness criteria (as above), the minute ventilation
test (appendix E) was carried out to predict the success of extubation.
Whilst on SIMV, data was recorded each minute for five minutes for heart rate,
respiratory rate, oxygen requirement (FIO2) to maintain normal saturation (90
to 95%) and minute ventilation VE (SIMV mode). Then whilst on SIMV mode,
control rate and pressure support was turned to zero (i.e., CPAP mode) and data
was recorded for every one minute for five minutes for same parameters (i.e., heart
rate, respiratory rate, oxygen requirement (FIO2) to maintain normal saturation
(90 to 95%) and minute ventilation VE) Baby was considered to have ‘passed’ the
test if
(a) The CPAP minute ventilation was >50% of SIMV mode.
(b) The rise in CPAP mode FIO2 was less than <10
(c) There was no significant episode of bradycardia.
If the baby did not meet the pass criteria, he/she continued SIMV ventilation and
the test was repeated every 6-12 hours till he/she passed the test.
4.1.2.10 Consent
Despite waiver of consent allowing us to randomise baby when considered eligible,
we obtained written informed consent from parents or a person with parental re-
sponsibility.
Every e ort was made to approach parents before delivery and provide them patient
information leaflet (appendix B).
In the trial run before commencement of the study, we realised that it was not prac-
tically feasible to obtain consent because baby would only meet the second essential
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criteria of needing intubation and ventilation after birth. Hence, unless parents had
expressed a desire against the trial before baby’s birth, we decided to approach for
consent in postnatal period once we were certain of the eligibility. Parents were
approached within 12 hours of randomisation. They received at least 24 hours to
read and understand the patient information leaflet. Once they expressed desire to
provide consent, it was obtained within 72 hours of randomisation.
Postnatally after randomisation, at an appropriate time, parents were approached
by myself or another Good Clinical Practice (GCP) competent member of sta  for
written consent. Parents had opportunity to ask questions or clarifications about
any aspect of the study before signing the consent form (appendix C). Reasons for
non-enrolment of the eligible babies were included in the enrolment log. (Figure
5.2)
4.1.2.11 Exit Criteria
Babies were discontinued on volume guarantee ventilation and switched to high
frequency oscillatory ventilation (HFOV) if any of the following occurred
• Inadequate ventilation (pH <7.25 and pCO2 >8 kPa)
• Inadequate oxygenation (FIO2 >0.6 to maintain SpO2 >91%)
• Clinical deterioration: Significant pulmonary haemorrhage or air leak
4.1.3 Primary outcome
Time to reach 25% reduction in initial PIP.
As our primary outcome was on 25% reduction in initial peak inspiratory pressure
(PIP), I noted the initial PIP by averaging PIP from first four hours and deduced
the time when average of four hours was about 75% of the initial PIP.
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4.1.4 Secondary outcome
As part of the study we also collected data for secondary outcomes as follows
• Time taken for extubation (duration of mechanical ventilation)
• E cacy of ventilation - Maintenance of stable pCO2 till primary outcome
(range 4.5-6.5 kPa)
• Pulmonary complication –
– Immediate - air leak (Pneumothorax or pulmonary interstitial emphysema)
– Delayed - Bronchopulmonary dysplasia
• Non-pulmonary complications –
– Sepsis
– Necrotising Enterocolitis (NEC)
– Patent ductus Arteriosus (PDA) requiring medical/ surgical treatment
– Intraventricular Haemorrhage (IVH)
– Periventricular leukomalacia (PVL)
– Retinopathy of prematurity (RoP)
– Weight gain
– Survival to discharge including survival to discharge without BPD
Though not part of secondary outcome, we also analysed the total duration of
respiratory support and duration of admission and ventilatory parameters to cover
all possible relevant clinical parameters for clinicians.
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4.2 Definitions of Secondary outcomes measured in
this study
4.2.1 Time taken for extubation (duration of mechanical
ventilation)
This was calculated as the period of invasive breathing support on mechanical vent-
ilator until extubation. To standardise the criteria for extubation, it was considered
only after meeting pre-defined criteria and once criteria were met, minute ventila-
tion test (appendix E) was used to determine whether baby could be extubated.
4.2.2 E cacy of ventilation –
Maintenance of stable pCO2 till primary outcome (range 4.5-6.5 kPa)
The babies were monitored for e cacy of ventilation by performing pCO2 assess-
ment on a regular basis. To mimic clinical conditions, the frequency of pCO2
assessment was determined by the attending team. After admission to the unit,
an arterial line was attempted. When it was not possible, capillary and venous
bloods were used for blood gas assessment. These values were then corrected to
make them equivalent to arterial result (arterialised). The method to arterialise
was used from the articles by Zavorsky and Byrne (Zavorsky et al. (2007), Byrne
et al. (2014)).
4.2.3 Pulmonary complications
4.2.3.1 Immediate: significant air leak (Pneumothorax or pulmonary
interstitial emphysema)
Significant Pneumothorax was defined as radiologically conformed intrathoracic,
extra pulmonary air needing intervention in the form of needle thoracocentasis
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or chest drain. Pulmonary interstitial emphysema was considered significant if it
warranted change in ventilatory strategy to high frequency ventilation. All the
x-rays were reported by a Paediatric radiologist who was blinded to the category
of randomisation.
4.2.3.2 Delayed:Bronchopulmonary dysplasia (Ryan (2006)
)
• Mild BPD - supplemental oxygen for Ø28 days and on room air at 36 weeks’
postmenstrual age (PMA) or at discharge (for infants <32 weeks at birth) or
at 56 days or at discharge (for infants Ø32 weeks at birth).
• Moderate BPD - supplemental oxygen for Ø28 days and a need for supple-
mental oxygen <30% at 36 weeks PMA/discharge (for <32 weeks) or at 56
days/discharge (for infants Ø32 weeks)
• Severe BPD - supplemental oxygen for Ø28 days and a need for Ø30% oxygen
or on nasal CPAP or mechanical ventilation at 36 weeks PMA/discharge (<32
weeks) or at 56 days/discharge (Ø32 weeks).
4.2.4 Non pulmonary complications
4.2.4.1 Sepsis
Sepsis was subdivided into early onset (<72 hours) and late onset sepsis (>72
hours). An early onset sepsis was considered significant when either the blood
culture was positive or baby was symptomatic with signs of sepsis or there were
significantly raised inflammatory markers (CRP/WBC). A late onset sepsis was
considered when there was a true nosocomial infection.
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4.2.4.2 Intraventricular Haemorrhage and periventricular
leucomalacia
All babies underwent routine ultrasound scan of head at 1st and 6th week of life.
This was performed by Paediatric radiologist in the unit. The ultrasound images
consisted of images in coronal plane from frontal lobe to occipital lobe and in
sagittal plane from left to right including midline.
Intraventricular haemorrhages were scored according to the Papile classification
(Papile et al. (1978)).
Grade 1 – Sub-ependymal haemorrhage only
Grade 2 – Intraventricular haemorrhage without ventricular dilatation
Grade 3 - Intraventricular haemorrhage with ventricular dilatation
Grade 4 - Intraventricular haemorrhage with parenchymal extension
Periventricular leukomalacia (PVL)- It was scored as no PVL or cystic periventricu-
lar leukomalacia
4.2.4.3 Patent ductus Arteriosus (PDA)
Patent ductus arteriosus was diagnosed on the basis of clinical signs (murmer and
hyperdynamic circulation) and colour Doppler echocardiography performed by per-
sonnel trained in neonatal echocardiography using Philips HD11TM , 5-12 MHz
probe.
A significant PDA (Kluckow and Evans (1995)) was defined as any duct requiring
medical or surgical closure based on findings of echocardiography of
• Left atrium: aortic root ratio > 1.4
• Pulse wave Doppler showing turbulent flow in the main pulmonary artery
with retrograde diastolic flow in mesenteric blood vessels
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• Duct diameter of > 1.5 mm measured at its attachment with the pulmonary
artery
Baby’s clinical condition was also taken into consideration while determining whether
the baby would benefit from treatment for significant PDA.
4.2.4.4 Necrotising Enterocolitis
A significant necrotising enterocolitis was recorded as one meeting criteria of Bell
stage 2 or worse (Walsh and Kliegman (1986)) on clinical presentation, radiological
appearance with or without surgical or autopsy confirmation.
4.2.4.5 Retinopathy of prematurity
Significant retinopathy of prematurity was defined as “threshold disease” defined
as stage III ROP present in eight cumulative clock hours or five contiguous clock
hours with plus disease (presence of tortuous vessels) in zone I or II (International
Committee for the Classification of Retinopathy of (2005)). Ophthalmologic ex-
amination were performed by designated paediatric ophthalmologist as per British
Association of Perinatal Medicine (BAPM) recommendations.
4.2.4.6 Weight gain
The weight gain from admission to discharge was obtained and weight gain per
kg/day was calculated. In addition, birth weight z scores were obtained using
Fenton charts (Fenton and Sauve (2007)). Fenton’s z scores were also calculated for
discharge weight and a di erence in birth and discharge score was also calculated.
4.2.4.7 Sample Size
We aimed to recruit 70 babies – 35 in each arm. As this was a pilot study, the
sample size was calculated on the clinically important di erence between the two
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study groups of 50%.
In addition to the above protocol following procedures were applied as well.
4.3 Adjunctive treatment
4.3.1 Surfactant
Babies received an additional dose of surfactant (poractant alphaR•) at twelve hours
after the first dose, if the baby was still requiring mechanical ventilation, and had
an oxygen requirement >30% and/or mean airway pressure was >10 cm H2O.
Some of the babies received an extra dose on top of the additional dose at the
discretion of the attending consultant. The total dose of surfactant was recoded
on the proforma and used for multiple regression analysis.
4.3.2 Ca eine
All babies were commenced on ca eine immediately after intubation and stabilisa-
tion. The babies received a loading dose of 20 mg/kg ca eine citrate followed by a
maintenance dose of 5-10 mg/kg/day until 34 weeks of corrected gestation.
4.3.3 Ibuprofen
If baby was diagnosed to have clinically significant PDA as per pre-defined criteria
and there was no contraindication for medication then baby received ibuprofen for
closure of duct.
4.3.4 Dexamethasone
Dexamethasone was used when a baby was considered “ventilator dependant” i.e.,
a baby who was ventilated for at least two weeks of life and/or had failed trial of ex-
tubations. These babies were considered high risk of developing bronchopulmonary
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dysplasia. The dose and duration of dexamethasone in this situation was according
to DART regime (Doyle et al. (2006)): twice daily dose of a 10-day tapering course
of dexamethasone sodium phosphate (150 microgram/kg /day for three days. 100
microgram/kg/day for three days, 50 microgram/kg/day for two days and 20 mi-
crogram/kg/day for 2 days and discontinue. Dexamethasone was also used when a
baby was suspected of having “laryngeal oedema”. In this situation baby received
three doses of 250 microgram/kg at 12 hour intervals. This could be started before
or after the extubation based on the clinical circumstances.
4.3.5 Bronchodialators and long term diuretics (>7 days)
These were not used in enrolled babies.
4.4 Routine clinical care and monitoring
Routine care and monitoring was done according to unit protocols. The baby was
formally reviewed at least twice a day by a senior neonatal doctor. The baby was
monitored continuously and his/her observations were recorded on an ITU chart.
These observations included vital parameters, ventilatory settings, blood gases and
pain chart. Any changes in the clinical management were formally recorded on
the charts as well. The regular monitoring continued even after extubation but
the frequency of observations reduced to four hours while on non-invasive support.
When baby graduated to special care, concentration was more focussed on apnoea
or desaturation episodes along with feeds and growth.
The babies also underwent mandatory screenings as per unit policy. This included
cranial ultrasound scan at 1st and 6th week of life. Babies had echocardiography
performed if there was suspicion of poor cardiac function or signs and symptoms
suggestive of PDA. The babies also ROP screening as per BAPM guidelines and
had hearing screen and formal newborn examination before discharge home.
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4.5 Duration of study
39 months – From July 2013 to September 2016
4.6 Data collection
The data for the study was collected from direct observation, regular observations
as performed by the sta  recording regular observations and from case notes, for
demographic information. It was initially entered into paper proformas (appendix
F) which were then transferred over to spreadsheets on password protected com-
puters complying with data protection guidelines. The relevant data then were
stored in Excel on NHS research computers. The computers were used for research
purposes only and are password protected. The research o ce, where the computer
was stored, could only be accessed by a member of research team. Accuracy of the
transcription of the case report forms onto the electronic database was checked by
reviewing all the records before final analysis.
4.7 Data Analysis
All analyses were conducted on data from the intention-to-treat population, which
included all patients who underwent randomisation. The normality of data was
assessed using the Kolmogorov-Smirnov statistic. For time dependant variables,
survival statistic was used. Log rank test using Kaplan Meier survival curve was
used for the primary outcome. This was also used for other time to event analysis
like duration of mechanical ventilation and duration of hospital stay (admission).
Multiple logistic-regression analysis using cox-regression was used to identify rel-
evant baseline covariates associated with the primary outcome, in addition to the
stratification variables. Variables tested in the model were selected if the p value
was less than 0.20 and if they were clinically relevant.
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A chi-square test (or Fisher’s exact test, when appropriate) was used for secondary
binary outcomes.
Continuous variables were compared with the use of an unpaired t-test or the
Mann–Whitney U (Wilcoxon rank sum) test. Adjusted analyses were performed
with the use of the same adjustment variables that were used in the linear-regression
model.
All analyses were conducted with the use of spss R• software, version 20 (IBM). A
two-sided p value of less than 0.05 was considered to indicate statistical significance.
The statistical analysis was supervised by Mr Kasim Adetayo, research statistician,
Durham University.
4.8 Ethics approval
REC Reference No: 13/NE/0110 (appendix A)
The study was approved by the NHS research ethics committee, the hospital re-
search and development peer review committee and Durham University. Though
the “waiver of consent” allowed us to randomise babies before formal consent, the
baby was formally included and data collected only after a written informed con-
sent from the parents or a person with parental responsibility was obtained. All
parents received patient information leaflet (appendix B) along with verbal explan-
ation and had at least 12 hours to read and discuss with partners if they wished so.
A complete confidentiality was maintained. Apart from data being stored in locked
research computers, all patients received a study number to obviate the need to
use name or other identity parameters of both baby as well as parents.
4.9 Roles
With the help of other team members, I identified the potential mothers whose
babies could be recruited in the trial. I then approached the mums with information
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of the trial with patient information leaflet. After baby’ birth, I obtained tracheal
aspirate before intubation. I ensured that baby was randomised after admission to
the unit by one of the members of clinical team. If the consent was not obtained so
far, I approached parents for written informed consent. I collected data on paper
proforma. In my absence, the attending neonatal registrar and consultant were
responsible to identify the potential recruits, speak to parents about the trial and
obtain consent. In my absence they were also responsible for collection of tracheal
aspirate, randomisation procedure and for the clinical monitoring of the baby.
4.10 Equipment
The study needed use of mechanical ventilation which was provided by DragerTM
Babylog C500 and AveaTM Viasys Carefusion ventilators (Figure 4.1). These were
machines owned by the neonatal department, hence no additional funding or any
financial support was received with regards to ventilators. We did, however, suc-
cessfully apply for a local research and development department grant to be able
to process the tracheal samples for inflammatory markers.
Measurements of Tidal Flow and Volume Direct measurement of tidal by respir-
atory flow signals have most commonly been obtained using a pneumotachograph
(PNT) connected in series to a silicon mask encompassing the infant’s nose, alone
or together with the mouth.
We ensured minimisation of technical dead space (ideally, <2 ml/kg) (Frey et al.
(2000)) is critical, since elevation of CO2 consequent to dead space or apparatus
resistance may alter control of breathing and a ect the tidal flow waveform.
The flow through technique enables acquisition of tidal flow data through an ap-
paratus with minimum dead space. Di erential flow occurring between a pneu-
motachograph placed before and after the airway opening is measured and is ideally
suited to studies in small (<2 kg) infants.
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4.11 Co-intervention and contamination
Contamination was avoided by not enrolling the baby in any other respiratory trial
until the primary outcome was reached. According to protocol, no cross over was
allowed during the study.
4.12 Pictures of equipment
The picture of the ventilatory equipments used in the study is shown in the Figure
4.1 (a) and Figure 4.1 (b). The equipment used to collect tracheal aspirate has
been depicted in Figure 4.2.
Protocol - Please refer to appendix D
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Figure 4.1: The Ventilators
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Figure 4.2: Tracheal aspiration equipment
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Chapter 5
Results
5.1 Introduction
The study was carried out between July 2013 and September 2016. During this
period, a total of 262 babies were screened of which 97 were eligible for enrolment
into the study. Of these, 70 babies were randomised (Figure 5.1). The remaining
27 babies could not be randomised for the reasons highlighted in Figure 5.3. All the
babies randomised to the study were confirmed to be eligible and their complete
data was available for analysis.
The enrolment commenced in July 2013 and was completed in September 2016.
During the time of the study, there were 265 babies in the eligible group (born at
less than 32 weeks or birth weight less than 1500 grams) who were admitted to
the unit. Out of these, 152 had required intubation and ventilation within first 12
hours of life. As 55 of these were ex-utero transfers whereby either the neonatal
team of the referral unit or the transport team had already intubated the babies
and commenced them on mechanical ventilation. That left 97 babies for possible
recruitment. Out of these 70 babies were randomised and consented by parents.
Out of these 70, 55 achieved primary outcome. Eleven babies died before discharge.
9 babies died when still ventilated
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Figure 5.1: CONSORT diagram showing recruitment and randomisation of babies
5.1.1 Projection versus enrolment
The study was commenced on 18th July 2013. Experience of the department over
the previous 12 months indicated that there were 90 babies admitted from the
eligible cohort of babies born at less than 32 weeks or birth weight between 500-
1500 grams. Out of these 45 babies were admitted for respiratory distress syndrome
within 12 hours of age. As 6 of them were ex-utero transfers who arrived intubated
and ventilated this made 39 babies eligible for the trial. As we set o  for the
numbers required for the trial and time frame, it became apparent that about 26
months were required to complete the enrolment keeping in mind various exclusions
and consent refusals. To achieve a sample target of 70 babies, the recruitment was
projected to be at 3 babies per month. This was based on trends in the rate
of admission to the unit over preceding 12 months. The target sample size was
91
5.1.1. Projection versus enrolment
reached over a period of 38 months.
Over the period of 26 months, we recruited 55 babies. Therefore we needed to
continue the trial until September 2016 whereby we managed to enrol 70 babies.
The graph of projection versus enrolment is shown in Figure 5.2.
To further explain this, we collated the figures for each category every year and
plotted them for the duration of preparation and performance of the study. These
figures combined with the total admissions of babies with low birth weight in the
neonatal unit presents a further interesting observation as in Table 5.1 Figure 5.4.
On close scrutiny, there was a trend of the number of extremely low birth weight
infants going down with less number of babies getting intubated hence being eligible
for the trial.
A further breakdown of missed babies (Figure 5.3) was also carried out. As severe
congenital anomaly was one of the excluding criteria, two babies were not ran-
domised because of their antenatal history. In 10 instances, the admitting team
used their own judgement and as there was a possibility, in view of pre-existing
requirement of oxygen or di culty in ventilating the baby, the team decided to
not to recruit the baby. Such a clinical condition in most cases led to use of high
frequency mode of ventilation. This was our rescue mode for this trial which again
vindicated their decision. On some occasions, as baby was very unwell and died in
first 48 hours, though the baby was randomised at the time of birth, we did not
feel it appropriate to approach grieving parents for consent.
We are grateful to have been considered for “waiver of consent”. Without this a
robust methodology for keeping the tidal volume constant from the birth, whilst
waiting for consent from parents, who are already stressed because of untimely
delivery, would have made it extremely di cult to recruit many babies. This is
well documented in randomised controlled trials where teams struggled to recruit
extremely unwell babies. Having said that, the parents still had the right to not
participate or if agreed, to withdraw from the study. Fortunately for us, we man-
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Figure 5.2: Graph of projections versus enrolment
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Figure 5.3: Flow diagram explaining non-recruitment for eligible babies
aged to get the consent in most cases, except for three babies. That left 12 babies
where the cause of not randomising the baby was not entirely clear.
In summary, The reasons for extending recruitment period were:
1. Overall number of eligible babies had come down.
2. Team/consultant decided not to randomise baby if baby was very unwell and
had imminent risk of escalating treatment or death.
3. On some occasions, as baby was very unwell and died in first 48 hours, though
the baby was randomised at the time of birth, we did not feel it appropriate to
approach grieving parents for consent.
Table 5.1: Breakdown of recruitment as per the category
Year Cumulative
Eligible
group
Cumulative
intubated
Cumulative
eligible
for trial
Cumulative
enrolled
Cumulative
missed
2013* 41 24 18 9 9
2014 80 45 30 26 4
2015 71 45 29 25 4
2016** 70 37 20 10 10
*From 18th July to 31st December 2013
**From 1st January to 31st September 2016
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Figure 5.4: Breakdown of recruitment as per the category
5.1.2 Study population
The characteristic of whole study population is provided in the Table 5.2. The
mean birth weight was 1044.23 gram (Figure 5.5) and median gestation of the
babies at birth was 27+2 (Figure 5.6). 91.4% Percent of babies had received at
least one dose of antenatal steroids. All the babies received at least one dose of
surfactant and ca eine. Mean severity of illness at birth assessed by CRIB II score
was 9.14.
5.2 Maternal characteristics
The babies in the two groups were compared for maternal demographics and clinical
characteristics. There were no di erences between any of the baseline maternal
characteristics between the two study groups (Table 5.3).
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Table 5.2: Profile of study population
Characteristic Study infants
N=70
Gestational age in weeks, mean (SD) 27.4 (2.14)
Birth weight in grams, mean (SD) 1044.23 (334.18)
Birth weight z score, mean (SD) 0.2 (0.9)
Birth weight Fenton’s centile, mean (SD) 55.57 (26.67)
Antenatal steroids
At least one dose, number (%) 64 (91.4%)
2 doses, count (%) 46 (65.7%)
Male sex, count (%) 44 (62.9%)
Multiple births, count (%) 19 (27.1%)
Born in study population, count (%) 69 (98.6%)
Postnatal transfer, count (%) 1 (1.4%)
Intubated at birth, count (%) 65 (92.8%)
CPAP before ventilation, count (%) 5 (7.1%)
Surfactant mg/kg, mean (SD) 237 (178)
CRIB II Score*, mean (SD) 9.14 (3.5)
Apgar Score at 1 min– median (IQR) 5(3-6)
Required chest compression, count (%) 5 (7.1%)
Temperature on admission in oC, mean (SD) 35.56 (0.96)
Oxygenation Index on admission, mean (SD) 5.71 (4.63)
A-a DO2 on admission, mean (SD) 17.04 (17.98)
CPAP – Continuous Positive Airway Pressure; CRIB II – Clinical Risk Index for babies
– II; A-a DO2 – Alveolar arterial Oxygen Gradient
5.3 Baseline infants’ characteristics
We compared the babies in the two groups by both demographic and clinical char-
acteristics.
5.3.1 Comparison of two study groups according to birth weight
and gestational age strata
There was no di erence between the two groups with when the groups were strat-
ified whether the birth weight was less than or more than 1000 grams (Table 5.4).
Further subdivision of the babies based on birth weights into four groups did not
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strata
Table 5.3: Baseline Maternal characteristics
Categories High TV
N=34
Low TV
N=36
p-value
Maternal Age in years,
Mean (SD)
29.3 (6.19) 27.7 (7.16) 0.321
White ethnicity, Count (%) 31 (91.2%) 36 (100%) 0.109
Rubella immune, Count (%) 30 (88.2%) 29 (80.66%) 0.672
Normal Anomaly Scan,
Count (%)
29 (85.36%) 33 (91.76%) 0.421
Maternal Pregnancy in-
duced Hypertension*,
Count (%)
4 (11.86%) 4 (11.16%) 1
Maternal diabetes, Count
(%)
4 (11.86%) 2 (5.66%) 0.422
Multiple pregnancy, Count
(%)
10 (29.4%) 9 (25%) 0.79
Two doses of Antenatal ster-
oids, Count (%)
24 (70.6%) 22 (61.1%) 0.259
Maternal chorioamnion-
itis**, Count (%)
7 (20.66%) 3 (8.36%) 0.182
Pre-labour rupture of mem-
branes, Count (%)
13 (38.2%) 14 (38.8%) 1
Rupture of membranes >18
hr, Count (%)
12 (35.36%) 11 (30.66%) 0.8
Antepartum Haemor-
rhage***, Count (%)
4 (11.86%) 5 (13.96%) 1
Spontaneous onset delivery,
Count (%)
22 (64.76%) 25 (69.46%) 0.8
Vaginal Mode of delivery,
Count (%)
19 (55.96%) 22 (61.16%) 0.81
*Pregnancy induced hypertension – significant enough to need intervention
**Chorioaminionitis – defined as fever in the mother with raised C-reactive protein
or white cell count or histopathological findings of chorioamnionitis on examination
of placenta
***Antepartum haemorrhage – significant enough to need intervention
Table 5.4: Breakdown of groups when stratified by birth weight
High TV
N=34 Count
(%)
Low TV
N=36 Count
(%)
p-value
Æ1000 gram (%) 16 (47.1%) 18 (50.0%) 0.497
>1000 gram (%) 18 (52.9%) 18 (50.0%)
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strata
Figure 5.5: Distribution of birth weight
reveal any statistically significant di erence (Table 5.5).
Table 5.5: Proportion of babies in study group according to birth weight
Weight Groups High TV
N=34
Count (%)
Low TV
N=36
Count (%)
<750 gram 7 (20.6%) 4 (11.1%)
751-1000 grams 11 (32.4%) 14 (38.9%)
1001-1250 grams 7 (20.6%) 10 (27.8%)
>1250 grams 9 9(26.5%) 8 (22.2%)
Similarly groups were not di erent when stratified based on birth gestation 28
weeks (Table 5.6).
Further subdivision of the babies based on gestation into four groups did not reveal
any statistically significant di erence (Table 5.7)
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Figure 5.6: Distribution of birth gestation
Table 5.6: Breakdown of groups when stratified by birth gestation
High TV
N=34
Count (%)
Low TV
N=36
Count (%)
p-value
Æ28w (%) 20 (58.8%) 23 (63.9%) 0.425
>28 w (%) 14 (41.2%) 13 (36.1%)
Table 5.7: Proportion of babies in study group according to gestation at birth
Gestation at birth High TV
N=34
Count (%)
Low TV
N=36
Count (%)
Æ25 weeks 7 (20.6%) 3 (8.3%)
25-26+6 9 (26.5%) 12 (33.3%)
27-28+6 8 (23.5%) 14 (38.9%)
>29 10 (29.7%) 7 (19.4%)
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5.3.2 Comparison of baseline clinical characteristics
The important demographic and clinical characteristic details of the two study
groups are shown in the Table 5.8. There were no di erences between the two
groups except baseline oxygenation index. This di erence was further explored by
comparing various parameters of baseline severity of initial lung disease.
Table 5.8: Comparison of infant characteristics in the two study groups
Parameter High TV Low TV p-value
N=34 N=36
Gestational age in weeks,
median (IQR)
27.29 (25.46-
29.53)
27.43 (26.43-
28.78)
0.892
Birth weight in grams,
mean (SD)
1064.15 (393.56) 1025.42 (270.89) 0.63
Birth weight Fenton’s z
score, mean (SD)
0.26 (0.96) 0.14 (0.86) 0.58
Birth weight Fenton’s
centile, mean (SD)
56.56 (26.5) 54.64 (27.1) 0.77
CRIB II Score, median
(IQR)
9 (6-12) 9 (7-11) 0.836
Male sex, number (%) 20 (45.5%) 24 (54.5%) 0.333
Apgar score at 1 min, me-
dian (IQR)
5 (3-6) 4.5 (3.25-7) 0.943
Apgar score at 5 min, me-
dian (IQR)
7 (6-8) 8 (6.25-9) 0.559
Temperature on admis-
sion in oC, mean (SD)
36.62 (1,02) 36.5 (0.91) 0.61
Male sex, count (%) 20/34 (58.8%) 24/36 (66.7%) 0.333
AGA, count (%) 30/34 (88.2%) 30/36 (83.3%) 0.736
inborn in study popula-
tion, count (%)
33 (97.1%) 36 (100%) 0.486
Age at intubation, mins,
mean (SD)
32.76 (123.2) 25.61 (70.5) 0.76
Required chest compres-
sion, count (%)
3 (8.8%) 2 (5.6%) 0.472
CPAP before ventilation,
count (%)
2 (5.9%) 3 (8.3%) 0.528
CRIB II – Clinical Risk Index for babies – II; CPAP – Continuous Positive Airway Pressure;
AGA – Appropriate for Gestation Age
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5.3.3 Comparison of babies based on baseline severity of initial
lung disease at the time of initial ventilation
The severity of lung disease at the time of initial ventilation was comparable
between the two groups as assessed by FIO2 and (Alveolar arterial oxygen gradient
A-aDO2) (Table 5.9).
On the contrary, there was a significant di erence between the two groups in other
baseline parameters like oxygenation index (OI), peak inspiratory pressure (PIP),
mean airway pressure (MAP), minute volume (MV) and partial pressure of CO2
(pCO2). Di erence in OI could be explained based on increased pressure required
to deliver the higher tidal volume which also altered oxygenation index. This is
reinforced by the fact that FIO2 and paO2 were no di erent in two groups.
The di erence in PIP and MAP can be explained on the basis of need for higher
pressure to generate high TV. Likewise, due to lack of control of RR initially, MV
was more in babies with high TV. High MV also correlated with higher initial
paCO2.
Table 5.9: Severity of initial lung disease at the time of initial ventilation in two
study groups
Severity of Initial lung
disease
High TV
N=34
Mean (SD)
Low TV
N=36
Mean (SD)
p-value
Initial A-aDO2 18.53 (18.68) 15.63 (17.46) 0.5
Initial FIO2 0.35 (0.18) 0.37 (0.23) 0.7
Initial OI 7.00 (5.44) 4.50 (3.30) <0.05*
Initial MAP 10.70 (2.38) 8.64 (1.94) <0.005*
Initial PIP 29.22 (4.94) 19.99 (8.62) <0.0001*
Initial paO2 7.95 (2.96) 9.04 (2.42) 0.096
Initial paCO2 4.45 (2.15) 5.47 (1.79) <0.05*
A-aDO2 - Alveolar to arterial oxygen gradient, PIP – Peak Inspiratory Pressure, MAP – Mean
Airway Pressure, FIO2 – Fractional inspired Oxygen; pO2 – Partial pressure of Oxygen, pCO2
– partial pressure of Carbon dioxide
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5.4 Primary outcome measures
The primary outcome for this study was chosen as the time to achieve 25% reduc-
tion in peak inspiratory pressure. Out of 70 babies enrolled, 15 babies exited from
trial for various reasons outlined in Table 5.11. Out of the remaining 55 babies, 50
babies survived to discharge while 5 babies died before discharge.
5.4.1 Success record of babies in the trial
On comparing the two groups for their success in achieving primary outcome, 29/34
and 26/36 babies in high and low TV group achieved primary outcome. This was
not statistically significant (p=.247) (Table 5.10).
Table 5.10: Primary outcome success
Successful in achiev-
ing primary out-
come
High TV Low TV Total p-value
Yes 29 26 55 0.247
No 5 10 15
Total 34 36 70
When the babies exited the trial, of note, hypercapnoea was responsible for 7
(19.4%) babies in low TV groups as compared to 1 (2.9%) baby in high TV group,
the di erence was not statistically significant. Comparison of other reasons behind
the exit did not reveal any clinical or statistically significant di erence. Majority
of the exited babies received high frequency ventilation, the pattern between them
was not statistically significant (Table 5.11).
5.4.2 Primary outcome after randomisation
The median duration of 25% drop in peak inspiratory pressure (PIP) in high and
low TV group was 13.8 hours (95% CI, 6.4-21.3) and 18.1 hours (95% CI, 10.4-
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Table 5.11: Record of exited babies in two study groups
High TV Low TV p-value
N=34 N=36
Count (%) Count (%)
Met trial exit criteria? 5 (14.7%) 10 (27.8%) 0.15
If yes, which one,
High pCO2 1 (2.9%) 7 (19.4%) 0.23
High FIO2 2 (5.8%) 2 (5.6%)
Pulmonary haemorrhage 1 (2.9%) 1 (2.8%)
Air leak 1 (2.9%) 0 (0%)
If yes, then switched to which mode of ventilation
HFO 5 (100%) 6 (60%) 0.38
Pr AC 0 (0%) 1 (10%)
Pr AC + VG with di erent TV 0 (0%) 2 (20%)
Vol AC 0 (0%) 1 (10%)
pCO2 – partial pressure of CO2, FIO2 – Fractional concentration of inspired oxygen, HFO
– High frequency oscillation ventilation, Pr AC – Pressure Assist Control Ventilation, VG –
Volume Guarantee, TV – Tidal Volume, Vol AC – Volume assist control Ventilation
25.8) respectively. The log rank statistic for equality of survival distribution for
randomisation arm was not significant (p=0.931) (Table 5.12, Figure 5.7).
Table 5.12: Comparison of primary outcome in the two study groups
High TV Low TV p-value
N=34 N=36
Primary outcome, Median
(95% CI)
13.8 (6.4-21.3) 18.1 (10.4-25.8) 0.931
5.4.3 Univariate analysis of primary outcome measure
We performed regression analysis for the continuous outcome measures. This con-
sidered e ects of variables which could influence primary outcome. On univariate
analysis, a number of factors such as birth weight less than 1000 gram, gestation less
than 28 weeks, fluid prescription in first week of life, were significantly associated
with primary outcome of 25% reduction in peak pressures (Table 5.13).
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Table 5.13: Univariate analysis of primary outcome measure
Variable Hazard ratio (95%
CI)
p-value
Randomised to High TV 1.024 (.598 – 1.754) 0.931
Stratified to Æ1000 g birth weight 1.592 (1.199 -2.114) 0.001
Gestation age Æ28 weeks at birth 1.889 (1.406 - 2.537) <0.001
Birth weight <10th centile .790 (.439 - 1.421) 0.431
Male Gender .992 (.752 - 1.309) 0.957
Singleton .994 (.741 - 1.3330) 0.968
Antepartum Haemorrhage 1.254 (.816 - 1.926) 0.302
Chorioamnionitis 1.199 (.802 - 1.793) 0.376
Maternal age 1.023 (.981 - 1.066) 0.296
Vaginal delivery 956 ((.728 - 1.254)) 0.744
Antenatal steroids – 2 doses 827 (.617- 1.110) 0.206
Apgars at 1 min 1.095 (.969 - 1.238) 0.147
Surfactant (x100mg/Kg) .708 (.478 - 1.048) 0.084
Temperature on admission 1.123 (.866 - 1.456) 0.381
Temp <36 1.184 (.871 - 1.609) 0.281
Severe lung disease based on OI 1.99 (0.98-4.1) 0.059
Severe lung disease based on A-aDO2 1.21 (0.92 – 1.6) 0.181
Base deficit on admission 1.041 (.972 - 1.115) 0.253
Metabolic acidosis, BD >5 1.184 (903 - 1.551) 0.221
Fluid (x10ml/kg) 1.099 (1.017 - 1.188) <0.05
CPAP before ventilation .778 (.465 - 1.302) 0.339
Mean Airway Pressure initial 1.069 (.977 - 1.170) 0.148
Peak airway pressure initial 1.016 (.984 - 1.049) 0.32
Fractional inspired oxygen initial .235 (.045 -1.222) 0.085
Chest expansion >8 ribs (L) 1.099 (813 - 1.484) 0.54
Chest expansion >8 ribs (R) 1.058 (.807 - 1.386) 0.684
Initial pCO2 (<4.5) .864 (.705 - 1.060) 0.162
OI – Oxygenation Index, A-aDO2 – Alveolar Arterial oxygen gradient, BE – Base Excess,
CPAP – Continuous Positive Airway Pressure, pCO2 – partial pressure of CO2
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Figure 5.7: Kaplan-Meier curve for 25% reduction in PIP for babies randomised to
high and low TV
5.4.4 Multiple logistic regression analysis of primary outcome
measure
For multiple linear regression analysis, only variables at significance of p<0.2 were
included from univariate analysis. These were: the gestation age less than 28 weeks,
Apgars at 1 min, Surfactant, initial PCO2, fractional inspired oxygen (FIO2), mean
airway pressure (MAP), fluids in first week. Out of these, gestation age less than
28 weeks, fractional inspired oxygen (FIO2) and fluids in first week turned out to
be significantly associated with primary outcome (Table 5.14).
5.4.5 Birth weight and primary outcome
Babies in the study were stratified at randomisation into two groups based on birth
weight: Æ1000 gram or >1000 gram. Out of total 70 babies randomised, 36 and 34
babies were stratified into Æ1000 grams and >1000 gram respectively. Out of these,
15 babies (13 and 2 babies in Æ1000 gram or >1000 gram respectively) met exit
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Table 5.14: Multiple logistic regression analysis of primary outcome measure
Variable Hazard ratio (95% CI) p-value
Gestation age <28 weeks .30 (.14 - .64) 0.002
Apgars at 1 min 1.07 (.93 - 1.23) 0.35
Surfactant (x100mg/Kg) .99 (.99 - 1.004) 0.69
Fractional inspired oxygen Initial .18 (.03 - .94) 0.04
Mean Airway Pressure initial .93 (.84 - 1.03) 0.18
Initial pCO2 (<4.5) .94 (.76 - 1.16) 0.55
Fluid (x10ml/kg) 1.10 (1.02 - 1.19) 0.018
criteria. The di erence between the groups with regards to providing successful
ventilation was statistically significant (Table 5.15).
Table 5.15: E ect of birth weight on primary outcome achieved
Primary outcome
achieved
High TV
N= 34
Count (%)
Low TV
N= 36
Count (%)
p-value
Æ1000 gram birth
weight
13 (72.2%) 10 (55.6%) 0.78
>1000 gram birth
weight
16 (100%) 16 (88.9%)
Post birth weight stratification, comparison between the two groups was not stat-
istically significant (Table 5.16, Figure 5.8, Figure 5.9).
Table 5.16: Comparison of the Primary outcome based on birth weight
Primary outcome High TV
Median (95%
CI)
Low TV
Median (95%
CI)
p-value
Æ1000 gram birth
weight
21.1 (1.9-40.1) 23.2 (19.1 – 27.4) 0.612
>1000 gram birth
weight
11.2 (5.8-16.7) 14.1 (6.5 – 21.8)
5.4.6 E ect of gestational age on primary outcome
The e ect of gestation age on primary outcome was studied by post-hoc analysis.
The study infants were subdivided into two subgroups, Æ28 weeks’ gestation and
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Figure 5.8: Primary outcome stratified according to birth weight Æ1000 grams
Figure 5.9: Primary outcome stratified according to birth weight >1000 grams
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>28 weeks’ gestation at birth.
The proportion of babies of Æ28 weeks’ gestation who met the exit criteria were
13/44 (29.5%) as compared to babies >28 weeks’ gestation who had failure rate of
2/26 (7.7%). Hence, babies in less than 28 weeks’ group were 3.83 times likely to
not to achieve the primary outcome as compared to the babies in >28 weeks group
(Table 5.17).
Table 5.17: E ect of gestation age at birth on primary outcome achieved
Primary outcome
achieved
High TV
N= 34
Count (%)
Low TV
N= 34
Count (%)
p-value
Æ28 weeks 16 (76.2%) 15 (65.2%) 1
>28 weeks 13 (100%) 11 (84.6%)
When stratified, babies in two groups were assessed for time to reach 25% drop in
peak inspiratory pressure. In either gestation strata, the di erence in both groups
was not statistically significant (Table 5.18, Figure 5.10, Figure 5.11).
Table 5.18: Comparison of the Primary outcome based on gestation age
Primary outcome High TV
Median (95% CI)
Low TV
Median (95% CI)
p-value
Æ28 weeks 23.9 (16.3-31.5) 24.6 (12.7-36.4) 0.928
>28 weeks 8.8 (7.4 – 10.2) 11.2 (5.1 – 17.4)
5.4.7 E ect of severity of lung disease at birth on primary
outcome
We also carried out subgroup analysis based on severity of respiratory illness as-
sessed by alveolar arterial oxygen gradient (A-aDO2) and oxygenation index (OI)
at initial ventilation. This did not return a clinically or statistically significant
result.
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Figure 5.10: Primary outcome stratified according to Æ28 weeks’ gestation at birth
Figure 5.11: Primary outcome stratified according to >28 weeks’ gestation at birth
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5.5 Total duration of mechanical ventilation in two
study groups
Out of 70 babies, 9 (12.8%) died before they could be extubated. 6/36 (16.6%)
and 3/34 (8.8%) babies could not be extubated in low and high group respectively.
When this was broken down as per birth weight stratification, 8/36 and 1/34
babies born at Æ1000g and >1000g died before extubation respectively. 8/44 and
1/26 babies born at Æ28 weeks and >28 weeks gestation died before extubation
respectively).
The median duration of ventilation in the high TV group was 35 hours (95% CI
(9.8-60.2 hrs)) as compared to 61.8 hours (95% CI 14.4 – 109.2 hrs) in low TV
group. The log rank statistic for equality of survival distribution for randomisation
arm was not significant (p=0.928) (Table 5.19, Figure 5.12).
Table 5.19: A Comparison of two groups for duration of mechanical ventilation
High TV
Median (CI)
Low TV
Median (CI)
p-value
Mechanical Ventilation
duration, hrs
35 (9.8-60.2) 61.8 (14.4 – 109.2) 0.928
5.5.1 E ect of birth weight on duration of mechanical ventilation
To assess the e ect of birth on duration of mechanical ventilation, babies were ana-
lysed in two groups, birth weight Æ1000 grams and >1000 grams. In the subgroup
of babies Æ1000 grams birth weight, babies in the high tidal volume group received
mechanical ventilation support for median duration of 368.9 hrs (95% CI 69.7-668
hrs) as compared to those on low tidal volume group who remained on mechanical
ventilation for a median duration of 137.9 hrs (95% CI 77.6 – 198.3 hrs). ( Table
5.20, Figure 5.13).
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Figure 5.12: Kaplan Meier survival curves for the duration of ventilation support
in two study groups
In the group of babies >1000 grams birth weight, babies in high tidal volume group
received mechanical ventilation support for median duration of 29.1 hrs (95% CI
21.2 – 36.9 hrs) as compared to those on low tidal volume group who remained
on mechanical ventilation for a median duration of 21.6 hrs (95% CI 0-61.6 hrs).
The di erence between the two study groups was not significant and the log rank
statistic for equality of survival distribution for randomisation arm was p=0.516
(Table 5.20, Figure 5.14).
Table 5.20: Comparison of duration of mechanical ventilation by birth weight
Birth weight High TV
Median (95% CI)
Low TV
Median (95% CI)
p-value
Æ1000 368.9 (69.7- 668) 137.9 (77.6 – 198.3) 0.516
>1000 29.1 (21.2 – 36.9) 21.6 (0-61.6)
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Figure 5.13: Kaplan Meier survival curves for the duration of mechanical ventilation
in two birth weight groups of Æ1000 gram
Figure 5.14: Duration of mechanical ventilation stratified according to birth weight
>1000 grams
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5.5.2. E ect of gestation age on duration of mechanical ventilation
Figure 5.15: Kaplan Meier survival curves for the duration of mechanical ventilation
in babies with Æ28 weeks of gestation age at birth
5.5.2 E ect of gestation age on duration of mechanical
ventilation
To asses the e ect of gestational age at birth on the duration of mechanical ventil-
ation on the whole, babies were analysed into two groups, those with gestation age
equal to or less than 28 weeks and more than 28 weeks.
In the group of babies less than or equal to 28 weeks’ gestation, babies in high
tidal volume group received mechanical ventilation support for median duration of
196.3 hrs (95% CI 0- 545.2 hrs) as compared to those on low tidal volume group
who remained on mechanical ventilation for a median duration of 83.4 hrs (95% CI
0-173.1 hrs). The di erence between the two study groups when considered their
birth gestation was not significant and the log rank statistic for equality of survival
distribution for randomisation arm was p=0.595 (Table 5.21, Figure 5.15).
Table 5.21: Comparison of duration of mechanical ventilation by gestation age
Gestation at
birth
High TV
Median (95% CI)
Low TV
Median (95% CI)
p-value
Æ28w 196.3 (0 – 545.2) 83.4 (0-173.1) 0.595
>28w 22 (9.9 – 34.1) 39.5 (3.2 – 75.8) 0.88
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Figure 5.16: Kaplan Meier survival curves for the duration of mechanical ventilation
in >28 weeks gestation group – comparison of low versus high tidal volume groups
In the group of babies more than 28 weeks of gestation, babies on high tidal volume
received mechanical ventilation support for a median duration of 22 hrs (95% CI
9.9-34.1 hrs) as compared to those on low tidal volume who received mechanical
ventilation support for 39.5 hrs (95% CI 3.2-75.8 hrs). This di erence in the two
study groups was not significant and log rank statistic (using Kaplan meier survival
statistics) for equality of survival distribution for randomisation arm was p= 0.88
(Table 5.21 Figure 5.16).
5.5.3 E ect of severity of lung disease at birth on duration of
mechanical ventilation
We carried out subgroup analysis based on severity of respiratory illness assessed by
alveolar arterial oxygen gradient (A-aDO2) and oxygenation index (OI) at initial
ventilation. The analysis did not reveal any clinical or statistically significant
di erence between the two groups.
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Figure 5.17: Comparison of duration of admission between the two randomised
groups
5.6 Duration of admission
Out of 70 babies enrolled, 30/34 babies and 29/36 babies from high and low TV
group were discharged home. The duration of admission was compared between
the two study groups. The median duration of admission in high tidal volume
group was 1932.7 hrs (95% CI 1416.1 – 2449.2 hrs) as compared to 1762.3 hrs (95%
CI 1576.7 – 1957 hrs). The long rank statistic for equality of survival distribution
for randomisation arm was p= 0.304 (Table 5.22, Figure 5.17)
Table 5.22: Duration of admission
High TV
Median (95% CI)
Low TV
Median (95% CI)
p-value
Duration of admis-
sion, hrs
1932.7 (1416.1 –
2449.2)
1762.3 (1576.7 –
1957)
0.304
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5.7 E cacy of the ventilation
The preterm infants enrolled in the study were monitored for their ventilator para-
meters. We also wanted to find out the e ciency and e ectiveness of the main-
taining the tidal volume and whether it had any correlation with the volume being
low or high.
5.7.1 Ventilatory parameters
The babies in both groups had blood gases monitored at regular intervals. The
normal limit of paCO2 was deemed to be 4.5-6.5 kPa in arterial blood gas. If the
source of blood gas was other than arterial, it was adjusted to match. The blood
gasses then were analysed to find out how many of these values, babies had pCO2 in
normal limits, higher than normal and lower than normal. One baby in high tidal
volume group exited because of either persistently high or low pCO2 as compared
to 7 babies in low tidal volume group.
We also compared the mean pCO2 between the two groups by independent t test.
While mean (SD) tidal volume were di erent between the two groups – 6 (1.6) and
4.4 (1.4) in high and low tidal volume group respectively (p=<.0001), there was
no di erence in minute volumes of the two groups. This could be explained on the
di erence in set respiratory rate (RR) which was adjusted to maintain the paCO2
in desired limit, as per protocol. Mean (SD) set RR for high and low TV group was
33.7 (6.7) and 38.5 (10.2). This was statistically significant (p=<0.05). There was
also di erence in two groups for mean PIP which was proportional to the di erence
in the tidal volume in both statistical and clinical significance (p=<0.0001, Table
5.23, Figure 5.18).
While mean paCO2 was not di erent between the two groups, the number of
low paCO2 values were higher in high tidal volume group (61.3% versus 32.6%,
p=<.005, Table 5.23, Figure 5.19).
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Table 5.23: Ventilatory Parameters
Ventilatory Parameters High TV
Mean (SD)
Low TV
Mean (SD)
p-value
PIP, cm H2O 26.27 (4.94) 18.81 (7.88) <0.0001*
TV, mL/Kg 6.06 (1.63) 4.40(1.44) <0.0001*
MV, mL/Kg/min 291.18 (104.1) 252.40 (108.25) 0.132
paCO2, kPa 4.55 (1.89) 5.17(1.9) 0.174
RR, count 52.66 (12.35) 54.57 (13.78) 0.544
Set RR, count 33.71 (6.77) 38.49 (10.22) <0.05*
Spontaneous RR, count 19.93 (15.66) 15.6 (13.18) 0.214
Mean pH 7.38 (0.1) 7.14 (1.23) 0.255
Normal paCO2 values, % 27.63% (30.78%) 43.52% (40.26%) 0.067
Low paCO2 values, % 61.63% (38.19%) 32.65% (39.44%) <0.005*
High paCO2 values, % 10.74% (22.89%) 21.05% (36.41%) 0.159
PIP – Peak Inspiratory Pressure, TV – Tidal Volume, MV – Minute Volume, pCO2 – partial
pressure of CO2, RR – Respiratory Rate
Figure 5.18: Ventilatory Parameters
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Figure 5.19: Comparison of normal paCO2 values between two groups
5.7.2 Oxygenation parameters
As per protocol, we tried to maintain saturation within the current acceptable
limits i.e., 90-95%. The fractional inspired oxygen (FIO2) was altered to achieve
these acceptable limits. As FIO2 was marker for oxygen requirement, this was
monitored on hourly basis in both groups. Two babies in high tidal volume group
exited because of excessive oxygen requirement as did 2 babies in low tidal volume
group. The data were collected as to what was the maximum requirement of FIO2
in each baby. The data led to median FIO2 in each group and described in the
table 5.24.
Babies in both groups were also monitored for mean airway pressure generated to
provide optimum oxygenation. The maximum mean airway pressure values were
then analysed to ascertain the di erence between the two groups. The mean max-
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imummean airway pressure in high tidal volume group was 12.3 as compared to 10.1
cm H2O in low tidal volume group. This was statistically significant (p=<0.0001)
probably because of increased peak inspiratory component in achieving the tidal
volume (Table 5.24, Figure 5.20).
Table 5.24: Oxygenation parameters
Oxygenation paramet-
ers
High TV
Mean (SD)
Low TV
Mean (SD)
p-value
Initial VG FIO2 0.35 (0.18) 0.37 (.23) 0.725
Max VG FIO2 0.40 (0.19) 0.41 (0.19) 0.837
Extubation VG FIO2 0.27 (0.1) 0.24 (0.05) 0.168
Max CPAP FIO2 0.35 (0.12) 0.36 (0.14) 0.8
Initial VG MAP, cm H2O 10.7 (2.4) 8.6 (1.9) <0.0001
Max VG MAP, cm H2O 12.3 (2.2) 10.1 (2) <0.0001
Max CPAP MAP, cm H2O 7.5 (1.3) 7 (1) 0.123
VG – Volume Guarantee, FIO2 – Fractional inspired Oxygen, CPAP – Continuous Positive
Airway Pressure, MAP – Mean Airway Pressure
5.8 Duration of respiratory support in two groups
We also monitored the time spent by each baby while receiving mechanical ventil-
ation, CPAP, high flow nasal cannula therapy and low flow oxygen therapy. This
was then compared separately and together between the two groups. There was no
di erence between the two groups (Table 5.25, Figure 5.21).
Table 5.25: Comparison of duration of respiratory support between the two groups
Duration of Respiratory
support
High TV
mean (SD)
Low TV
mean (SD)
p-
value
Mechanical ventilation Dura-
tion, hrs
400.1 (467.8) 208.4 (401.42) 0.09
CPAP Duration, hrs 258.5 (289.6) 286.5 (318.4) 0.725
HHFNC Duration, hrs 228.9 (268.1) 317.7 (403.8) 0.322
Non-Invasive support Dura-
tion (CPAP+HFC), hrs
487.5 (452.5) 604.2 (531.9) 0.367
Total respiratory support dur-
ation (MV+CPAP+HF), hrs
887.6 (802.5) 812.6 (838.5) 0.727
CPAP – Continuous Positive Airway Pressure, HFNC – High Flow Nasal Cannula, MV –
Mechanical Ventilation
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Figure 5.20: Oxygenation Parameters
5.9 Other outcome measures
5.9.1 Pulmonary complications
Premature infants are known to be prone to various pulmonary complications which
are contributed by many factors, most important of them are prematurity and mode
of respiratory support.
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Figure 5.21: Duration of respiratory support between the two groups
5.9.1.1 Short term pulmonary complication - air leaks and pulmonary
haemorrhage
The babies in two groups were compared for incidence of air leak and whether it
was severe enough to warrant any intervention during the period of mechanical
ventilation using volume guarantee. One baby in high tidal volume group exited
because of air leak (pulmonary interstitial emphysema) as compared to none in
low tidal volume group (Table 5.11) . The total number of significant incidences (3
and 0 in high and low TV group respectively) in two groups were not significantly
di erent (p=0.10, Table 5.26, Figure 5.22).
The babies in two groups were also compared for incidence of pulmonary haem-
orrhage and whether it was severe enough to warrant any intervention during the
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period of mechanical ventilation using volume guarantee. One baby each in high
tidal volume group and low tidal volume group exited because of pulmonary haem-
orrhage (Table 5.11). The total number of significant incidences (5 and 7 in high
and low TV group respectively) in two groups was not significant either (p=0.754,
Table 5.26, Figure 5.22).
Table 5.26: Comparison of incidence of air leaks and pulmonary haemorrhage in
two groups
High TV
N= 34
count (%)
Low TV
N= 36
count (%)
p-value
Number of episodes of air leaks 3 (8.8%) 1 (2.8%) 0.35
Number of episodes of signific-
ant air leaks
3 (8.8%) 0 (0%) 0.109
Number of episodes of pulmon-
ary haemorrhage
5 (14.7%) 8 (22.2%) 0.543
Number of significant pulmon-
ary haemorrhage
5 (14.7%) 7 (19.4%) 0.754
5.9.1.2 Incidence of bronchopulmonary dysplasia
We defined bronchopulmonary dysplasia as requirement of oxygen or respiratory
care at 36 weeks post menstrual age. To get a full perspective on its comparison
between the two groups, we also identified the babies needing oxygen or respiratory
care at 28 days of age and categorised the severity of chronic lung disease, whether
babies received postnatal steroids, required home oxygen and if yes, how much. On
analysis, there was no statistical significance between the two groups. (Table 5.27,
Figure 5.22)
5.9.2 Non-pulmonary complications related to prematurity
Premature babies are prone to non-pulmonary complications like sepsis, intra-
ventricular haemorrhage (IVH), periventricular leukomalacia (PVL), Patent duc-
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Table 5.27: Comparison of incidence of Bronchopulmonary Dysplasia between the
two groups
High TV
N=34
Count (%)
Low TV
N=36
Count (%)
p-value
Received postnatal steroids,
count (%)
10 (29.4%) 5 (13.9%) 0.238
Respiratory support at 28 days,
count (%)
23 (67.6%) 25 (69.4%) 0.534
BPD at 36 PMA, count (%) 20 (58.8%) 16 (44.4%) 0.599
Severity of BPD, count (%) 0.054
Mild 1 (2.9%) 5 (13.9%)
Moderate 11 (32.4%) 13 (36.1%)
Severe 9 (26.5%) 3 (8.3%)
Home Oxygen, count (%) 18 (52.9%) 16 (44.4%) 0.795
Amount of home oxygen, mean 0.17 0.21 0.617
BPD – Bronchopulmonary Dysplasia
tus arteriosus (PDA), hypotension (requiring inotropes), necrotising enterocolitis
(NEC) and retinopathy of prematurity (ROP).
There were no significant di erences in the incidence of the complications related
to prematurity in the two study groups. (Table 5.28, Table 5.29,Figure 5.23)
5.10 Use of therapeutic agents
All babies received surfactant before intubation and ca eine before extubation.
There was no di erence in use of the dose of surfactant, postnatal steroids, medic-
ally treated PDA between the two groups (Table 5.30).
5.11 Weight gain/postnatal growth
As shown in the section of baseline characteristics, the birth weights of the two
groups were similar. The mean total weight gain from admission to discharge in
babies ventilated initially with high and low tidal volume was 1466.1 and 1566.1
gram respectively. This weight gain when taken into consideration of the number
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Table 5.28: Comparison of non-pulmonary complications of prematurity in two
groups
Outcome High TV
N=34
Low TV
N=36
p-value
Sepsis suspected in first 72 hours,
Count (%)
13 (38.2%) 14 (38.9%) 0.575
Sepsis proven in first 72 hours,
Count (%)
0 (0%) 1 (2.78%) 0.514
Courses of antibiotics in >72
hours, Median (IQR)
1 (1-3) 2 (0.5-3) 0.947
BC positive sepsis in >72 hours,
Count (%)
14 (41.2%) 13 (36.1%) 0.942
Any IVH, Count (%) 14 (41.2%) 12 (33.3%) 0.588
Severe IVH (grade 3 or 4), Count
(%)
2 (5.9%) 7 (19.4%) 0.32
PVL, Count (%) 2 (5.9%) 6 (16.7%) 0.438
Significant PDA, Count (%) 13 (38.2%) 14 (38.9%) 0.901
Inotropes required?, Count (%) 10 (29.4%) 15 (41.7%) 0.206
Inotrope score Æ20, Count (%) 8 (23.5%) 8 (22.2%) 0.561
NEC, Count (%) 9 (26.5%) 17 (47.2%) 0.173
NEC Øbell stage II, Count (%) 4 (11.8%) 8 (22.2%) 0.667
ROP, Count (%) 16 (47.1%) 11 (30.6%) 0.236
ROP Ø Stage 3, Count (%) 7 (20.6%) 5 (13.9%) 0.445
BC – Blood Culture, IVH – Intraventricular Haemorrhage, PVL – Periventricular leukomala-
cia, PDA – Patent Ductus Arteriosus, NEC – Necrotising Enterocolitis, ROP – Retinopathy
of Prematurity
Table 5.29: Comparison of bacterial growth between the two groups
Bacteria High TV
N=34
Count (%)
Low TV
N=36
Count (%)
p-value
Negative 17 (50%) 19 (52.8%) 0.354
CONS 13 (38.2%) 10 (27.8%)
Staph aureus 0 (0%) 3 (8.3%)
E coli 1 (2.9%) 0 (0%)
Enterococcus* 1 (2.9%) 0 (0%)
Strep porcinus* 1 (2.9%) 0 (0%)
CONS – Coagulase Negative Staphylococcus Aureus
*1 baby had more than bacteria positive blood culture
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Figure 5.22: Pulmonary complications (% of total babies)
Table 5.30: Comparison of use of therapeutic agents between the two groups
Pharmacological treat-
ment
High TV Low TV p-value
N= 34 N=36
Dose of surfactant in mg/kg,
mean (SD)
245.3 (105.4) 230.5 (66.5) 0.486
Postnatal steroids for BPD,
count (%)
10 (29.4%) 5 (13.9%) 0.201
Ibuprofen for PDA, count
(%)
5 (14.7%) 6 (16.7%) 0.542
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Figure 5.23: Non-pulmonary complications (% of total babies)
of days admitted and birth weight was – 19.7 and 19.6 gram/kg/day respectively.
None of them showed any significant di erence between the two groups. The data
was also assessed using weight z-score (Fenton’s) and when the two groups were
compared, the mean change in z-score were -1.65 and -1.45 respectively in high and
low tidal volume group. This was also not statistically significant (p=0.335, Table
5.31, Figure 5.24, Figure 5.25).
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Table 5.31: Comparison of weight gain during hospitalisation in two groups
Weight gain High TV Low TV p-value
Total weight gain, mean (SD) 1466.1 (613.4) 1566.17 (637.2) 0.541
daily weight gain, mean (SD)
g/kg/day
19.7 (6.4) 19.6 (4.9) 0.966
Change in the z-score, mean
(SD)
-1.65 (0.92) -1.45 (0.57) 0.335
Figure 5.24: Weight gain from birth to discharges
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5.12. Cytokines/Inflammatory markers
Figure 5.25: Change in z-score
5.12 Cytokines/Inflammatory markers
We obtained tracheal aspirate at pre-intubation and pre-extubation/48 hours.
The baseline characteristic of the inflammatory markers were not di erent between
the two groups (Table 5.32). Many babies did not have a second sample because:
it was early extubation, patient exited, patient transferred etc. Hence there were
28 pairs of sample of the babies. We then compared the di erence between the
two samples in the same baby (Table 5.33). The di erence between the two groups
were not statistically significant.
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Table 5.32: Comparative analysis of pre-intubation tracheal aspirates between the
two groups
Inflammatory marker High TV Low TV p-value
IL-6, mean (SD) 2.74 (4.14) 2.65 (4.2) 0.933
IL-8, mean (SD) 53.94 (159.5) 7.31 (12.89) 0.158
TNF-–, mean (SD) 0.15 (0.32) 0.17 (0.37) 0.864
IL-6 – Internleukin 6, IL8-8 – Internleukin 8, TNF-– Tumour Necrosis Factor – Alpha
Table 5.33: Comparative analysis of change in tracheal aspirates between the two
groups
Di erence between
pre and post intuba-
tion
High TV Low TV p-value
IL-6, mean (SD) - 0.02 (4.02) 0.57 (3.2) 0.727
IL-8, mean (SD) - 58.9 (189.89) 26.18 (32.27) 0.178
TNF-–, mean (SD) -0.07 (0.19) -0.06 (0.28) 0.924
IL-6 – Internleukin 6, IL-8 – Internleukin 8, TNF-– – Tumour Necrosis Factor – Alpha
5.13 Survival to discharge
Overall 70 babies were enrolled in the trial. Out of which 34 and 36 babies were
randomised to high and low TV arm respectively. 5 and 10 babies exited due to
meeting the exit criteria in high and low arm respectively before achieving the
primary outcome.
On intention to treat analysis, out of total 70 enrolled babies, 30/34 and 29/36
babies survived to discharge home in high and low tidal volume respectively.
Out of these, 20/34 and 16/36 babies were still requiring oxygen at 36 weeks post
menstrual age in in high and low arm respectively. Eventually 26 babies survived
without chronic lung disease, out of which, 11 and 13 babies were in high and low
arm respectively (p=0.80, Table 5.34, Figure 5.26).
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Table 5.34: Comparison of Survival to discharge between two groups
High TV Low TV p-value
N=34 N=36
Count (%) Count (%)
Exited 5 (14.7%) 10 (27.8%) 0.398
Survived to discharge 30 (88.2%) 29 (80.6) 0.515
Survived to discharge without
BPD at 36 weeks PMA
11(32.3%) 13 (36.1%) 0.804
Figure 5.26: Comparison of survival between two groups
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5.14. Profile of enrolled babies who did not survive
5.14 Profile of enrolled babies who did not survive
Out of the 11 babies died, 9 remained intubated until death. Four babies died in
the high tidal volume group as opposed to 7 babies in the low tidal volume group.
Of all these 7 babies had exited before death (4 in high TV and 3 in low TV). The
common causes of death were – extreme prematurity, multiple organ failure, severe
IVH, pulmonary haemorrhage, maternal chorioamnionitis, pneumothorax, sepsis,
NEC, intestinal perforation, severe BPD, severe RDS, and pulmonary hypoplasia
as shown in Table 5.35.
5.15 Comparison of study infants and eligible non
enrolled infants
This section compares the study infants with the eligible but not enrolled infants
for the study period. During the study period there were 27 infants who fulfilled
the inclusion criteria but could not be enrolled. The reason for non-enrolment of
these infants are depicted in Table 5.36. Out of these, 12 died before discharge.
5.15.1 Baseline characteristics
The unenrolled infants were compared with enrolled infants to identify any possible
underlying reasons or patterns behind their unenrollment. (Table 5.37, Figure
5.27).
5.15.2 Ventilation in study infants versus not-enrolled infants
High frequency mode was the most common mode of ventilation for unenrolled
infants. The rest of the modes are shown in table 5.38.
There was no di erence in duration of mechanical ventilation between two groups.
The median duration of mechanical ventilation in study infants cohort was 37.4
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5.15.2. Ventilation in study infants versus not-enrolled infants
Table 5.36: Reasons for non-enrolment
Reason No of babies (N=27)
Count (%)
Born in very poor condition 10 (37%)
Consultant decision 12 (44.4%)
Severe congenital anomaly 2 (7.4%)
Refused consent 3 (11.1%)
Table 5.37: Comparison of baseline characteristics of the enrolled and non-enrolled
infants in the study
Variable Enrolled in-
fants
Unenrolled in-
fants
p-value
N=70 N=27
Birth weight in grams, mean
(SD)
1021.04 (389.6) 1044.23 (334.1) 0.771
Gestation in weeks, mean
(SD)
27.31 (3.05) 27.40 (2.14) 0.888
Male sex, count (%) 44 (69.8%) 19 (70.4%) 0.636
Ethnic group- White British,
count (%)
67 (95.7%) 23 (85.2%) 0.92
Singleton, count (%) 51 (72.9%) 18 (66.7%) 0.619
Normal Serology and Anom-
aly Scan, count (%)
63 (90%) 24 (88.9%) 0.836
Normal Vaginal Delivery,
count (%)
41 (58.6%) 12 (44.4%) 0.258
2 doses of Antenatal steroids,
count (%)
64 (91.4%) 16 (59.3%) 0.001*
Admission temperature in oC,
mean (SD)
36.4 (1.36) 36.5 (0.88) 0.632
CRIB 2 score, mean (SD) 10.04 (4.89) 9.14 (3.5) 0.332
VG – Volume Guarantee, HFO – High-Frequency Oscillation Ventilation, Vol AC – Volume
Assist Control, Pr AC – Pressure Assist Control
*Baby born in extremely poor condition and died before could be commenced on formal
ventilation
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Figure 5.27: Comparison of baseline characteristics of the enrolled and non enrolled
infants in the study
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5.15.3. Survival and complications related to prematurity
hours (95% CI, 18.96-55.95 hrs) and median duration of mechanical ventilation in
those not enrolled was 96.57 hours (95% CI, 0 – 239.8 hrs) (p= 0.358, Table 5.39,
Figure 5.28).
Table 5.38: Primary mode of ventilation for non-enrolled babies
Primary mode of ventilation No of babies (N=27)
Count (%)
VG 7 (25.9%)
HFO 8 (29.6%)
Vol AC 5 (18.5%)
Pr AC 6 (22.2%)
Never ventilated in NNU* 1 (3.7%)
*Baby perished before admission to NNU
Table 5.39: Comparison of duration of mechanical ventilation in enrolled versus
not-enrolled infants
Enrolled
N=70
Median (95 %
CI)
Unenrolled
N=27
Median (95 %
CI)
p-value
Duration of mechanical
ventilation, hrs
37.4 (18.96-55.95) 96.57 (0 – 239.8) 0.358
5.15.3 Survival and complications related to prematurity
There were 11/70 (15.7%) and 12/27 (44.4%) deaths in enrolled and non-enrolled
infants respectively which was statistically significant (p=0.<01).
There were also di erences in incurring complications of prematurity between
the two groups. The groups had significant di erences in severe IVH (12.9%
versus 25.%, p=<0.05), PVL (11.4% versus 3.7%, p=<0.05), significant ROP
(17.1% versus 7.4%, p=<0.05), respiratory support at 28 days (68.6% versus 51.9%,
p=<0.05), need for home oxygen (48.6% versus 14.8%, p=<.01) and survival
(84.3% versus 55.6%, p =<.01). The di erence in medium term complications
can be explained on the basis that almost 45% of unenrolled babies did not survive
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Figure 5.28: Kaplan Meier survival curves for the duration of mechanical ventilation
in babies enrolled or not enrolled in the study
and hence the denominator was artificially higher in the group (Table 5.40, Figure
5.29).
5.16 Summary of important positive and negative
findings
1. The trial enrolled babies from July 2013 to October 2016 and recruited 70 in-
fants. (Table 5.1).
2. Comparison of maternal characteristics: there were no di erences between the
two groups. (Table 5.3).
3. Baseline infants’ characteristics: No di erences in demographics or clinical char-
acteristics. (Table 5.8).
4. Primary Outcome measures
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Table 5.40: Comparison of complications of prematurity of the enrolled and non-
enrolled infants of the study
Parameter Study-group
(N=70)
Non-enrolled in-
fants (N=27)
p-value
Count(%) Count(%)
Significant Air Leak 3 (4.3%%) 4 (14.8%) 0.147
Significant Pulmonary haem-
orrhage
12 (17.1%) 4 (14.8%) 0.457
Severe IVH 9 (12.9%) 7 (25.9%) <0.05*
PVL 8 (11.4%) 1 (3.7%) <0.05*
NEC Ø2A 12 (17.1%) 1 (3.7%) <0.0005*
PDA requiring Med-
ical/surgical treatment
9/34 (26.4%) 7/36 (19.4%) 0.574
BPD – 28 days 48 (68.6%) 14 (51.9%) <0.05*
BPD – 36 weeks PMA 36 (51.4%) 10 (37%) 0.18
Home oxygen 34 (48.6%) 4 (14.8%) <.01*
Survived 59 (84.3%) 15 (55.6%) <.01*
Survived without BPD at 36
weeks PMA
24 (34.3%) 6 (22.2%) 0.183
IVH– Intraventricular Haemorrhage, PVL – Periventricular leukomalacia, NEC – Necrotising
Enterocolitis, ROP – Retinopathy of Prematurity, PDA – Patent Ductus Arteriosus, BPD –
Bronchopulmonary Dysplasia
• The median duration of 25% drop in high and low TV group was 13.8 hours
(95% CI, 6.4-21.3) and 18.1 hours (95% CI, 10.4-25.8) respectively. The log
rank statistic for equality of survival distribution for randomisation arm was
not significant (p=.931) (Table 5.12).
• On multiple linear regression analysis, gestation age less than 28 weeks, frac-
tional inspired oxygen (FIO2) and fluids in first week turned out to be signi-
ficantly associated with primary outcome (Table 5.14).
• There were no di erences between the two groups on subgroup analysis based
on birth weight (Æ1000 gram versus >1000 gram), gestation age (Æ28 weeks
versus >28 weeks) and severity of lung disease (as assessed by alveolar arterial
oxygen gradient (A-aDO2) and oxygenation index (OI) at initial ventilation)
(Table 5.15, Table 5.16, Table 5.17, Table 5.18).
5. Duration of mechanical ventilation
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Figure 5.29: Comparison of Outcomes between enrolled and unenrolled babies
• The median duration of mechanical ventilation in the high TV group was 35
hours (95% CI (9.8-60.2 hrs)) as compared to 61.8 hours (95% CI 14.4 – 109.2
hrs) in low TV group. The log rank statistic for equality of survival distri-
bution for randomisation arm was not significant (p=0.928) (Table 5.19).
• There were no di erences between the two groups on subgroup analysis based
on birth weight (Æ1000 gram versus >1000 gram), gestation age (Æ28 weeks
versus >28 weeks) and severity of lung disease (as assessed by alveolar arterial
oxygen gradient (A-aDO2) and oxygenation index (OI) at initial ventilation)
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(Table 5.20, Table 5.21).
6. Duration of admission
• The duration of admission was compared between the two study groups. The
median duration of admission in high tidal volume group was 1932.7 hrs (95%
CI 1416.1 – 2449.2 hrs) as compared to 1762.3 hrs (95% CI 1576.7 – 1957).
The log rank statistic for equality of survival distribution for randomisation
arm was p= 0.304 (Table 5.22).
7. E cacy of the ventilation
• Mean (SD) tidal volume was di erent between the two groups – 6 (1.6) and
4.4 (1.4) in high and low tidal volume group respectively (p=<0.0001). There
was no di erence in minute volumes of the two groups. Mean (SD) set RR for
high and low TV group was 33.7 (6.7) and 38.5 (10.2). This was statistically
significant (p=<0.05). There was also di erence in two groups for mean PIP
which was proportional to the di erence in the tidal volume in both statistical
and clinical significance. While mean paCO2 was not di erent between the
two groups, the number of low paCO2 values were higher in high tidal volume
group (61.3% versus 32.6%, p=<.005) (Table 5.23).
• The mean maximum mean airway pressure in high tidal volume group was
12.3 .as compared to 10.1 cm H2O in low tidal volume group. This was stat-
istically significant (<.0001) probably because of increased peak inspiratory
component in achieving the tidal volume (Table 5.24).
8. Duration of respiratory support in two groups: No di erences between the two
groups in duration of non-invasive (CPAP or HHFNC) or combined respiratory
support (Table 5.25).
9. Other outcome measures
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• Pulmonary complications: No di erences in short term pulmonary complica-
tions (air leak, pulmonary haemorrhage) or medium term pulmonary complic-
ations (BPD at 28 days’ life and 36 weeks PMA, severity of BPD, requirement
and amount of home oxygen) (Table 5.26, Table 5.27).
• Non-pulmonary complications: There were no di erences between the two
groups when compared for sepsis, IVH, NEC, PDA and ROP (Table 5.28).
10. Use of Therapeutic agents: no di erences in use of surfactant, postnatal steroids
or ibuprofen (Table 5.30).
11. Weight gain/postnatal growth: there were no di erences between the two
groups while comparing for total weight gain, weight gain per day and change in z
scores (Table 5.31).
12. Cytokine/inflammatory markers: no di erences between the baseline or change
in cytokines (IL6, IL8 and TNF alpha) (Table 5.32, Table 5.33).
13. Survival to discharge: no di erences in number of babies that died or survived
without BPD at 36 weeks (Table 5.34).
14. Profile of babies who did not survive: on analysing the profile of 11 babies
who did not survive the admission, the common causes of death were found to
be - extreme prematurity, multiple organ failure, Severe IVH, pulmonary haemor-
rhage, maternal chorioamnionitis, pneumothorax, sepsis, NEC, intestinal perfora-
tion, severe BPD, severe RDS, and pulmonary hypoplasia (Table 5.35).
15. Comparison of enrolled versus eligible non-enrolled infants: There were no
di erences in baseline demographic and clinical characteristics (Table 5.37).There
was no di erence in duration of mechanical ventilation (Table 5.39). However
there were di erences in incurring complications of prematurity between the two
groups. The groups had significant di erences in severe IVH (12.9% versus 25.9%,
p=<0.05), PVL (11.4% versus 3.7%, p=<0.05), significant ROP (17.1% versus
7.4%, p=<0.05), respiratory support at 28 days (68.6% versus 51.9%, p=<0.05),
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need for home oxygen (48.6% versus 14.8%, p=<0.01) and survival (84.3% versus
55.6%, p =<0.01) (Table 5.40).
141
Chapter 6
Discussion and Conclusions
6.1 Summary of Main results
6.1.1 Introduction
Preterm infants are born with a varying degree of respiratory distress syndrome
known to be proportionate to the degree of prematurity. A moderate to severe
spectrum of the disease requires support with mechanical ventilation. Traditionally
this support was provided by targeting pressure ventilation. The physiological
studies by Dreyfuss and Hernandez et al. (Dreyfuss et al. (1988), Hernandez et al.
(1989), Dreyfuss and Saumon (1998)) proposed the superiority of volume targeting.
A meta analysis (Klingenberg et al. (2017))vindicated the concept in providing a
safer way of providing respiratory support to preterm infants. With developments
in technology, hybrid modes like volume guarantee not only provide the best of both
the worlds but are sophisticated enough to deliver the tiny volumes. These small
volumes can be as low as 2 millilitres, a testament to the use of nanotechnology
in modern clinical medicine. While the precision of the technology has helped us
to achieve which was considered impossible not long ago it has created a dilemma
regarding better tidal volume within the broad range of 4-8 ml/kg. This question
has been addressed in adult and paediatric clinical care. In neonatal medicine,
there have been a few studies addressing this but they are mostly experimental or
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cross-over studies making it di cult for the clinician to base decision making on
current evidence. Our study is the first ever clinical study to address this vital
question.
6.1.2 Summary of the main results
Babies in both groups were similar at baseline with regards to maternal, demo-
graphic and clinical characteristics. There was no di erence in the primary out-
come of time di erence to reach a 25% reduction in baseline peak pressure. There
was also no di erence in the duration of mechanical ventilation or hospitalisation.
There was no di erence between the baseline or any change in cytokines (IL-6,
IL-8 and TNF-–). Whilst the tidal volume, peak inspiratory pressure and mean
airway pressures were di erent and higher in the assigned high tidal volume group,
the minute volume, paCO2 or FIO2 requirements were not significantly di erent.
There was no di erence in short term secondary outcomes (air leak, pulmonary
haemorrhage, sepsis, IVH, NEC, PDA and ROP) or medium-term complications
(CLD at 28 days’ life and 36 weeks PMA, severity of CLD, amount of home oxygen,
survival to discharge and survival without BPD at 36 weeks PMA).
The study highlights that it is possible that both tidal volumes ranges selected
for this study are at the functional residual capacity and that more considerable
di erences might be necessary to show a change (Figure 6.1).
6.2 Relationship with other studies
Our study is the first ever randomised controlled trial to compare low versus high
tidal volume in a real life clinical situation. Without any precedence for such a
study, this warranted an innovation to make it feasible. We chose a 25% reduction in
baseline peak inspiratory pressure, as our pilot demonstrated that it was generally
the average drop in peak inspiratory pressure when the baby was deemed to be
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Figure 6.1: Functional Residual capacity
ready for extubation. However, the uniqueness of the parameter also meant that
we could not compare this with any previous study. We hope that this will lead to
further studies using the same parameters, providing us adequate data to help us
interpret this in the future.
The trial did include other parameters as significant secondary outcomes. One of
the most studied secondary outcomes is the impact on the duration of mechan-
ical ventilation by the intervention. Sousse et al. (Sousse et al. (2015)), in their
prospective cross over study of mechanical ventilation of children with inhalation
injury, showed that use of high tidal volume reduced the duration of ventilation. In
our study, though the median duration was less in high TV group, the statistical
analysis failed to show any significant di erence.
Pneumothorax has been correlated with the magnitude of lung injury. Rouby
et al. (Rouby and Brochard (2007)) found that the incidence of pneumothorax
was significantly higher (8 versus 2) in the patient group ventilated with higher
pressures and tidal volumes. Sousse et al. (Sousse et al. (2015)) in their study
on children with inhalation injury also demonstrated that children with high tidal
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volume had a higher incidence of pneumothorax: 52 (28%) versus 75 (19%) (p <
0.03). Our study had 3 (8.8%) infants in high tidal volume group had significant
air leak as opposed to 0 (0%) in the low tidal volume group. It was not statistically
significant (p=0.109).
In our study, when compared for survival to discharge, there was no di erence
between the two groups (High TV – 88.2%, Low TV – 80.5%, p= 0.51). Sousse
LE et al. (Sousse et al. (2015)) reported that mortality was approximately 22%
for those ventilated with high TV, as compared with 15% for those ventilated with
low TV which was statistically insignificant (p = 0.10). A meta-analysis performed
by de Jager et al. (de Jager et al. (2014)) studying the impact of tidal volume on
critically ill mechanically ventilated children did not find any di erence in mortality
of two groups. Hence it can be safely concluded that tidal volumes do not appear
to be having an impact on survival to discharge.
Our study showed that while the respiratory rate (RR) in the low TV group was
higher as suggested in various other studies, di erences between both groups were
not statistically significant. As an interesting observation, we also looked at the
set RR (back up RR for pressure assist control and SIMV mode) between the
two groups and found that this was not only higher in low TV group, but the
di erence was statistically significant. This could have been because of using SIMV
as weaning mode which meant that weaning of support in low TV groups was
slower, keeping them intubated longer (median duration of mechanical ventilation,
statistically insignificant).
Our study showed that while PIP and TV were altered significantly due to inter-
vention. It showed a higher PIP among infants ventilated with high tidal volume.
While this has theoretically plausible explanation, this has also been replicated
in the study by Sousse et al. (Sousse et al. (2015)) who showed a significantly
increased maximum peak inspiratory pressure (43±18 versus 38±16, p=< 0.02)
compared with those in patients with LTV. There were no di erences in MV and
pCO2. This is consistent with the findings of a prospective interventional study
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by Mishra et al(Mishra et al. (2003)) where authors showed that the preterm in-
fants showed fantastic capability to maintain pCO2 despite the change in PIP by
modulating their respiratory rate.
Patel et al. (Patel et al. (2009)) in their study of infants’ work of breathing also
found that babies had increased work of breathing at lower tidal volume. The
authors speculated that this increased work of breathing could be due to the need
for increased respiratory rate in order to maintain the minute volume and normo-
capnoea. While we did not measure the work of breathing as part of our study, our
study corroborates a similar observation of increased respiratory rate at lower tidal
volumes. In our study, this di erence, however, was not statistically significant.
Ca eine
We emphasised having ca eine at the beginning of the mechanical ventilation as
it is known to a ect ventilator parameters. In fact, Kraaijenga et al. (Kraaijenga
et al. (2015)) studied the impact of ca eine on tidal volume and found that it
increased tidal volume by a median of 30% (IQR, 7%-48%).
Growth
Deficient postnatal growth is known to be associated with poor neurological out-
come for AGA and SGA preterm in EPIPAGE study.(Guellec et al. (2016))Babies
in this study were assessed using Fenton z scores. The mean change in z-scores
were -1.65 and -1.45 respectively in the high and low tidal volume group. This was
also not statistically significant.
paCO2
Hypocapnia is a significant problem in the early stages of life of premature babies.
Luyt et al. (Luyt et al. (2001)) in their study of premature infants reported an
incidence of inadvertent hyperventilation to the partial pressure of arterial carbon
dioxide PaCO2 <25 torrs (<3.3 kPa) was reported in 30% of ventilated newborn
infants during the first day of life.
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Dawson et al. (Dawson and Davies (2005)) set out to review the arterial carbon
dioxide tensions (paCO2) in newborn infants ventilated using synchronised inter-
mittent mandatory ventilation (SIMV) in volume guarantee mode with a TV of
4 mL/kg in preterm infants less than 33 weeks in their prospective observational
study. They reported that Severe hypo- or hypercapnoea occurred in 8% of infants
at the time of their first blood gas measurement and in <4% of blood gas measure-
ments in the first 48 h. In our study, 43.5% of the values in the low tidal volume
group were within range. This was not statistically di erent from a corresponding
value of 27.6% in the high tidal volume group. The di culty in maintaining normal
paCO2 in extremely preterm infants was demonstrated by Cheema et al. (Cheema
et al. (2007)) when researchers used volume guarantee with the TV of 4 ml/kg and
reported that 100% babies less than 25 weeks’ gestation had out-of-range paCO2
values with 2/4 had hypercarbia and 2/4 hypocarbia.
Cytokines
Cytokines are an increasingly studied class of compounds because of their rela-
tionship with short term inflammation and long term outcomes. There have been,
however, conflicting reports about their relationship to tidal volumes. In a non-
blinded prospective randomised controlled trial by Determann et al., (Determann
et al. (2010)) the authors reported that in critically ill adult patients, that Plasma
interleukin 6 (IL-6) levels decreased significantly more strongly in the lower tidal
volume group. The authors concluded that mechanical ventilation with conven-
tional tidal volumes is associated with sustained cytokine production and contrib-
utes to the development of lung injury in patients without ALI at the onset of
mechanical ventilation. A similar study assessing cytokines levels in preterm in-
fants by Lista et al. (Lista et al. (2006)), found that cytokine (IL-8 and TNF-–)
levels collected on day 7 were significantly higher in the low tidal volume group.
The authors concluded that when compared with 3mL/kg, ventilation with tidal
volume of 5 mL/kg reduced the inflammatory response. In our study, though we
did not compare the two (3 mL/kg versus 5 mL/kg), we did not find any di erences
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between our two groups of low and high tidal volumes.
We speculate that using SIMV as weaning mode did not lead to a drop in PIP
as anticipated. Scopesi et al. (Scopesi et al. (2007)) in their cross over study of
comparing SIMV and SIPPV with VG in the weaning phase found that PIP was
lower in SIPPV as compared to SIMV.
6.3 Justification of methods
We chose SIMV as weaning mode as it is a widely recognised mode for weaning
and study. We did not reduce the tidal volume as a means of weaning. This was
because, firstly, VG is considered an auto weaning modality as demonstrated by a
drop in peak pressures as demonstrated by Lista et al. (Lista et al. (2004)) in their
study of using VG against PSV. Secondly, there are concerns about the increasing
work of breathing at low tidal volumes as found by Patel et al. (Patel et al. (2009))
who reported an increase in the work of breathing at lower tidal volumes and thus
advised against the strategy. Of note, they did not show any di erence in work
of breathing between pressure assist control (PAC) and synchronised intermittent
mandatory ventilation (SIMV) modes while used with volume-targeted ventilation.
Chowdhury et al. (Chowdhury et al. (2012)) and Lista et al. (Lista et al. (2006))
also demonstrated that lower tidal volume did not translate into lower work of
breathing or less inflammation. Hence while it is a conventional practice of reducing
tidal volume as part of weaning, we stuck to maintaining the purity of tidal volume.
Statistical analysis
We used survival statistics using Kaplan Meier and log-rank test to compare the
durations rather than a chi-square test. Sousse et al. (Sousse et al. (2015)) in
their study have demonstrated the di erence practically. The authors found the
di erence between the two groups which while considered censoring as used in
survival statistics, it vanished.
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6.4 Strengths of the study
Our study is the first ever e ort to compare the two spectra of the tidal volumes
in the normal range in the clinical setting. The study dealt with real life clinical
dilemmas like the suitable primary outcome and appropriate secondary outcomes.
The study is extension of previous smaller studies. As the previous cross over
studies demonstrated that a lower tidal volume could be associated with increase
in work of breathing, we desisted from using strategy of reducing tidal volume dur-
ing weaning. We also used cytokines assessment to ascertain the di erence between
the two groups. The study was randomised controlled trial where randomisation
was carried out by blocked envelope to avoid bias. The study groups represented
the clinical population and did not have any di erences between them which com-
promised the methodology of e cient randomisation. Finally, during the study
we encountered some technical di culties and we hope that identification of such
issues will help and facilitate future studies in this direction.
6.5 Limitations of the study
The study did not have enough participants to satisfy the initial power calcu-
lations. In the absence of precedence, we decided to go for a pilot study so that
lessons learnt from this study could be used for designing future studies. The study
obtained permission for a "waiver of consent" due to the narrow time window re-
quired for the randomisation process. However, the narrow window also led to us
missing some babies for the study. The study was accompanied by the introduc-
tion of volume guarantee in the baby unit and we discovered errors in the software
and problems with the hardware, leading to glitches. These glitches appeared in
the form of delivery to auto cycling, too high or too low pressures being delivered
than expected. Some of these were picked up during the pilot phase and addressed
by an update in software. The hardware related issues mainly involved the flow
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sensor. The error-prone flow sensors needed replacing. In our experience, reusable
flow sensors were found to be more reliable. We learnt that the VG mode is more
sensitive to ventilator malfunction than conventional modes and hence instituted
a close observation of equipment and a programme of continuing education among
sta  to deal with such a situation. With more experience in the modality, the sta 
grew in confidence, and incidences of mishaps came down drastically to allow us
to conduct the study with scientific vigour. We are not alone in encountering dif-
ficulties in introducing new modes. Keszler et al. (Keszler and Abubakar (2004))
carried out an RCT to compare VG combined with SIPPV to SIPPV alone with
regards to maintaining normal tidal volume and normocarbia. The authors high-
lighted the di culties associated with the use of new and unfamiliar technologies
in which human errors also contributed to the alteration of results. They suggested
similar caution in dealing with new and unfamiliar technologies
PIP appeared to be higher than traditional PIP in pressure targeted modes. Poli-
meni et al. (Polimeni et al. (2006)) in their study of comparing VG with and
without SIMV also reported that PIP was higher in babies with VG. We also ac-
knowledge that the infants who received CPR were included in the study and so
introducing an element of error related to lung injury.
The absence of precedence meant that sample size analysis was di cult to carry
out. We chose to recruit 70 infants as per the feasibility of recruitment. While
this is a significant number for a clinical study, it remains a small number for a
study to provide conclusive answers. It is possible that sample size may have been
too small to detect a real di erence in the outcome. Whilst e orts were taken to
equipoise the two arms, it was di cult to blind the study from caregivers or the
research team.
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6.6 Clinical relevance
The study addressed the vital clinical question of di erences in low versus high
tidal volume in providing mechanical ventilation in preterm infants. While there
are several studies to address this in adult and paediatric clinical care it presents
a genuine dilemma in neonatal units across the world. Preterm infants are born
with respiratory distress syndrome and require mechanical ventilation for life saving
support. The modality of mechanical ventilation is known to have short, medium
and long term impacts and it remains vital to improve upon the technique to
maximise e ectiveness while minimising its side e ects. Our study is the first ever
such e ort in the real life clinical setting managing preterm infants with respiratory
distress syndrome. Whilst bearing in mind the important limitations of sample size,
the study did, however, helped to dispel the myths regarding the perceived risks
associated with higher tidal volumes. We understand that it is a negative study
with limited final conclusions. The negative results, however, add to confidence
about ventilating at higher tidal volumes as demanded by clinical situations. The
study, therefore, provides a template for future work to address this important
question.
6.7 Summary and Conclusions
The results of the study can be summarised as follows.
The study recruited 70 babies from July 2013 to September 2016. There were no
di erences in baseline maternal and infants’ characteristics between the two groups.
When assessed for the primary outcome measure of time di erence to drop in peak
pressure by 25%, the median duration of 25% drop in PIP in high and low TV
group was 13.8 hours (95% CI, 6.4-21.3 hrs) and 18.1 hours (95% CI, 10.4-25.8
hrs) respectively. The log rank statistic for equality of survival distribution for
randomisation arm was not significant (p=.931) (Table 5.12). On multiple linear
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regression analysis, gestation age less than 28 weeks, fractional inspired oxygen
(FIO2) and fluids in the first week turned out to be significantly associated with
the primary outcome (Table 5.14).
When durations of mechanical ventilation were compared between the two groups,
median duration in the high TV group was 35 hours (95% CI 9.8-60.2 hrs)) as
compared to 61.8 hours (95% CI 14.4 – 109.2 hrs) in low TV group. The log
rank statistic for equality of survival distribution for randomisation arm was not
significant (p=0.928) (Table 5.19). Similarly, there were no di erences between the
two groups in the duration of hospitalisation, non-invasive (CPAP or HHFNC) or
combined respiratory support (Table 5.22, Table 5.25).
With regards to the tidal volumes, these were di erent between the two groups: 6
(1.6) and 4.4 (1.4) in the high and low tidal volume group respectively (p=<.0001).
There was also a di erence in two groups for mean PIP and MAP which was
proportional to the di erence in the tidal volume in both statistical and clinical
significance. However, there was no di erence in minute volumes of the two groups.
We also noted that while mean paCO2 was not di erent between the two groups,
the number of low paCO2 values were higher in high tidal volume group (Table
5.23).
We did not find any di erences with regards to pulmonary complications (air leak,
pulmonary haemorrhage, CLD at 28 days’ life and 36 weeks PMA, severity of
CLD, requirement and amount of home oxygen) and non-pulmonary complications
(sepsis, IVH, NEC, PDA and ROP). Also, there was no di erence in number of
babies who died or survived without BPD at 36 weeks. We also found that the
cytokines (IL-6, IL-8 and TNF-–) levels were comparable in both groups.
In summary, the study was the first ever to compare low versus high tidal volume
in preterm infants in clinical circumstances. The study did not show any di erence
in respiratory or non-respiratory complications of prematurity.
The study also highlighted the di culties in carrying out a research project with
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a narrow eligibility window in critically sick babies. The study speculates that it
is possible that both tidal volumes ranges selected for studies are at the functional
residual capacity and that more substantial di erences might be necessary to show
a change.
6.8 Suggestions for further research
From this experience, we would recommend a multicentre randomised controlled
trial to address the relevant clinical questions. This, we hope, would provide the
necessary numbers to address the essential secondary outcomes of chronic lung
disease and survival without chronic lung disease.
We would also recommend devising algorithms to address the technical di culties
in dealing with volume guarantee both for patient care as well as research purpose.
6.9 Reflections
When I took to this project, I was full of enthusiasm. I had participated in other
people’s trials and looked forward to conducting my own and to make a contribution
to improving the lives of babies I am passionate about.
While I was prepared for the hard work, I was not ready for the bureaucracy in
research work which takes much time to get things running. I also encountered
di culty in getting everyone on the same page to help recruit babies. While the
unit had run trials before, it remained primarily a clinical unit which meant that
there was an extra burden on the existing workload. I tried to put in extra hours in
acknowledgement of their extra e ort to help recruit the patients. It was challenging
to convince the ethics committee of the need to permit a "waiver of consent" to
randomise babies while awaiting formal consent from parents at a less stressful
circumstances. This was to ensure the consistency and vigour of the methodology
in maintaining a constant tidal volume. As the majority of the preterm infants
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required mechanical support soon after birth, a waiver of consent also meant that
we had a very narrow time-window to randomise the baby. This led to missing
babies in the early period of the research but this was something we could address,
and eventually, we managed to recruit the vast majority of eligible infants.
This was clinical research within the pragmatic working environment and I am
grateful to have been funded for the time and for the opportunity to carry this
out. The trade o  was to return the favour as a clinician, which I later realised
was quite demanding. I had to continue the recruitment even after leaving the
job to ensure the required babies for the trial. This, and the write, up was to be
done while fulfilling other commitments was demanding. I am sure I am not the
only one to have had di culties in the pragmatic clinical research world, but it did
appear to be a mammoth task and sometimes nearly impossible. I am grateful to
everyone around me, especially my mentors to help me complete this project.
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Information leaflet for Parents 
 
 
 
  
 
HILO Trial 
(High vs. Low Tidal Volume for Mechanical Ventilation in Preterm Babies) 
What is the purpose of the study? 
Babies born prematurely can have breathing problems due to immaturity of the lungs. 
This is due to lack of a chemical called surfactant (normally present in the lungs of 
babies born at full term). Surfactant keeps airways open by preventing collapse of the 
lungs. A proportion of these premature babies can require help for breathing. This is 
provided by a plastic tube placed in the wind pipe (endotracheal tube) and attached to a 
breathing machine called a ventilator. 
 
The ventilator works by pushing a volume of gas (oxygen/air) called the tidal volume 
into baby’s lungs with every breath. The normal reference range for this tidal volume is 
between 4 and 8 ml per kg. This is a wide range and it is not known whether there are 
any advantages of targeting tidal volumes at narrow upper or lower end of normal 
range.  
 
Why am I being asked to participate in the study? 
You are being asked to take part in this study as your baby is born very early (more 
than 8 weeks before the due date) and/or weighs less than 1500g and requires 
breathing support on a ventilator. 
 
Does my baby have to take part? 
Taking part in the study is voluntary and your decision would not affect the care 
provided to your baby. 
 
What will happen to my baby if I agree to take part in the trial? 
Your baby will be provided breathing support through a ventilator delivering tidal 
volumes within normal range. This could be low normal (4-5 ml/Kg) or high normal (7-8 
ml/kg) tidal volume from birth. The allocation to these two groups is done using a 
computer generated random sequence to allow comparison of any differences between 
the two study groups scientifically.  
 
We would also request for your permission to test the fluids from your baby’s windpipe 
for inflammatory markers. This fluid is routinely suctioned from the windpipe to clear 
airways and would be discarded after testing. No extra blood tests or injections are 
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necessary over and above routine care. Your baby would continue to receive the same 
care on the neonatal unit independent of your decision regarding taking part in the study 
or not.  
 
What will happen to my baby if I do not agree to take part in the trial?  
Your decision whether or not to take part will not affect the care provided to your baby. If 
you are not able to decide or decline to take part, your baby will receive the same 
standard care provided to all babies born prematurely and would receive breathing 
support utilising tidal volume in the normal wide range of 4-8 ml/kg as per current 
practice. 
 
What are the possible side effects or complications of the treatment?  
As, your baby would be ventilated utilising standard practice, there are no perceived 
side effects of participating in this study. Also, as the study follows standard practice, 
complications and risks associated with premature birth are expected to be comparable 
between study groups. The study conforms to the manufacturers’ recommendations for 
the ventilators and utilises the recommended tidal volume range for use in newborn 
infants.  
 
Irrespective of allotted group, your baby would be monitored very closely by the medical 
and nursing staff in the neonatal intensive care unit and in accordance with standard 
practices on the neonatal unit. 
 
What are the possible advantages and disadvantages of taking part in this trial? 
While ventilators are life saving machines, they have the potential to cause injury to the 
lungs. This injury can be in the form of risk of chest infections in the short term and risk 
of damage to the lungs (chronic lung disease). The results of the study could improve 
our practice of ventilation and ventilation associated injury in very preterm babies in the 
future. There are no perceived disadvantages of participating in this trial. 
 
 
What if new information becomes available? 
The clinicians caring for your baby would inform you of any new information that 
becomes available during the course of the study. 
 
What if something goes wrong? 
As this study follows current standard practice, your baby is unlikely to have any 
additional adverse effects while participating in this trial. During the study period data in 
all expected or unexpected adverse events will be collected and monitored. You will be 
covered by the trust indemnity scheme and participating in the trial does not affect your 
legal rights. 
 
Will taking part in this study be kept confidential? 
We assure you that strict policies and procedures will be followed as per best practice 
guidance issued by the Department of Health in relation to confidentiality. Your GP 
would be informed about participation of in this study unless you decide not to inform. 
Your baby’s details will be kept securely and will only be seen by the study team and 
people from the regulatory authorities. Information about your baby will not be used for 
any purpose other than to answer the research question. 
 
What will happen to the results of the research study? 
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At the end of the study, the results will be analysed and published anonymously in peer 
reviewed medical journals and will be presented in medical seminars and conferences. 
We will send you a summary of the final results of the study if you would like. A copy of 
the full journal article can be requested from the Chief Investigator. You and your baby 
will not be identified in any report or publication of the study. 
 
Who is organising and funding this study? 
The study is sponsored by University Hospital of North Tees. This study is a topic for a 
higher degree with the Durham University pursued by the co-investigator. 
 
Who has reviewed the study? 
The study has been assessed and approved by Sunderland NHS Research Ethics 
Committee and Trust Research and Development Committee. It has also been 
reviewed by parents of babies and by an external expert in the field of newborn 
ventilation. 
 
Approval means the Committees are satisfied that the study is safe, participants are 
protected and there are no additional risks. It also assures that you have been given 
sufficient information to make an informed decision regarding taking part in this study. 
 
What if I have concerns? 
If you have any concerns or questions about this study or the way it has been carried 
out, you could contact the Chief Investigator or member of the team. If you have any 
questions about this study you may also choose to get information from the Trust 
Research and Development department (Floor 2, South Wing, University Hospital of 
North Tees, Hardwick Road Stockton-on-Tees TS19 8PE). You could also alternatively 
contact INVOLVE  (http://www.invo.org.uk/resourcecentre/ or Tel 02380 651088) for 
more advice and support. 
 
If you have any complaint about the conduct of the study, you could also contact PALS 
(Patient Advice and Liaison Service) Tel 01642 624719/ mobile 07796 958658/ 
freephone 0800 092 0084 or email at PALS.NT@nth.nhs.uk. 
 
Thank you for reading this information leaflet. Should you desire to discuss the study in 
more detail a member of the team would be happy to provide further information. 
Alternatively, the contact details of the study team are provided on this leaflet. 
 
Local contact for your Hospital is 
 
Co-investigator: 
Dr Anup Gupta 
Neonatal Research Registrar 
01642 624247 
 
Chief Investigator:  
Professor Samir Gupta 
Consultant Neonatologist 
01642 624250 
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Consent form. AG/Version 4/HILO Trial                    01/06/2013 
         
 
HILO Trial 
 
Consent from Parents 
 
 
Neonatal unit 
University Hospital of North Tees 
Stockton TS19 8PE 
Tel: 01642 624247/48
Study No: CH-087    Hospital Name: University Hospital of North Tees 
 
Formal Title: High vs. Low Tidal Volume for Mechanical Ventilation in Preterm Babies with 
respiratory distress syndrome - A randomised controlled trial 
Name of Researcher: Dr Anupam Gupta 
 
          Please initial each box 
I, ………………………………………mother/father of …………………………… 
Do hereby give my consent for my baby to be included in this study. 
 
 
I also give consent for testing of fluid from the windpipe (tracheal aspirate).  
 
 
I confirm that I have been given the information leaflet (version 5 May 15 2013) which I 
have read and understood. I have been given an opportunity to ask my questions which 
have been answered. 
 
 
I can confirm that my baby’s participation in this trial is entirely voluntary. I understand 
what will happen to my baby during this trial. I am aware of my rights to withdraw my 
baby from the trial at any time. In such an event if I chose to do so, his/her future care 
or legal rights will not be affected in any way. 
 
 
I also give my consent to publish the trial results in scientific journals and to present the 
data in national and international meetings and conferences provided no personal 
details will be made available at any stage.  
 
 
I understand that relevant sections of any of my baby’s medical notes and data 
collected during the study, may be looked at by responsible individuals from regulatory 
authorities or from the NHS trust, where it is relevant to my baby taking part in this 
research. I give permission for these individuals to have access to my baby’s records. 
 
 
I agree for the Neonatal unit to inform my GP about my baby’s participation in this trial  
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Name of Parent 
 
 
Signature 
Date 
Signature 
Date 
Name of health professional taking consent 
 
 
 
Copy to –  Parents   
Case notes 
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                                                                                                      HILO PROTOCOL                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Randomisation on basis of Birth Weight 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pCO2 (kPa) 
Decrease 
PEEP to 4 cm 
H2O 
Continue 
same 
Increase 
PEEP to 6 cm 
H2O 
 
Switch to SIMV mode with 
back up rate 40/min and No 
pressure support if MAP≥10 
PS 5-6cm H20 if MAP≤10 
Continue 
same 
Start HFOV 
 
<0.3 > 0.5  0.3-0.5 
 <4.5 
& pH>7.4 
 4.5-6.5  6.5-8 >8 
& pH<7.25 
 
Increase rate 
FIO2 
Low Normal Vt 
4 ml/Kg 
 
High Normal Vt 
8 ml/Kg 
 
High Normal Vt 
7 ml/Kg 
Low Normal Vt 
5 ml/Kg 
 
Monitor oxygenation and ventilation as standard care 
spO2 91-95% and pCO2 4.5-8 cm H2O 
Collection of tracheal aspirate @ 48 
hours/ pre-extubation whichever is 
earlier 
Extubate 
 
Continue ventilation and 
retry after 6-12 hours 
<1000 g ≥1000g 
Wean onto SIMV mode with back up rate 40/min and same 
Vt with pressure support 5-6 cm H2O if  
1. >50% breaths are spontaneous 
2. FIO2 <0.4 
3. MAP <10 cm H2O 
 
Tracheal aspirate @ Birth 
and then Surfactant 200 mg/Kg 
Pr A/C+VG 
Back up rate 40/min 
PEEP 5 cm  
PIP – 10 cm above baseline 
I time – < 1 Kg - 0.26 and for ≥ 1 Kg - 0.30 sec 
 
If switched onto SIMV - 
Reduce rate by 10 every 6-12 
hrs as applicable 
Exit Criteria: 
Babies may be discontinued on volume guarantee ventilation and 
switched to high frequency oscillatory ventilation (HFOV) if any of the 
following occurs 
1. Inadequate ventilation (pH <7.25 and pCO2 >8 kPa);  
2. Inadequate oxygenation (FIO2 >0.6 to maintain SpO2 >91%) 
3. Massive pulmonary haemorrhage or pulmonary hypertension 
 
Exclusion criteria: 
1. Serious underlying congenital anomaly 
a. Congenital diaphragmatic hernia 
b. Cyanotic congenital heart disease 
c. Airway anomalies 
d. Abdominal wall defects 
2. Multiple pregnancies – only the first-born will be 
randomized; the others will receive the same strategy AND 
WOULD BE ENROLLED 
3. Babies initiated on ventilation after 12 hours of life or 
transferred from other centres ventilated 
 
Minute ventilation test if 
MAP <8 
FIO2 <0.3 
 
Passed 
Not passed 
Birth weight ≤1500 g OR Gestation ≤ 32+0 weeks 
Evidence of RDS requiring intubation and ventilation 
  
   
H          I 
L  O 
Sequence of events  
 
Enrol if - Intubated at birth OR  less than 12 hours of age + GA≤32+0 OR  
B. wt ≤1500g 
 
Tracheal aspirate before surfactant – sample stays in local fridge/freezer 
with baby’s label and time of collection 
 
Randomised to arm based on randomisation envelope (different for <1Kg and 
≥1Kg) 
 
Manage the baby as per standard practice keeping the tidal volume same 
and weaning by switching over to SIMV and coming down on rate 
 
Second tracheal aspirate at 48 hours or before extubation whichever is 
earlier 
 
 
 
 
 
 
AppendixE
Minute Volume Test Protocol
169
  
Whilst on Mechanical ventilation (SIMV): 
Time (mins) Heart 
Rate 
Respiratory 
Rate 
FIO2 Saturations Tidal 
volume 
Minute ventilation 
(Ml/kg/min) 
End of 1st 
minute 
     MV1  
End of 2nd 
Minute 
     MV2  
End of 3rd 
minute 
     MV3  
End of 4th 
minute 
     MV4  
End of 5th 
minute 
     MV5  
Average Minute ventilation on mechanical ventilation (MVsimv): MV1+MV2+MV3+MV4+MV5  = 
                                                                            5 
Whilst on ETCPAP: 
Time (mins) Heart 
Rate 
Respiratory 
Rate 
FIO2 Saturations Tidal 
volum
e 
Minute ventilation 
(Ml/kg/min) 
End of 1st 
minute 
     CPAP1  
End of 2nd 
Minute 
     CPAP2  
End of 3rd 
minute 
     CPAP3  
End of 4th 
minute 
     CPAP4  
End of 5th 
minute 
     CPAP5  
Average Minute ventilation on ETCPAP (MVetcpap): CPAP1+CPAP2+CPAP3+CPAP4+CPAP5  = 
                                        5 
MVetcpap/MVsimv =  
Baby is ready for extubation if  
• MV etcpap/MV simv is more than 0.5 
• No bradycardia needing IPPV 
• Rise of FIO2 no more than 10% 
Date and time of extubation: 
   
H          I 
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Name  
Hospital Number: 
Date:                                               Time: 
HILO TRIAL Minute Ventilation TEST 
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HILO Proforma  
 
Patient Number:     HNTH 
 
Gestation Age: 
Gender:     M  /  F 
Multiple Pregnancy:    Singleton / Twin / Triplet / Quad 
 
Birth weight:       grams   centiles  
Weight ≤10th centile:    Yes  /  No 
Birth weight z score: 
OFC        cm   centiles 
Inborn      Yes  /  No 
Randomised to:    High (  7  /  8  ml/kg)  OR Low (  4  /  5  ml/kg) 
 
MATERNAL DETAILS: 
Booked at      UHNT  /  UHH  /  
Parity:         G             P    
Steroids:     Complete  /  Incomplete  /  None 
PROM (>18 hrs):    Yes  /  No  
Pre-labour ROM:    Yes  /  No 
Chorioamnionitis (↑CRP/WCC/Histology) Yes  /  No 
Maternal Temperature   Yes  /  No  
Antibiotics in labour    Yes  /  No 
Antepartum H’ge (needing intervention) Yes  /  No 
Diabetes     Yes  /  No 
PIH      Yes  /  No 
Medical Problems 
Obstetric Problems 
Rubella    Immune / Non-Immune / Not performed 
Syphilis    Negative / Positive / Not performed  
Hep B     Negative / Positive / Not performed 
HIV     Negative / Positive / Not performed 
Anomaly scan    Normal / Not performed /  
 
PERINATAL EVENTS: 
Reason for delivery:   Spontaneous onset /  
Delivered by :     NVD / EmLSCS / ElLSCS / Ventouse / Forceps  
SP1 –Birth    Date:   Time: 
Resuscitation: 
Time first Gasp    min 
Time regular respiration   min  
Intubated at Birth   Yes  /  No 
Intubated at     mins 
Apgars:      @1 min @5 mins @10 min 
External cardiac massage  Yes / No 
Drugs during resuscitation  No /  
Tracheal aspirate collected?  Yes  /  No 
 
NEONATAL COURSE: 
SP2 – Admission to NNU   Date:   Time: 
Age admitted to NNU 
Initial Temperature     ºC 
Worst base excess in first 12 hours   kPa 
CRIB 2 score 
 
SP3 – 1st intubation    Date:   Time: 
Age at ventilation 
CPAP before ventilation   Yes  /  No 
Received surfactant    Yes  /  No 
Number of surfactant doses 
OI admission 
A-DO2 on admission 
Initial FIO2     Max FIO2 
Initial PIP     Max PIP 
Initial MAP     Max MAP 
X-ray report of Chest x-ray on admission: 
 
 
Chest ribs seen 
Gases until 1st cycle of MV 
Age of 
Life 
Date Time C/V/A pH PCO2 BE Comments 
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
       
 
 
 
SP4 –25% reduction in PIP:    Date:   Time: 
Age at 25% reduction in PIP 
Time to 25% extubation in PIP (SP4-SP3) 
SP5 –MVT      Date:   Time: 
MVT done before ext     Yes  /  No 
MVT passed ?      Yes  /  No  
MVT number when MVT passed 
Ve (M) – MVT passed 
Ve (S) – MVT passed 
Ve (M) / Ve (S) –  
SP6 – Extubation      Date:   Time: 
Age at extubation 
Duration of intubaton  (SP6-SP3) 
Cydn – Ext 
FIO2 – Ext 
Total RR 
Did baby receive caffeine before extubation   Yes  /  No 
Extubated to:        CPAP / HHFO2 / LFO2 / SVIA 
From - Changed to: When: 
Date 
When: 
Time 
Why? Total 
Time 
spent 
      
      
      
      
      
      
      
      
      
      
      
      
 
Met Exit Criteria      Yes  /  No 
If yes, when       Date:   Time: 
If yes, which ventilation 
Total fluid intake in first week of life 
SP7 –came off CPAP and remained off for 7 days Date:   Time: 
SP8 –came off low flow and stayed off for 7 days Date:   Time: 
On CPAP for 
Max CPAP pressures 
Max CPAP FIO2 
On HHFNC for 
Max HF Flow 
Max HF FIO2 
On low flow oxygen for (SP8-SP6) 
Total duration of invasive respiratory support 
Total duration of Invasive and Non-invasive Respiratory support (MV+CPAP+HF) 
Tracheal aspirate – 1st / pre-intubation 
Tracheal aspirate – 2nd / at 48 hr / pre-extubation 
Received steroids?    Yes  /  No  
O2 or respiratory support at 28 days  Yes  /  No 
O2 or respiratory support at 36 CGA  Yes  /  No 
Survival without CLD at 36 weeks  Yes  /  No 
Discharged on home oxygen:   Yes  /  No  If yes, -  
Oxygen trace performed   Yes  /  No 
If yes, on how much oxygen 
Trace report  
 Median 
 Time spent <92% 
 Time spent <94% 
 
OUTCOME:       Discharge / Death / Transfer  
SP9  - Date and time of discharge/death   Date:   Time: 
Age at discharge       days  CGA 
If transferred, Base hospital     NA /  
Discharge weight      grams   centiles 
If died, Censor Primary 
If died, Censor death 
 
 
 
Complications of prematurity: 
Sepsis :    Yes / No 
Blood culture positive  Yes / No  
Air Leak    No / Pneumothorax / Pneumomediastinum / drained 
IVH at 1st week   Rt  Nil  / Gr 1 / 2 / 3 / 4   Lt Nil  / Gr 1 / 2 / 3 / 4 
IVH at 6th week  Rt  Nil  / Gr 1 / 2 / 3 / 4  Lt Nil  / Gr 1 / 2 / 3 / 4 
PVL    Yes / No 
NEC    Nil  / Gr 1/ Gr 2 / Gr 3 / Surgically treated 
ROP    Rt- Nil / Stage    / Zone      ;Lt - Nil/ Stage   / Zone    ;Lasered 
PDA Nil Significant / Significant but not treated / Medically treated / 
Surgically ligated  
  
 
 
 
Protocol violations (and Other Comments): 
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GP Letter. AG/Version 1/HILO Trial   12/03/2013 
 
 
                            
 
 
To, 
 
 
 
 
Date:      /      / 201       
Neonatal Unit 
University Hospital of North Tees 
Hardwick Road TS19 8PE 
01642 624247/4248
 
 
 
Dear Dr 
 
Re: Baby …………………………..; DoB………………………………………………….. 
Gestation at birth………………… 
Infant of ……………………………; DoB………………………………………………….. 
Address……………………………………………………………………………………….. 
 
 
Subject: HILO Trial (REC Ref No: …………………………………..) 
 
 
This is to inform you that above baby was admitted to the neonatal unit in view of 
prematurity and needed ventilatory support. After obtaining parental consent the 
infant was randomised to ……………..group of the trial. Full results of the trial are not 
available yet. 
 
A summary of the trial will be made available to the parent when the trial is 
completed. If the parent wishes a complete published report can be made available 
by requesting to the chief investigator. The participation into the trial should not 
change any approach to the healthcare needs in the future. 
 
If you need any further information, please do not hesitate to contact us. 
 
Many thanks. 
 
 
Yours sincerely 
 
 
 
Dr Anupam Gupta 
Neonatal research Fellow to 
Chief Investigator: Professor Samir Gupta 
Consultant Neonatologist  
University Hospital of North Tees 
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